Abstract
Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer drugs are similar to traditional drugs of abuse. Stimulants, such as amphetamines and cathinones, primarily interact with monoamine transporters and mostly induce sympathomimetic adverse effects. Agonism at μ-opioid receptors and γ-aminobutyric acid-A (GABAA) or GABAB receptors mediates the pharmacological effects of sedatives, which may induce cardiorespiratory depression. Dissociative designer drugs primarily act as N-methyl-d-aspartate receptor antagonists and pose similar health risks as the medically approved dissociative anesthetic ketamine. The cannabinoid type 1 (CB1) receptor is thought to drive the psychoactive effects of synthetic cannabinoids, which are associated with a less desirable effect profile and more severe adverse effects compared with cannabis. Serotonergic 5-hydroxytryptamine-2A (5-HT2A) receptors mediate alterations of perception and cognition that are induced by serotonergic psychedelics. Because of their novelty, designer drugs may remain undetected by routine drug screening, thus hampering evaluations of adverse effects. Intoxication reports suggest that several designer drugs are used concurrently, posing a high risk for severe adverse effects and even death.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The term “designer drugs” was originally introduced to describe novel substances that are derived from clandestine alterations of well-known drugs of abuse, preserving or enhancing pharmacologic effects while remaining outside of legal control (Jerrard 1990). The term is currently applied more widely to include substances that originate from industrial or academic research but never receive medical approval. Some substances that are referred to as designer drugs may be medically approved in different countries, thus not fitting the classic definition of a designer drug (Bäckberg et al. 2019; Manchester et al. 2018; Owen et al. 2016; Zawilska and Wojcieszak 2019). The Internet plays a crucial role in the distribution of designer drugs and in the acquisition of information about them (Miliano et al. 2018). The number of available designer drugs is constantly growing, and trends and patterns of use change over time. This poses a challenge to drug-regulatory authorities and can jeopardize public health. Designer drugs can generally be divided into the same categories as traditional drugs of abuse, namely stimulants, sedatives, dissociatives, cannabinoids, and psychedelics. However, in contrast to traditional drugs of abuse, newly emerging drugs can remain undetected by routine drug screening, and information about associated adverse effects is often scarce. Knowledge of the mechanism of action and potential clinical complications of designer drugs is key for healthcare workers who treat intoxicated patients. The present review provides an overview of the main mechanisms of action and adverse effects of currently available designer drugs.
Stimulants
Monoaminergic stimulants, such as amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), and cocaine, are among the most popular drugs of abuse. Other stimulants, such as methylphenidate and dextroamphetamine, are widely prescribed for the treatment of attention-deficit/hyperactivity disorder (ADHD). MDMA is currently being investigated as a prescription drug for the treatment of posttraumatic stress disorder (Amoroso and Workman 2016; Mithoefer et al. 2011, 2016; Sharma and Couture 2014). Stimulants modulate monoaminergic neurotransmission mainly by interacting with norepinephrine, dopamine, and serotonin (5-hydroxytryptamine [5-HT]) transporters (NET, DAT, and SERT, respectively), in addition to interacting with monoaminergic receptors and other targets. At monoamine transporters, monoaminergic stimulants act as either transporter inhibitors or substrates that mediate non-exocytotic monoamine efflux (Fleckenstein et al. 2000; Rothman and Baumann 2003; Sitte and Freissmuth 2015). Different selectivity (Fig. 1) and potency (Fig. 2) at the different transporters result in different pharmacological effects, different clinical potencies (i.e., the dose that is necessary to induce a psychoactive effect), and different abuse liabilities (Aarde and Taffe 2017; Gannon et al. 2018; Javadi-Paydar et al. 2018; Kuhar et al. 1991; Luethi and Liechti 2018; Ritz et al. 1987; Vandewater et al. 2015; Wee et al. 2005; Wee and Woolverton 2006). In rats, substances that are selective for DAT vs. SERT facilitate dose-dependent and abuse-related intracranial self-stimulation, indicating high abuse potential. In contrast, substances that are selective for the SERT vs. DAT depress dose-dependent intracranial self-stimulation (Suyama et al. 2019), indicating a lower risk of abuse. Repeated exposure to substances with similar activity at the DAT and SERT may sustain the expression of DAT-mediated abuse-related effects while developing tolerance to SERT-mediated abuse-limiting effects, thus resulting in a higher abuse potential (Suyama et al. 2019). The number of available designer stimulants is constantly increasing, and their use can cause various physiological complications and mood disturbances, which are discussed in the subsequent sections for the different classes of designer stimulants.
Amphetamines
In addition to traditional amphetamines that are used both medically and recreationally, several amphetamine designer drugs without approved medical uses have become available. MDMA is by far the most popular amphetamine designer drug. It was first synthesized by Merck in 1912 as a precursor in a new chemical pathway, but it was not further investigated until many years later (Freudenmann et al. 2006). In the 1980s, MDMA started to be used in psychotherapy and became popular as a recreational drug under the street name “ecstasy,” which led to a ban of MDMA in most countries soon afterward (Freudenmann et al. 2006; Green et al. 2003). MDMA has slowly found its way back into psychotherapy as a promising agent for the treatment of posttraumatic stress disorder (Amoroso and Workman 2016; Mithoefer et al. 2016, 2011). Recently, various other, often ring-substituted amphetamine derivatives (Fig. 3) have gained increasing popularity as designer drugs, many of which were initially legally obtainable.
Mechanism of action of amphetamines
Most amphetamines are substrate-type monoamine releasers (Rothman and Baumann 2003; Simmler et al. 2013, 2014a; Sitte and Freissmuth 2015). In addition to potent effects at the NET, many amphetamines predominantly act at the DAT vs. SERT, resulting in greater reinforcing effects and higher abuse liability (Kuhar et al. 1991; Ritz et al. 1987; Wee et al. 2005; Wee and Woolverton 2006). In contrast, some amphetamines, including MDMA, have more pronounced effects at the SERT vs. DAT, resulting in an entactogenic effect profile and lower abuse liability (Baumann et al. 2000, 2012; Luethi et al. 2019a; Simmler et al. 2013). Para-substitution at the phenyl ring of amphetamines has been shown to shift their pharmacological profile toward more pronounced activity at the SERT vs. DAT (Luethi et al. 2018c, 2019b; Rickli et al. 2015a; Simmler et al. 2014a; Wee et al. 2005). In addition to their interactions with plasma membrane transporters, amphetamines are substrates at vesicular monoamine transporters (VMATs) and inhibit monoamine oxidases (Fleckenstein et al. 2007; Partilla et al. 2006; Sitte and Freissmuth 2015; Volz et al. 2007). Furthermore, amphetamine designer drugs have been reported to interact with various monoaminergic receptors, including serotonergic and adrenergic receptors, and trace amine-associated receptor 1 (TAAR1), which negatively modulates monoaminergic neurotransmission (Di Cara et al. 2011; Rickli et al. 2015a; Simmler et al. 2014a, 2016).
Adverse effects of amphetamines
Numerous studies have reported the adverse effects of amphetamine, lisdexamfetamine, and methamphetamine. Among amphetamine-derived designer drugs, MDMA is the best studied. For traditional amphetamines, mainly sympathomimetic adverse effects (e.g., anxiety, insomnia, headaches, mydriasis, bruxism, dry mouth, hyperthermia, hypertension, tachycardia, chest pain, palpitations, anorexia, nausea, vomiting, and abdominal pain) can be expected for newly emerged amphetamine-derived designer drugs (Carvalho et al. 2012; Derlet et al. 1989; Dolder et al. 2017; Heal et al. 2013; Vizeli and Liechti 2017; Wijers et al. 2017). Hyperthermia is a significant contributor to potentially severe adverse effects of amphetamines, including disseminated intravascular coagulation, renal failure, and rhabdomyolysis (Bingham et al. 1998; Carvalho et al. 2012; Cunningham 1997; Fahal et al. 1992; Ginsberg et al. 1970; Greene et al. 2003; Halachanova et al. 2001; Henry et al. 1992; Kendrick et al. 1977; Richards et al. 1999; Screaton et al. 1992; Vanden Eede et al. 2012). The uncoupling of oxidative phosphorylation in skeletal muscle through the activation of uncoupling protein 3 (UCP-3) and agonism at adrenergic receptors by norepinephrine release has previously been identified as an important contributor to MDMA-induced hyperthermia (Mills et al. 2003, 2004). Many adverse effects are similar for most amphetamines, but the prevalence of some events is higher for certain specific amphetamines. A comparison of the structures and pharmacological profiles of newly emerged amphetamine designer drugs with well-studied amphetamine derivatives helps to shed light on the likelihood of these specific adverse events. Hepatotoxicity is a potentially fatal adverse effect that has been associated with the use of amphetamines, and MDMA is the designer drug that has been most frequently linked to liver injury (Andreu et al. 1998; De Carlis et al. 2001; Ellis et al. 1996; Garbino et al. 2001; Jones et al. 1994; Kamijo et al. 2002). Different mechanisms may contribute to MDMA-induced hepatotoxicity, including monoamine release, hyperthermia, oxidative stress, impairments in the antioxidant response, mitochondrial dysfunction, and the formation of catechol metabolites by demethylenation (Carvalho et al. 2010, 2012). Cardiotoxicity is another potential complication of amphetamine use and largely attributable to sympathomimetic activation and additionally to secondary mechanisms, such as metabolic bioactivation and hyperthermia (Carvalho et al. 2012). The activation of 5-HT2B receptors in cardiovascular tissues may potentially result in cardiac valvulopathy and is thus a concern for drugs that increase plasma 5-HT levels or directly activate 5-HT2B receptors (Elangbam 2010; Elangbam et al. 2008; Huang et al. 2009; Roth 2007). Mild-to-moderate valvular heart disease has been observed in a population of heavy recreational MDMA users, and the 5-HT2B receptor-mediated proliferation of cardiac valvular interstitial cells that was induced by MDMA was demonstrated in vitro (Droogmans et al. 2007; Setola et al. 2003). The MDMA metabolite 4-hydroxy-3-methoxymethamphetamine (HMMA) exhibits higher potency in stimulating vasopressin secretion; together with the excessive intake of hypotonic liquids and hyperthermia, it may cause potentially fatal hyponatremia, especially in female users likely because of effects of estrogen on vasopressin (Campbell and Rosner 2008; Fallon et al. 2002; Farah and Farah 2008; Forsling et al. 2001; Forsling et al. 2002; Ghatol and Kazory 2012; Hartung et al. 2002; Moritz et al. 2013; Rosenson et al. 2007; Simmler et al. 2011; Van Dijken et al. 2013). Monoamine depletion and reactive species contribute to the neurotoxicity of amphetamines (Carvalho et al. 2012). However, despite extensive research, the extent to which different amphetamines are neurotoxic remains largely unknown. Compared with amphetamine, an increase in serotonergic toxicity has been reported for the para-chlorinated derivative 4-chloroamphetamine, likely explained by highly potent serotonergic activity coupled with considerably potent dopaminergic activity (Colado et al. 1993; Fuller 1992; Johnson et al. 1990; Luethi et al. 2019b; Miller et al. 1986). However, unlike other halogenated stimulants, such as 4-fluoroamphetamine, 4-chloroamphetamine never achieved popularity as a designer drug, possibly because of its well-documented neurotoxicity. Nevertheless, the widely used 4-fluoroamphetamine has been associated with various mild-to-moderate adverse effects (e.g., agitation, severe headache, anxiety, confusion, tachypnea, hypertension, tachycardia, chest pain, electrocardiographic abnormalities, and nausea) and severe adverse effects (e.g., coma, convulsions, cerebral hemorrhage, inverted takotsubo cardiomyopathy, myocardial infarction, and fatalities following cardiac arrest) (Hondebrink et al. 2018). A detailed review of amphetamine toxicity, including toxicological pathways that involve the formation of reactive species, the depletion of antioxidants, and microglial activation, was previously published (Carvalho et al. 2012).
Cathinone and pyrovalerone derivatives
Cathinone designer drugs are derivatives of the β-keto-amphetamine cathinone, an alkaloid that is found in the leaves of the Catha edulis plant. The large-scale recreational use of synthetic cathinones is a relatively new phenomenon, although several compounds have been known for a long time. For example, the first synthesis of 4-methylmethcathinone (mephedrone) was published in 1929 (Sanchez 1929). Several other synthetic cathinones have been investigated for their medical potential, mostly as antidepressant or anorectic agents, but only a few were ever marketed because of concerns about abuse (Canning et al. 1979; Cunningham 1963; Dal Cason et al. 1997; Seaton et al. 1961; Soroko et al. 1977; Valente et al. 2014). Pyrovalerone derivatives represent a subgroup of synthetic cathinones based on the structure of pyrovalerone, which was developed in the 1960s as a treatment option for lethargy, fatigue, and obesity (Gardos and Cole 1971). As a result of their initial misleading marketing as “bath salts”, synthetic cathinones are still often referred to by that term (Baumann et al. 2013). Currently, synthetic cathinones (Fig. 3) represent the largest group of designer stimulants that are monitored by the European Monitoring Center for Drugs and Drug Addiction (EMCDDA) (European Monitoring Centre for Drugs and Drug Addiction 2019).
Mechanism of action of cathinone and pyrovalerone derivatives
Similar to other monoaminergic stimulants, the psychoactive effects of synthetic cathinones are primarily mediated by interactions with monoamine transporters. Many cathinones are partially or fully effective substrate-type releasers at one or several monoamine transporters, but some compounds, such as pyrovalerone derivatives, are transporter inhibitors (Baumann et al. 2012; Eshleman et al. 2013, 2017; Luethi et al. 2018c; Mayer et al. 2016,2019a; Niello et al. 2019; Rickli et al. 2015a; Simmler et al. 2013). Mephedrone has additionally been shown to mediate monoamine release via organic cation transporter 3 (OCT3), indicating that cathinones target both high-affinity and low-affinity/high-capacity transporters (Mayer et al. 2019b). Similar to amphetamines, cathinone designer drugs also interact with several adrenergic and serotonergic receptors (Luethi et al. 2018c; Rickli et al. 2015a; Simmler et al. 2014a). Compared with amphetamines, however, cathinone designer drugs have been shown to interact less potently with TAAR1 and VMAT2 (Eshleman et al. 2013; Simmler et al. 2016). These less potent interactions at TAAR1 may result in a higher risk of cathinone dependence compared with amphetamines.
Adverse effects of cathinone and pyrovalerone derivatives
The use of synthetic cathinones has been associated with mainly sympathomimetic toxicity, which may manifest as agitation, tachycardia, hypertension and less frequently as lower levels of consciousness, hallucinations, hyponatremia, chest pain, palpitations, and nausea (Bäckberg et al. 2015c; Beck et al. 2015, 2016; Borek and Holstege 2012; Boulanger-Gobeil et al. 2012; Franzén et al. 2018; James et al. 2011; Ross et al. 2011, 2012; Umebachi et al. 2016; Wood et al. 2010). Rarely, severe adverse effects (e.g., seizures, significant peripheral organ damage, and rhabdomyolysis) have been reported (Bäckberg et al. 2015c; Beck et al. 2015, 2016; Borek and Holstege 2012; Boulanger-Gobeil et al. 2012; Franzén et al. 2018; Fröhlich et al. 2011; Penders et al. 2012; Ross et al. 2011, 2012). In vitro studies in neuronal, skeletal muscle, and hepatic cells indicated various cytotoxic mechanisms of synthetic cathinones, including mitochondrial dysfunction, glutathione depletion, oxidative stress, and apoptosis pathway activation, which are aggravated under hyperthermic conditions (Dias da Silva et al. 2019; Luethi et al. 2017, 2019b; Valente et al. 2016a, b, 2017a, b; Zhou et al. 2019). Unclear, however, is the extent to which these mechanisms contribute to clinical adverse effects of cathinones relative to sympathomimetic toxicity. Numerous cathinone-related fatalities have been reported (Adamowicz et al. 2014, 2016; Bäckberg et al. 2015c; Barrios et al. 2016; Beck et al. 2016; Busardò et al. 2015; Carbone et al. 2013; DeRoux and Dunn 2017; Eiden et al. 2013; Forrester 2012b; Kesha et al. 2013; Kudo et al. 2015; Lee et al. 2015; Liveri et al. 2016; Majchrzak et al. 2018; Marinetti and Antonides 2013; Maskell et al. 2011a; Nagai et al. 2014; Pearson et al. 2012; Pieprzyca et al. 2018; Potocka-Banas et al. 2017; Schifano et al. 2012; Sellors et al. 2014; Thirakul et al. 2017; Umebachi et al. 2016; Wood et al. 2010; Wright et al. 2013; Wyman et al. 2013; Zaami et al. 2018). Analytically confirmed cases of cathinone-related deaths were mainly attributed to hyperthermia, hypertension, cardiac arrest, and serotonin syndrome (Busardò et al. 2015; Zaami et al. 2018).
Benzofuran and indole derivatives
Various analogs of MDMA and its metabolite 3,4-methylenedioxyamphetamine (MDA) have become available as designer drugs, in which a dihydrobenzofuran, benzofuran, or indole group replaces the benzodioxole group (Fig. 4). Some benzofuran designer drugs were originally investigated as part of a study that examined the role of ring oxygen atoms in interactions between MDA and monoamine transporters (Monte et al. 1993). The indole designer drugs 5-(2-aminopropyl)indole (5-IT, 5-API) and 6-(2-aminopropyl)indole (6-IT, 6-API) emerged from industrial research and are positional isomers of the psychedelic tryptamine α-methyltryptamine (αMT) (Hofmann and Troxler 1962).
Mechanism of action of benzofuran and indole derivatives
In addition to norepinephrine uptake inhibition, stimulant benzofuran and dihydrobenzofuran designer drugs have moderate-to-high selectivity in inhibiting 5-HT vs. dopamine uptake, often with substrate activity at the transporters (Monte et al. 1993; Rickli et al. 2015b). Furthermore, affinity at adrenergic, serotonergic, and histaminergic receptors, partial agonism at 5-HT2A receptors, and partial to full agonism at 5-HT2B receptors have been reported for these designer drugs (Dawson et al. 2014; Iversen et al. 2013; Rickli et al. 2015b). The indoles 5-IT and 6-IT are potent substrates at the NET, DAT, and SERT in rat synaptosomes (Marusich et al. 2016). The position of the alkylamine side chain is determining of DAT vs. SERT selectivity, with 5-IT having significantly (eightfold) more potent monoamine-releasing actions at the DAT vs. SERT in rat synaptosomes, whereas 6-IT is eightfold more selective for the SERT (Marusich et al. 2016). In human transporter-transfected cells, 5-IT has been shown to be a very potent inhibiter of norepinephrine uptake, but it did not significantly induce norepinephrine efflux at a single high concentration. However, it had substrate activity at the DAT and SERT (Luethi et al. 2018c). Additionally, 5-IT has affinity for adrenergic and serotonergic receptors and partially activates 5-HT2A and 5-HT2B receptors, which may result in additional perceptual psychedelic-like effects at high doses (Luethi et al. 2018c). Furthermore, 5-IT is an inhibitor of human monoamine oxidase (MAO)-A (Herraiz and Brandt 2014).
Adverse effects of benzofuran and indole derivatives
Benzofuran designer drugs may cause agitation, insomnia, headache, drowsiness, dry mouth, dry eyes, bruxism, hyperthermia, tachycardia, palpitations, nausea, diarrhea, hot flashes, clonus of the hands and feet, and psychological symptoms, including visual and auditory hallucinations, depression, anxiety, panic attacks, paranoia, and psychosis (Jebadurai et al. 2013; Nugteren-van Lonkhuyzen et al. 2015). A case of drug-induced psychosis with symptoms of self-harm, paranoia, and suicidal thoughts but unremarkable physical examination was reported with the analytically confirmed presence of 6-(2-aminopropyl)benzofuran (6-APB) in combination with metabolites of a synthetic cannabinoid and tetrahydrocannabinol (Chan et al. 2013). In addition to fatal intoxications that involve benzofurans combined with other designer drugs (Adamowicz et al. 2014; Elliott and Evans 2014), benzofuran toxicity was implicated as the cause of death in an accidental intoxication, in which 5-APB and presumptively a smaller amount of 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB) were detected as sole compounds in addition to alcohol (McIntyre et al. 2015a). Autopsy revealed white foam in the trachea, marked congestion and edema of the lungs, and congestive splenomegaly (McIntyre et al. 2015a). Benzofurans induce oxidative stress, disrupt mitochondrial function, and activate apoptosis cascades in vitro, but the in vivo relevance of these sequelae remain unclear (Roque Bravo et al. 2019). 5-IT has been linked to various sympathomimetic adverse effects, including extreme agitation, anxiety, confusion, insomnia, restlessness, hallucinations, seizures, tremors, dilated pupils without light reaction, hyperthermia, sweating, hypertension, tachycardia, arrhythmias, renal failure, myoclonus, muscle rigidity, rhabdomyolysis, and in some cases, serotonergic toxicity (Bäckberg et al. 2014; Coppola and Mondola 2013b; Katselou et al. 2015). Furthermore, 5-IT was involved in several intoxication cases with a fatal outcome within a time span of only a few months (Katselou et al. 2015; Kronstrand et al. 2013; Seetohul and Pounder 2013). Many of 5-IT-associated deaths have been attributed to cardiac arrest, to which 5-HT2B receptor activation by 5-IT may have contributed (Katselou et al. 2015; Luethi et al. 2018c; Seetohul and Pounder 2013). In most of the fatal and non-fatal intoxication cases, additional substances have been detected. In some cases, the users reported to be unaware that they took 5-IT, because the products were mislabeled as 6-APB (Bäckberg et al. 2014; Kronstrand et al. 2013; Seetohul and Pounder 2013). Although the reported doses of 5-IT and 6-APB are similar, they differ in their selectivity for the dopaminergic vs. serotonergic system (Luethi et al. 2018c; Luethi and Liechti 2018; Rickli et al. 2015b). The extent to which mislabeling played a role in 5-IT intoxication remains unclear.
Aminoindanes
Aminoindane designer drugs (Fig. 4) have become widely available when first-generation designer stimulants, including mephedrone, were finally placed under legal control (Pinterova et al. 2017; Sainsbury et al. 2011). Aminoindanes are conformationally restricted analogs of amphetamine that were originally investigated as bronchodilatory, analgesic, and anti-Parkinson agents, and subsequently as drugs with psychotherapeutic value (Pinterova et al. 2017; Solomons and Sam 1973). Some aminoindane designer drugs have been reported to be entactogens with lower serotonergic neurotoxicity relative to non-aminoindane entactogens (Johnson et al. 1990; Nichols et al. 1991). The desired psychoactive effects of aminoindane designer drugs include euphoria, the mild distortion of vision, time, and space, a greater intensity of perceptions and colors, empathy, and arousal (Coppola and Mondola 2013a; Corkery et al. 2013).
Mechanism of action of aminoindanes
Similar to amphetamines, aminoindane designer drugs are monoamine transporter substrates, with relevant affinity for adrenergic, dopaminergic, and serotonergic receptors (Iversen et al. 2013; Luethi et al. 2018c; Simmler et al. 2014b). Ring-substituted aminoindanes, such as 5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodoaminoindane (5-IAI), and 5-methoxy-6-methyl-2-aminoindane (MMAI), are selective for the SERT vs. DAT (Luethi et al. 2018c; Simmler et al. 2014b). Potent actions of MDAI and 5-IAI on the NET result in an in vitro pharmacological profile that is similar to MDMA, suggesting similar entactogenic effects (Simmler et al. 2014b). MMAI acts as a selective 5-HT releaser with less pronounced effects on the NET, indicating that its effects are different from typical entactogens, such as MDMA (Luethi et al. 2018c). According to in vitro studies, the non-ring-substituted aminoindanes 2-aminoindane (2-AI) and N-methyl-2-AI are selective norepinephrine releasers and devoid of pharmacologically relevant DAT or SERT interactions (Luethi et al. 2018c; Simmler et al. 2014b).
Adverse effects of aminoindanes
Self-reported undesirable effects of aminoindane designer drugs include agitation, anxiety, panic attacks, headache, insomnia, hallucinations, and tachycardia (Coppola and Mondola 2013a). Three fatal cases were reported with confirmed MDAI intake, and serotonin syndrome could have been a factor that contributed to death (Corkery et al. 2013). The likelihood of the serotonergic toxicity of aminoindanes in humans has not been investigated, but signs of serotonin syndrome were reported for a high dose of MDAI in rats (Palenicek et al. 2016).
Piperazines
Piperazine designer drugs (Fig. 4) have been widely sold as legal party pills or powders and appeared as pure substances or adulterants in pills that are sold as “ecstasy” because of their somewhat MDMA-like pharmacological profile, alone or combined (Baumann et al. 2005; Bossong et al. 2010; Lin et al. 2011; Sheridan et al. 2007; Wood et al. 2008). Various therapeutic drugs have a piperazine moiety, and some piperazine designer drugs have a history of medical use. For example, 1-benzylpiperazine (BZP) has been investigated as an antihelmintic agent and antidepressant, and meta-chlorophenylpiperazine (m-CPP) is an active metabolite of different antidepressants (Arbo et al. 2012; Schep et al. 2011). Other frequently used piperazine designer drugs include trifluoromethylphenylpiperazine (TFMPP), 1-(3,4-methylenedioxybenzyl)piperazine (MDBZP), and 4-methoxyphenylpiperazine (MeOPP).
Mechanism of action of piperazines
Piperazine designer drugs exert mixed effects at monoamine transporters. TFMPP and m-CPP are selective 5-HT vs. dopamine reuptake inhibitors (DAT/SERT ratio < 0.05), and m-CPP also inhibits norepinephrine uptake with potency that is similar to the inhibition of 5-HT uptake (Simmler et al. 2014b). Both substances bind to several serotonergic, adrenergic, dopaminergic, and histaminergic receptors with submicromolar or low micromolar affinity (Simmler et al. 2014b). In contrast, BZP is a selective NET inhibitor with relatively weak inhibition of dopamine and 5-HT uptake, without any potent affinity at monoamine receptors (Simmler et al. 2014b). BZP was also shown to be a DAT substrate in rat synaptosomes and human DAT-transfected cells, and m-CPP was reported to elicit 5-HT efflux in human SERT-transfected cells (Baumann et al. 2005; Simmler et al. 2014b). TFMPP mediated 5-HT efflux in rat synaptosomes but not in transfected cells at a single high concentration of 100 μM (Baumann et al. 2005; Simmler et al. 2014b). A combination of TFMPP and BZP was reported to closely mimic the effects of MDMA in rats (Baumann et al. 2005).
Adverse effects of piperazines
Adverse effects of piperazine designer drugs are mostly sympathomimetic, including agitation, insomnia, headaches, dizziness, dilated pupils, hyperthermia, tachycardia, nausea, urine retention, and inducible clonus (Arbo et al. 2012; Gee et al. 2005, 2008, 2010; Katz et al. 2016a; Kovaleva et al. 2008; Schep et al. 2011; Wilkins et al. 2008; Wood et al. 2008). In addition to sympathomimetic toxicity, dissociative symptoms, visual and auditory hallucinations, and psychological symptoms (e.g., short temper, confusion, anxiety, depression, and paranoia) have been associated with the use of piperazine designer drugs (Gee et al. 2008; Kovaleva et al. 2008; Schep et al. 2011; Wilkins et al. 2008; Wood et al. 2008). Furthermore, toxic seizures were frequently observed in patients who were admitted to the emergency department after the use of BZP-containing party pills. Although there seems to be a trend toward higher concentrations being more frequently associated with seizures, they may also occur at low doses (Gee et al. 2005, 2008). Other severe adverse effects of BZP include hyponatremia, severe combined metabolic and respiratory acidosis, hepatic injury, renal failure, disseminated intravascular coagulation, and rhabdomyolysis (Gee et al. 2010; Katz et al. 2016a). A case of severe hyperthermia with resultant multi-organ failure and a case of hyponatremia that led to fatal brain edema were reported for the concomitant use of piperazine designer drugs and MDMA (Balmelli et al. 2001; Gee et al. 2010). The contribution of these individual compounds to the observed clinical manifestations remains unclear, but piperazines and MDMA may elicit additive or synergistic toxicity. In vitro, piperazine designer drugs have been reported to upregulate key enzymes of cholesterol biosynthesis, induce oxidative stress, disrupt mitochondrial function, and activate apoptosis pathways, all of which may potentially contribute to clinical toxicity (Arbo et al. 2016a, b; Dias da Silva et al. 2017; Dias-da-Silva et al. 2015; Majrashi et al. 2018).
Phenidate derivatives
Derivatives of the piperidine prescription drug methylphenidate have appeared as designer drugs (Fig. 4), with substitutions at the phenyl ring and different lengths of the carbon side chain (Luethi et al. 2018b). Similar to methylphenidate, phenidate derivatives may be used to induce euphoria or as cognitive enhancers (Ho et al. 2015; Lüthi and Liechti 2019). Various methylphenidate-based designer drugs originated from drug development efforts and later appeared on the recreational drug market as pure compounds or in the form of branded products (Bailey et al. 2015; Deutsch et al. 1996; Ho et al. 2015; Markowitz et al. 2013; Misra et al. 2010). When insufflated, the pharmacological and subjective-effect profile of methylphenidate is similar to cocaine, and phenidate derivatives may, therefore, be used as substitutes for cocaine (Vogel et al. 2016).
Mechanism of action of phenidate derivatives
Similar to methylphenidate, methylphenidate-based designer drugs act as potent NET and DAT inhibitors that are devoid of substrate activity (Luethi et al. 2018b; Simmler et al. 2014b). Some less potent interactions with the SERT and adrenergic and serotonergic receptors have been reported but are not likely to play a relevant role in the psychoactive actions of most phenidate derivatives (Luethi et al. 2018b).
Adverse effects of phenidate derivatives
Adverse effects of phenidate derivatives are similar to amphetamines and include agitation, anxiety, hypertension, tachycardia, and palpitations (Bailey et al. 2015). Because of their relatively slow onset of action when taken orally, the nasal insufflation or injection of phenidate derivatives is common, especially in heavy users. Nasal pain and septum perforations after insufflation and infections after intravenous injection may occur (Ho et al. 2015; Lafferty et al. 2016; Parks et al. 2015). The rapid onset of action after nasal or intravenous use, combined with the marked DAT vs. SERT selectivity of phenidate derivatives, has been linked to a higher risk of addiction (Luethi et al. 2018b). In several cases, phenidate derivatives have been analytically confirmed post-mortem, in which ethylphenidate is the most frequently detected compound (Krueger et al. 2014; Maskell et al. 2016; Parks et al. 2015; Shoff et al. 2019). Many decedents had a history of heroin use, and intravenous injection was a common route of administration. In addition to phenidate derivatives, other drugs, including benzodiazepines and opioids, have been detected in most fatal cases (Krueger et al. 2014; Maskell et al. 2016; Parks et al. 2015).
Aminorex analogs
Various analogs of the anorectic agent aminorex have become available as designer drugs (Fig. 4). Aminorex was first marketed as an over-the-counter appetite suppressant in parts of Europe in the 1960s, but it was withdrawn a few years later because of an epidemic of chronic pulmonary hypertension that was associated with many fatalities (Maier et al. 2018a). Aminorex analogs that have found their way onto the designer drug market include 4-methylaminorex (4-MAR) and 4,4′-dimethylaminorex (4,4′-DMAR), the reported effects of which include euphoria, mental and physical stimulation, sociability, empathy, arousal, and changes in visual perception (European Monitoring Centre for Drugs and Drug Addiction 2015; Glanville et al. 2015; Loi et al. 2017). A comprehensive review of the history of aminorex use and the emergence of its designer drug analogs was recently published (Maier et al. 2018a).
Mechanism of action of aminorex analogs
In human transporter-transfected cells, 4,4′-DMAR is a potent inhibitor of norepinephrine, dopamine, and 5-HT reuptake. 4-MAR has similarly potent dopamine and norepinephrine reuptake properties as 4,4′-DMAR, but 5-HT uptake inhibition is less pronounced compared with its para-methylated counterpart (Maier et al. 2018b; Rickli et al. 2019). Aminorex and its derivative 4-MAR mediate norepinephrine and dopamine efflux in rat synaptosomes, with weak substrate activity at the SERT (Brandt et al. 2014; Rothman et al. 2001). 4,4′-DMAR and 3′,4′-methylenedioxy-4-methylaminorex (MDMAR) induce norepinephrine, dopamine, and 5-HT efflux in rat synaptosomes (Brandt et al. 2014; McLaughlin et al. 2015). Dynamic superfusion experiments revealed the substrate activity of 4,4′-DMAR at human monoamine transporters (Maier et al. 2018b). In human transporter-transfected cells that were preloaded with monoamines and exposed to drugs at a single high concentration (100 μM), only dopamine efflux was observed for 4,4′-DMAR, and dopamine and 5-HT efflux was observed for 4-MAR (Rickli et al. 2019). In addition to interactions with plasmalemmal transporters, 4,4′-DMAR has been shown to inhibit human VMAT2-mediated dopamine uptake (Maier et al. 2018b). In addition to their primary effects on transporters, minor interactions with serotonergic 5-HT2C and adrenergic α2A receptors have been described for 4-MAR, and low affinity at 5-HT2A and 5-HT2C receptors has been described for 4,4′-DMAR (Maier et al. 2018b; Rickli et al. 2019).
Adverse effects of aminorex analogs
Adverse effects of aminorex designer drugs that have been reported by users on various Internet discussion platforms include agitation, dysphoria, insomnia, amnesia, panic attacks, psychosis, hallucinations, facial spasms, dilated pupils, foaming at the mouth, dry mouth, jaw clenching, elevations of body temperature, sweating, elevations of heart rate, nausea, and restless legs (Glanville et al. 2015; Loi et al. 2017; Maier et al. 2018a). Pulmonary hypertension (i.e., the adverse effect that led to the removal of aminorex from the market) has been associated with the recreational use of 4-MAR (Gaine et al. 2000). Designer drug analogs of aminorex have been analytically confirmed in several drug-related deaths (Cosbey et al. 2014; Davis and Brewster 1988; European Monitoring Centre for Drugs and Drug Addiction 2015). Although other substances were present in most fatal cases, 4,4′-DMAR was mentioned to be the cause of death or to have played a contributory role in several of these fatalities (European Monitoring Centre for Drugs and Drug Addiction 2015). Brain edema, seizures, hyperthermia, respiratory and cardiac arrest, and internal bleeding were all listed as adverse events or autopsy findings that were associated with the use of 4,4′-DMAR (European Monitoring Centre for Drugs and Drug Addiction 2015).
Phenmetrazine derivatives
Phenmetrazine is a reinforcing stimulant, which was previously used as an appetite suppressant before it was eventually withdrawn from the market (Chait et al. 1987). Phenmetrazine-derived designer drugs (Fig. 4) represent a relatively understudied class of drugs, among which 3-fluorophenmetrazine (3-FPM) use appears to be the most widespread.
Mechanism of action of phenmetrazine derivatives
Like the parent compound, ring-fluorinated derivatives of phenmetrazine are substrates at the NET and DAT, with minor substrate activity at the SERT (Mayer et al. 2018; Rothman et al. 2002). Ring-methylated phenmetrazine derivatives were reported to have greater potency at the SERT, in addition to activity at the NET and DAT (McLaughlin et al. 2018). Para-substituted compounds were shown to have the greatest serotonergic effects among the phenmetrazine derivatives, similar to ring-substituted amphetamine and cathinone designer drugs (Luethi et al. 2019b; Rickli et al. 2015a).
Adverse effects of phenmetrazine derivatives
Based on their mechanism of action, phenmetrazine designer drugs are expected to elicit stimulatory toxicity that is similar to amphetamines. A series of non-fatal intoxications that involved 3-FPM were reported within the Swedish STRIDA project, mostly with sympathomimetic adverse effects (Bäckberg et al. 2016). However, polydrug intoxication prevented attribution of the observed effects to 3-FPM, underscored by the fact that the clinical features included some oppositional effects (e.g., both miotic and dilated pupils and both hypertension and hypotension) (Bäckberg et al. 2016). Nevertheless, the authors of this case series suggested that 3-FPM is a harmful compound, as one-third of patients presented severe adverse events (Bäckberg et al. 2016). In addition to other polydrug intoxications that involve 3-FPM (Benesch and Iqbal 2018; Ellefsen et al. 2017), a case of severe kidney injury and limb ischemia that were associated with intravenous 3-FPM use was reported (Fawzy et al. 2017). The authors of the latter case report hypothesized that the intravenous use of 3-FPM resulted in severe vasoconstriction, possibly with concomitant infection, and caused widespread ischemia (Fawzy et al. 2017).
Thiophene designer drugs
Various analogs of amphetamines and cathinones with a thiophene group that replaces the phenyl ring have appeared as designer drugs (Fig. 4). Some of the thiophene designer drugs were first described in the 1940s and elicited effects that were reported to be comparable to their phenyl ring analogs (Alles and Feigen 1941; Blicke and Burckhalter 1942). To date, most pharmacological studies and toxicological reports involve methiopropamine (MPA), the thiophene analog of methamphetamine.
Mechanism of action of thiophene designer drugs
MPA is a quasi-equipotent inhibitor of norepinephrine and dopamine uptake and was reported to interact with various serotonergic, adrenergic, dopaminergic, N-methyl-d-aspartate (NMDA), and sigma-1 receptors (Iversen et al. 2013).
Adverse effects of thiophene designer drugs
MPA use has been associated with significant acute toxicity and psychotic, cardiovascular, and gastrointestinal symptoms, including agitation, anxiety, confusion, a lower level of consciousness, insomnia, visual hallucinations, elevations of creatine kinase, tachycardia, palpitations, chest tightness, nausea, and vomiting (Daveluy et al. 2016; Lee et al. 2014; White et al. 2019). However, for most intoxication cases, the use of multiple substances was reported, and the extent to which MPA contributed to the reported adverse effects remains unclear. A death from isolated MPA use was described, in which cardiac arrhythmia that induced cardiovascular collapse was named as the probable cause of death (Anne et al. 2015). Dopaminergic neurodegeneration and myocardial, renal, and gastrointestinal damage were observed in mice that were exposed to MPA (Foti et al. 2019; Nguyen et al. 2019).
Miscellaneous stimulants
Several designer drugs have appeared that do not belong to any classes that are discussed in the previous sections. Any substance that interacts with monoamine transporters may potentially be sold as a stimulant designer drug, even if it is not or only remotely chemically related to the widely used stimulant classes. One example of such a substance is the potent NET, DAT, and SERT blocker diclofensine, a tetrahydroisoquinoline derivative that was originally developed as an antidepressant (Luethi et al. 2018a).
Sedatives
Synthetic opioids
While being essential for pain treatment, the non-medical use of opioids has been a public health threat for centuries and includes the recreational use of illegal substances, the abuse of prescription medications, and drug adulteration with non-pharmaceutical opioids (Armenian et al. 2018b). Opioids induce euphoria, anxiolysis, feelings of relaxation, and drowsiness (Suzuki and El-Haddad 2017). Repeated use leads to the development of dependence. In recent years, the growing prevalence of non-pharmaceutical fentanyl, highly potent designer fentanyls, and other novel synthetic opioids (Fig. 5) has critically contributed to the opioid crisis, particularly in the United States (Daniulaityte et al. 2017; Denton et al. 2008; Lucyk and Nelson 2017; Peterson et al. 2016; Rudd et al. 2016; Scholl et al. 2018; Seth et al. 2018). Notably, fentanyl-type substances are often detected in fatalities that are presumably associated with intravenous heroin use (Gladden et al. 2019). The higher potency of fentanyl and its analogs compared with classic heroin results in a higher risk of overdose, particularly when they are mistaken for heroin. Fentanyl itself was first synthesized in 1960 and has become essential and widely used for intraoperative analgesia and in the form of transdermal patches for the management of chronic pain (Stanley 2014). Following its medical approval, reports of fentanyl misuse among clinicians and subsequently patients began to emerge, and several fentanyl analogs appeared on the illicit market (Armenian et al. 2018b; Suzuki and El-Haddad 2017). In Europe’s drug market, 49 new synthetic opioids were detected between 2009 and 2018, 34 of which are fentanyl derivatives (European Monitoring Centre for Drugs and Drug Addiction 2019).
Mechanism of action of synthetic opioids
Novel fentanyl analogs and other synthetic opioids interact with G protein-coupled opioid receptors in the brain and spinal cord as partial to full agonists at μ-, δ-, and κ-opioid receptor subtypes, with selectivity for the μ-opioid receptor (Armenian et al. 2018b; Baumann et al. 2018; Codd et al. 1995; Maguire et al. 1992; Prekupec et al. 2017). Multiple lines of evidence indicate that agonism at μ-opioid receptors drives the main pharmacological effects of opioids, including euphoria, analgesia, respiratory depression, and the development of dependence (Charbogne et al. 2014; Kieffer 1999). A detailed overview of signaling mechanisms and behavioral effects of opioid receptor activation is provided elsewhere (Al-Hasani and Bruchas 2011). In vitro pharmacological profiling appears to be only a limited predictor of the clinical potency of opioids (Baumann et al. 2018). However, rodent tail flick tests suggest mostly distinctively greater potencies of novel synthetic opioids compared with morphine (Armenian et al. 2018b). For example, the potency of fentanyl is reported to be 50- to 200-fold higher than morphine, and the potency of carfentanil is reported to be approximately 10,000 times higher than morphine (Armenian et al. 2018b; Concheiro et al. 2018; Suzuki and El-Haddad 2017). Several prescription opioids inhibit the NET and SERT and interact with 5-HT2 receptors (Codd et al. 1995; Rickli et al. 2018). Fentanyl has affinity for 5-HT1A and 5-HT2A receptors but is devoid of relevant monoamine transporter interactions (Barann et al. 2015; Rickli et al. 2018). No data are currently available on monoamine transporter interactions of designer opioids.
Adverse effects of synthetic opioids
Adverse effects of novel synthetic opioids include typical symptoms of opioid overdose, such as dizziness, a lower level of consciousness, miosis, central nervous system depression, respiratory depression, pulmonary edema, hypoxia, bradycardia, pruritus, nausea, vomiting, constipation, and also such symptoms as agitation, hypertension, and tachycardia (Armenian et al. 2017, 2018b; Bäckberg et al. 2015b; Domanski et al. 2017; Helander et al. 2014, 2016, 2017a; Jones et al. 2017; Müller et al. 2019; Schneir et al. 2017; Siddiqi et al. 2015; Wilde et al. 2020). Pulmonary edema, acute lung injury, diffuse alveolar hemorrhage, renal insufficiency, and rhabdomyolysis were also reported in patients who presented with designer opioid intoxication (Cole et al. 2015; Helander et al. 2016, 2017a). The synthetic opioid 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) has been associated with bilateral hearing loss and hearing disturbances, with likely irreversible and pronounced sensorineural hearing impairment in one case (Helander et al. 2014). Furthermore, acute skin and hair symptoms followed by severe delayed eye complications were reported in patients with confirmed MT-45 use; cataract surgery was required in two of these patients (Helander et al. 2017b). Remaining unclear, however, is whether the aforementioned complications are solely attributable to MT-45 toxicity. Serotonergic toxicity is one adverse effect that needs to be considered for opioid designer drugs when combined with other serotonergic agents (Baldo 2018; Rickli et al. 2018). Similar to traditional opioids, withdrawal from designer opioids may result in physiological and psychological distress (Siddiqi et al. 2015). Numerous fatalities have been attributed to either designer opioids alone or designer opioids combined with other psychoactive substances (Coopman et al. 2016a, b; Cunningham et al. 2016; Dussy et al. 2016; Dwyer et al. 2018; Elliott et al. 2016; Fels et al. 2017, 2019; Fort et al. 2016; Garneau et al. 2019; Gillespie et al. 1982; Guerrieri et al. 2017; Helander et al. 2017a; Karinen et al. 2014; Koch et al. 2018; Kriikku et al. 2019; Kronstrand et al. 2014; Krotulski et al. 2018; Martucci et al. 2018; McIntyre et al. 2015b, 2016, 2017; Mohr et al. 2016; Nash et al. 2019; Ojanperä et al. 2006; Papsun et al. 2016; Partridge et al. 2018; Poklis et al. 2016; Richeval et al. 2019; Ruan et al. 2016; Sofalvi et al. 2017; Staeheli et al. 2016; Swanson et al. 2017; Takase et al. 2016; Vorce et al. 2014; Yonemitsu et al. 2016). Frisoni and colleagues recently published an overview of opioid-related fatalities that were attributed to synthetic opioids (Frisoni et al. 2018). In addition to central nervous system and respiratory depression, chest wall rigidity after intravenous use could be a cause of death in synthetic opioid overdose cases (Burns et al. 2016). The competitive μ-opioid receptor antagonist naloxone rapidly reverses central and peripheral effects of opioids and is thus an effective antidote for opioid toxicity (Armenian et al. 2018b). The initial care of patients who are intoxicated with designer opioids should focus on airway protection and maintaining breathing and circulation (Armenian et al. 2018b). Naloxone should be administered as soon as possible (Armenian et al. 2018b; Kim and Nelson 2015).
Designer benzodiazepines
In 1960, chlordiazepoxide became the first of several medically approved benzodiazepines that today represent a widely prescribed class of drugs for the treatment of psychiatric and neurological conditions, particularly insomnia and anxiety disorders (Longo and Johnson 2000; Sternbach 1979). Benzodiazepine abuse is frequent. The main reasons for such abuse are to facilitate sleep, cope with stress, ease effects of stimulants, self-treat withdrawal symptoms, and get high (Kapil et al. 2014; Vogel et al. 2013; Zawilska and Wojcieszak 2019). Benzodiazepines have limited potential as euphoriants when administered alone. When taken in combination with opioids, however, benzodiazepines appear to enhance the euphoric effects of opioid use (Jones et al. 2012). Since 2007, several benzodiazepine designer drugs (Fig. 5) have become available, some of which are precursors or metabolites of prescription benzodiazepines and are approved for medical use in other countries (Bäckberg et al. 2019; Manchester et al. 2018). Effects of designer benzodiazepines reported on internet forums resemble those of prescription benzodiazepines (El Balkhi et al. 2020). Chronological overviews of the appearance of benzodiazepine designer drugs on the recreational drug market were recently published (Manchester et al. 2018; Moosmann and Auwärter 2018).
Mechanism of action of designer benzodiazepines
The mechanism of action of most benzodiazepine designer drugs currently remains understudied. In silico experiments suggest that they mediate their effects through interactions at γ-aminobutyric acid-A (GABAA) receptors such as prescription benzodiazepines (Waters et al. 2018). GABAA receptors are ion channels that consist of pentamers of different subunit compositions, responding to the inhibitory neurotransmitter GABA. Benzodiazepines enhance the effects of GABA as positive allosteric modulators by binding to a receptor site that is different from the binding site of GABA (Manchester et al. 2018; Moosmann and Auwärter 2018).
Adverse effects of designer benzodiazepines
Despite their depressive actions on central nervous system function and respiration, the isolated use of benzodiazepines is rarely fatal. However, in reported intoxication cases, designer benzodiazepines have mostly been detected in combination with other psychoactive substances, such as stimulants or depressants (Bäckberg et al. 2019). The concurrent use of benzodiazepines and other depressants, such as opioids and alcohol, may produce prolonged and potentially fatal respiratory depression (Jones et al. 2012; Zawilska and Wojcieszak 2019). Reported adverse effects of isolated benzodiazepine designer drugs are typical for a sedative-hypnotic toxidrome but may include atypical symptoms in some cases, such as agitation, hyperthermia, and tachycardia (Bäckberg et al. 2019; Carpenter et al. 2019; Zawilska and Wojcieszak 2019). The recent review by Zawilska and Wojcieszak mentioned the following adverse effects of designer benzodiazepines: fatigue, impairment of thinking, confusion, dizziness, drowsiness, lethargy, amnesia, blurred vision, slurred speech, palpitations, and muscle weakness, as well as auditory and visual hallucinations, delirium, seizures, deep sleep, and coma at high doses (Zawilska and Wojcieszak 2019). The chronic use of designer benzodiazepines may also lead to the development of tolerance and dependence (Zawilska and Wojcieszak 2019). Withdrawal symptoms, such as anxiety, panic attacks, restlessness, insomnia, seizures, and life-threatening convulsions, may follow the abrupt cessation of chronic designer benzodiazepines use (Andersson and Kjellgren 2017; Zawilska and Wojcieszak 2019). Designer benzodiazepines have been reported to contribute to numerous deaths (Bailey et al. 2010; Crichton et al. 2015; Domingo et al. 2017; Karinen et al. 2014; Koch et al. 2018; Liveri et al. 2016; Maskell et al. 2011b; Papsun et al. 2016; Partridge et al. 2018; Shearer et al. 2015; Tanaka et al. 2011a, b). In a few cases, the cause of death was solely attributed to the designer benzodiazepine phenazepam (Crichton et al. 2015; Shearer et al. 2015) or etizolam (Carpenter et al. 2019). A more detailed summary of benzodiazepine-related fatalities was recently published (Zawilska and Wojcieszak 2019).
γ-Aminobutyric acid analogs
γ-Hydroxybutyrate (GHB) is a short-chain fatty acid analog of the inhibitory neurotransmitter GABA. It has become popular among drug users because of its ability to induce feelings of euphoria and relaxation, reduce social anxiety, and increase sexual drive (Brennan and Van Hout 2014; Brown et al. 2011). Although it is an endogenous compound and its sodium salt is approved as a prescription drug against narcolepsy, GHB and its metabolic precursors (e.g., γ-butyrolactone [GBL] and 1,4-butanediol [1,4-BD]) are often referred to as designer drugs because of their widespread illicit production in clandestine laboratories (Brennan and Van Hout 2014; Fuller et al. 2004). Other structural analogs of GABA that have become available as designer drugs (Fig. 5) include the 4-methyl-substituted GHB derivative γ-hydroxyvaleric acid (GHV) and 4-amino-3-phenyl-butyric acid (phenibut) (Carter et al. 2005; Owen et al. 2016).
Mechanism of action of GABA analogs
Metabotropic G protein-coupled GABAB receptors are the primary targets of designer drug analogs of GABA (Brennan and Van Hout 2014; Carai et al. 2001; Lapin 2001). Other postulated mechanisms of action include high-affinity binding to receptor sites that are distinct from the GABAB receptor (i.e., GHB receptors), binding to specific GABAA receptor subtypes, and monoaminergic modulation (Bay et al. 2014; Carter et al. 2009; Crunelli et al. 2006; Lapin 2001; Wood et al. 2011).
Adverse effects of GABA analogs
Comprehensive reviews of the potential clinical complications of the use of GHB and its metabolic precursors are provided elsewhere (Busardò and Jones 2015; Schep et al. 2012). The subjective benefits of GHB and its analogs outweigh adverse events only over a narrow range of doses. Adverse events include a lower level of consciousness, hypothermia, respiratory depression, aspiration, bradycardia, gastrointestinal upset, and nonsedative adverse effects, such as agitation, seizures, and myoclonus (Busardò and Jones 2015; Isoardi et al. 2020; Liakoni et al. 2016; McCabe et al. 2019; Schep et al. 2012; Zvosec and Smith 2005). These adverse effects typically have a relatively short duration and are usually managed with supportive care (Busardò and Jones 2015; Schep et al. 2012; Wood et al. 2011). GABAB and monocarboxylate transporter inhibitors have been proposed as potential treatment options for GHB-induced respiratory depression (Morse et al. 2012). GHB and its analogs are associated with the rapid development of tolerance. Abrupt cessation after regular use may trigger a potentially life-threatening withdrawal syndrome that can manifest as agitation, anxiety, confusion, disorientation, paranoia, aggression, insomnia, auditory and visual hallucinations, tremors, sweating, hypertension, and tachycardia (Busardò and Jones 2015; Owen et al. 2016; Schep et al. 2012; Wood et al. 2011). Benzodiazepines appear to be the treatment of choice for withdrawal from GHB and its analogs (Busardò and Jones 2015; Schep et al. 2012; Wood et al. 2011). Zvosec and colleagues reported a series of 226 GHB-associated deaths, 213 of which were attributed to cardiorespiratory arrest and 13 of which were attributed to fatal accidents (Zvosec et al. 2011). In approximately one-third of these fatal cases, GHB was the sole toxicant detected (Zvosec et al. 2011). Similar findings were reported by Corkery and colleagues, who reported a series of 159 GHB and GBL-associated fatalities (Corkery et al. 2015). The co-ingestion of opioids increases the depressant toxicity of GHB, and stimulant intake does not appear to prevent GHB toxicity (Knudsen et al. 2010).
Dissociatives
Arylcyclohexylamine and diarylethylamine designer drugs
Dissociative agents are appreciated in medicine because of their unique pharmacological effects. These pharmacological effects, however, are also popular among recreational drug users. The dissociative anesthetic ketamine produces analgesia without cardiovascular or respiratory depression at doses that produce anesthesia, a feature that is not shared by other common anesthetics (Li and Vlisides 2016). Furthermore, ketamine induces rapid and sustained antidepressant actions at a single sub-anesthetic dose and has become a widely abused recreational drug because of its dissociative effects, including sensory and tactile distortions, euphoria, and depersonalization (Li and Vlisides 2016; Zanos and Gould 2018). Ketamine was first synthesized in 1962 as a short-acting anesthetic with lower potency in producing emergence delirium compared with the structurally similar phencyclidine (PCP). PCP was developed before ketamine as a promising dissociative anesthetic, but its use in humans and animals was discontinued because of its unfavorable side effects (Domino 1980). Various similar substances have been clinically investigated. Dissociatives began to appear on the illicit drug market in the late 1960s (Morris and Wallach 2014). Today, several dissociative designer drugs (Fig. 6) are available, mostly arylcyclohexylamines (e.g., ketamine and PCP) and diarylethylamines. Morris, Wallach, and Brandt previously published comprehensive overviews of the history, availability, and use of several arylcyclohexylamine and diarylethylamine designer drugs and other dissociative agents (Morris and Wallach 2014; Wallach and Brandt 2018a, b).
Mechanism of action of arylcyclohexylamine and diarylethylamine designer drugs
Similar to ketamine and PCP, dissociative arylcyclohexylamine and diarylethylamine designer drugs act as relatively selective noncompetitive antagonists at ionotropic glutamatergic NMDA receptors. Their NMDA receptor affinity is strongly correlated with their clinical potency in inducing dissociative effects in vivo (Anis et al. 1983; Morris and Wallach 2014; Wallach et al. 2016). Some dissociative designer drugs also moderately inhibit the reuptake of norepinephrine and dopamine, whereas others have appreciable affinity for the SERT (Luethi et al. 2018a; Roth et al. 2013; Wallach et al. 2016). Binding affinity at various receptors, including α adrenergic, serotonergic, histaminergic, cholinergic, opioidergic, and sigma receptors, has been reported for arylcyclohexylamines and diarylethylamines (Luethi et al. 2018a; Roth et al. 2013; Wallach et al. 2016). Summarized, NMDA receptor antagonism mainly mediates the dissociative effects of arylcyclohexylamines and diarylethylamines, and interactions with other pharmacological targets may modify the activity of different compounds.
Adverse effects of arylcyclohexylamine and diarylethylamine designer drugs
Adverse effects of dissociative arylcyclohexylamine and diarylethylamine designer drugs resemble adverse effects of traditional dissociatives, including agitation, confusion, disorientation, dissociation, hallucinations, amnesia, nystagmus, slurred speech, diaphoresis, hypertension, tachycardia, renal deficiency, nausea, ataxia, and muscle rigidity (Bäckberg et al. 2015a; Dunlop et al. 2019; Gerace et al. 2017; Helander et al. 2015; Hofer et al. 2012, 2014; Johansson et al. 2017; Shields et al. 2012; Thornton et al. 2017; Ward et al. 2011; Wood et al. 2012; Zawilska 2014; Zidkova et al. 2017). In severe cases, dissociative designer drugs may potentially cause neurological impairment, manifested as cerebellar toxicity (Shields et al. 2012) or rhabdomyolysis (Bäckberg et al. 2015a; Lam et al. 2016). Severe adverse effects associated with inhalation of the designer drug methoxetamine include seizures, hyponatremia, and sinus bradycardia (Imbert et al. 2014). Regular ketamine use has been associated with potentially irreversible bladder dysfunction and subsequent renal impairment (Chu et al. 2007; Tsai et al. 2009). Animal studies suggest that this may also be a consequence of regular methoxetamine use (Dargan et al. 2014; Wang et al. 2017). In a survey of methoxetamine users, approximately one-fourth reported urinary symptoms (Lawn et al. 2016). The prevalence of urinary symptoms was related to the frequency of methoxetamine use during the previous month, but prior ketamine use could have also contributed to these symptoms (Lawn et al. 2016). Other dissociative designer drugs may also cause such severe urinary tract dysfunction, but detailed research has not been conducted. Additionally, the acute and chronic use of dissociative designer drugs potentially elicits wide-ranging effects on memory systems, similar to ketamine (Morgan and Curran 2006). Dissociative designer drugs have been involved in numerous fatal intoxications, mostly in combination with other designer drugs, including stimulants, opioids, cannabinoids, and psychedelics (Adamowicz and Zuba 2015; Bakota et al. 2016; Chiappini et al. 2015; De Jong et al. 2019; Elliott et al. 2015; Johansson et al. 2017; Krotulski et al. 2018; Kudo et al. 2015; Kusano et al. 2018; McIntyre et al. 2015c; Mitchell-Mata et al. 2017; Wiergowski et al. 2014; Wikström et al. 2013). Wallach and Brandt previously published a detailed overview of the clinical toxicology of individual PCP analogs (Wallach and Brandt 2018b) and diarylethylamine- and ketamine-based designer drugs (Wallach and Brandt 2018a).
Synthetic cannabinoids
The endocannabinoid system is involved in various physiological functions, including cognition, behavior, memory, motor control, pain sensation, appetite, cardiovascular parameters, gastrointestinal motility, and immunoregulation (Le Boisselier et al. 2017). The term “cannabinoid” refers to a class of compounds that are produced by Cannabis sativa and Cannabis indica, and endogenous and exogenous ligands that interact with G protein-coupled cannabinoid type 1 (CB1) and CB2 receptors (Banister and Connor 2018; Le Boisselier et al. 2017). CB1 receptors are mainly expressed in the brain and modulate neurotransmitter signaling, whereas CB2 receptors are abundant in immune tissues (Banister and Connor 2018; Le Boisselier et al. 2017). The first synthetic cannabinoids were developed in the second half of the twentieth century to study human endocannabinoid receptor systems (Banister and Connor 2018; Le Boisselier et al. 2017; Trecki et al. 2015). Today, synthetic cannabinoids (Fig. 7) represent the largest and most structurally diverse class of designer drugs, and some of these compounds are similar to phyto- and endocannabinoids (Banister and Connor 2018; Trecki et al. 2015). Synthetic cannabinoids are often referred to as “Spice,” based on the first branded synthetic cannabinoid product. They are commonly applied to dried herbs that mimic cannabis (Banister and Connor 2018; Le Boisselier et al. 2017; Trecki et al. 2015). Desired effects of synthetic cannabinoids include relaxation, euphoria, and disinhibition, thus not significantly differing from desired effects of Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive constituent of cannabis (Le Boisselier et al. 2017). However, compared with cannabis, synthetic cannabinoids have a less desirable effect profile and are associated with more severe adverse events that sometimes can result in death (Trecki et al. 2015; Winstock and Barratt 2013).
Mechanism of action of synthetic cannabinoids
Various synthetic cannabinoids have been reported to bind to CB1 and CB2 receptors with higher efficacy at both receptors compared with Δ9-THC (Banister et al. 2015a, b, 2016, 2019; Gamage et al. 2018; Sachdev et al. 2019). Biased signaling at cannabinoid receptors or the disruption of mitochondrial homeostasis may play a role in the difference between clinical effects of Δ9-THC and synthetic cannabinoids, but research in this area is still in its infancy (Finlay et al. 2019; Silva et al. 2018, 2019). CB1 receptors are involved in multiple mechanisms that lead to the suppression of synaptic transmission. Compared with CB2 receptor expression, the predominance of CB1 receptors in the central nervous system indicates that they mainly mediate the psychoactive effects of synthetic cannabinoids (Atwood et al. 2010; Castillo et al. 2012; Kano et al. 2009; Le Boisselier et al. 2017). This assumption is strengthened by studies that reported that CB1 receptor antagonism but not CB2 receptor antagonism inhibits the synthetic cannabinoid-induced lowering of heart rate and body temperature in rodents (Banister et al. 2015a, 2019a). In vitro studies showed that various metabolites of synthetic cannabinoids retain some cannabimimetic activity, indicating that they could contribute to the pharmacological effects of the drugs (Longworth et al. 2017). In contrast, some substances that are promoted as cannabinoid designer drugs have only low in vitro affinity for cannabinoid receptors and fail to exert significant cannabinoid activity in vivo, thus calling into question their classification as synthetic cannabinoids (Banister et al. 2019b). Only a few synthetic cannabinoids have been studied to date with regard to their interactions with non-cannabinoid targets, with low or no affinity for most major neurotransmitter receptors (Wiley et al. 2016). This suggests that different effects of synthetic cannabinoids compared with Δ9-THC are mainly related to greater potency and efficacy at CB1 receptors, but possible effects on non-cannabinoid receptors and different signaling pathways that have not yet been discovered cannot be ruled out (Finlay et al. 2019; Wiley et al. 2016). Furthermore, pharmacokinetic differences may contribute to these differences.
Adverse effects of synthetic cannabinoids
The most common adverse effects of synthetic cannabinoids include agitation, drowsiness, dizziness, confusion, hallucinations, hypertension, tachycardia, chest pain, nausea, and vomiting, which typically have a short duration and require only symptomatic or supportive treatment (Forrester 2012a; Forrester et al. 2011, 2012; Hoyte et al. 2012; Law et al. 2015; Tait et al. 2016). Nevertheless, compared with cannabis, complications that are associated with synthetic cannabinoid use are more frequent and in some cases, more severe (Alipour et al. 2019; Bäckberg et al. 2017; Mensen et al. 2019; Tait et al. 2016; Trecki et al. 2015). Various severe adverse events that are associated with synthetic cannabinoids have been reported. However, many of these cases were attributed to synthetic cannabinoid use based solely on statements by patients or witnesses, without analytical confirmation of the identity and amount of substances in bodily fluids or remaining drug products. Severe clinical complications that have been reported to be associated with synthetic cannabinoid use include convulsions and seizures (Adamowicz et al. 2017; Bäckberg et al. 2017; Bebarta et al. 2012; De Havenon et al. 2011; Gugelmann et al. 2014; Harris and Brown 2013; Hermanns-Clausen et al. 2013a, b; Hoyte et al. 2012; Lapoint et al. 2011; McQuade et al. 2013; Pant et al. 2012; Schep et al. 2015; Schneir and Baumbacher 2012; Tofighi and Lee 2012), status epileptics (Babi et al. 2017), catatonia (Khan et al. 2016; Leibu et al. 2013; Smith and Roberts 2014), delirium (Armenian et al. 2018a; Armstrong et al. 2019; Bäckberg et al. 2017; Schwartz et al. 2015; Tyndall et al. 2015), ischemic stroke (Bernson-Leung et al. 2014; Faroqui et al. 2018; Freeman et al. 2013; Moeller et al. 2017; Raheemullah and Laurence 2016; Takematsu et al. 2014; Wolff and Jouanjus 2017), intracranial hemorrhage (Aydin and Bakar 2019; Rose et al. 2015), pulmonary embolism (Raheemullah and Laurence 2016; Yirgin et al. 2018), pneumonia and pulmonary infiltrates (Alhadi et al. 2013; Alon and Saint-Fleur 2017; Berkowitz et al. 2015; Chinnadurai et al. 2016; Öcal et al. 2016), respiratory depression (Alon and Saint-Fleur 2017; Jinwala and Gupta 2012), supraventricular and ventricular arrhythmias (Davis and Boddington 2015; Ibrahim et al. 2014; Ozturk et al. 2019; Young et al. 2012), myocardial ischemia and infarction (Clark et al. 2015; Hamilton et al. 2017; Hirapara and Aggarwal 2015; McIlroy et al. 2016; McKeever et al. 2015; Mehta et al. 2017; Mills et al. 2018; Mir et al. 2011; Ozturk et al. 2019; Shah et al. 2016; Sherpa et al. 2015; Tse et al. 2014), takotsubo cardiomyopathy (Mohammed 2019), liver injury (Shahbaz et al. 2018), acute kidney injury (Argamany et al. 2016; Armstrong et al. 2019; Bhanushali et al. 2013; Buser et al. 2014; El Zahran et al. 2019; Gudsoorkar and Perez 2015; Kamel and Thajudeen 2015; Katz et al. 2016b; Kazory and Aiyer 2013; Srisung et al. 2015; Thornton et al. 2013; Zarifi and Vyas 2017; Zhao et al. 2015), hyperemesis syndrome (Argamany et al. 2016; Bick et al. 2014; Hopkins and Gilchrist 2013; Ukaigwe et al. 2014), and rhabdomyolysis (Adedinsewo et al. 2016; Argamany et al. 2016; Armstrong et al. 2019; Durand et al. 2015; El Zahran et al. 2019; Katz et al. 2016b; Sherpa et al. 2015; Sweeney et al. 2016; Zhao et al. 2015). Furthermore, various psychiatric adverse effects have been reported, including paranoia, psychosis, and ideations of self-harm and suicide (Akram et al. 2019; Altintas et al. 2016; Bassir Nia et al. 2019; Benford and Caplan 2011; Berry-Caban et al. 2013; Bonaccorso et al. 2018; Darke et al. 2019; Deng et al. 2018; Derungs et al. 2013; Durand et al. 2015; Every-Palmer 2010; Glue et al. 2013; Hermanns-Clausen et al. 2013b; Hobbs et al. 2018; Hurst et al. 2011; Kraemer et al. 2019; Martinotti et al. 2017; Meijer et al. 2014; Mensen et al. 2019; Müller et al. 2010; Oliveira et al. 2017; Oluwabusi et al. 2012; Papanti et al. 2013; Patton et al. 2013; Peglow et al. 2012; Roberto et al. 2016; Skryabin and Vinnikova 2019; Sweet et al. 2017; Thomas et al. 2012; Van Amsterdam et al. 2015; Van der Veer and Friday 2011; Welter et al. 2017; Yeruva et al. 2019). The sudden discontinuation of synthetic cannabinoid use in regular
Psychedelics
Serotonergic psychedelics induce alterations of perception and cognitive states in users (Nichols 2004, 2016). Traditional psychedelics, such as the phenethylamine 3,4,5-trimethoxyphenethylamine (mescaline), the tryptamines N,N-dimethyltryptamine (DMT) and psilocybin, and the ergot alkaloid lysergic acid diethylamide (LSD), have a history of being used for religious purposes, as therapeutic agents, and as illicit black market drugs. Although psychedelics interact with various pharmacological targets, their psychedelic effects are mainly mediated by 5-HT2A receptor agonism (Geyer and Vollenweider 2008; Kraehenmann et al. 2017; Madsen et al. 2019; Nichols 2004, 2016; Preller et al. 2018; Vollenweider et al. 1998). Affinity for 5-HT2A and 5-HT2C receptors is correlated with the amount of drug that induces psychedelic effects in humans (Fig. 8) (Luethi and Liechti 2018). Designer drug analogs of all the traditional psychedelic drugs are available, some of which were originally developed by industry or university laboratories but have eventually found their way onto the illicit drug market.
Phenethylamines
Derivatives of mescaline comprise a large amount of psychedelic designer drugs (Fig. 9). The most widespread phenethylamine psychedelics are 2,5-dimethoxyphenethylamines, which bear a small lipophilic substituent at the 4-position (referred to as 2C series because they bear two carbon atoms between the benzene ring and amino group), and their slightly more potent α-methyl (amphetamine) analogs (Shulgin and Shulgin 1995). Psychedelic phenethylamine derivatives are mostly but not exclusively chemically modified at the phenyl ring. The introduction of an N-benzylmethoxy (“NBOMe”) group has been shown to increase the potency of the resulting derivatives (Eshleman et al. 2018; Halberstadt 2017; Heim 2004; Rickli et al. 2015c). The incorporation of 2′- and 5′-methoxy groups into rigid rings resulted in tetrahydrobenzodifuran and benzodifuran analogs that have been sold as designer drugs. These tetrahydrobenzodifuran and benzodifuran designer drugs are referred to as “FLY” and “dragonFLY” analogs, respectively, because of the shape of their chemical structure (Halberstadt et al. 2019; Trachsel et al. 2013). In one of the few clinical studies of a designer drug, 4-bromo-2,5-dimethoxyphenylethylamine (2C-B) was shown to induce euphoria, well-being, and changes in perception, and to have mild stimulant properties (González et al. 2015). 2C-B may thus be classified as a psychedelic with entactogenic properties, an effect profile that is similar to various other phenethylamine psychedelics (Shulgin and Shulgin 1995).
Mechanism of action of phenethylamines
Similar to other psychedelics, substituted phenethylamines mainly interact with serotonergic receptors, with the highest affinity for 5-HT2A receptors (Eshleman et al. 2018; Kolaczynska et al. 2019; Luethi et al. 2018d; Rickli et al. 2015c). NBOMe derivatives have higher affinity for 5-HT2A and 5-HT2C receptors and lower affinity for 5-HT1A receptors compared with their 2C analogs (Rickli et al. 2015c). At 5-HT2A receptors, 2C and NBOMe derivatives were shown to be partial or full agonists, depending on the functional in vitro assay (Eshleman et al. 2014, 2018; Jensen et al. 2017; Kolaczynska et al. 2019; Luethi et al. 2018d, 2019c; Moya et al. 2007; Rickli et al. 2015c). NBOMe derivatives and most 2C derivatives have been shown to be partial agonists at 5-HT2B receptors (Eshleman et al. 2018; Jensen et al. 2017; Kolaczynska et al. 2019; Luethi et al. 2018d; Rickli et al. 2015c). At 5-HT2C receptors, 2C derivatives were shown to be partial or full agonists (Eshleman et al. 2014; Moya et al. 2007), and NBOMe derivatives were shown to be full agonists (Eshleman et al. 2018; Jensen et al. 2017). Consistent with the in vitro findings, psychedelic phenethylamines were shown to induce 5-HT2A-dependent behaviors in vivo, such as wet dog shakes, back muscle contractions, and a head twitch response (Elmore et al. 2018; Fantegrossi et al. 2005; Halberstadt et al. 2020; Halberstadt and Geyer 2014). In addition to interactions with serotonergic receptors, phenethylamine psychedelics have been shown to interact with other monoaminergic targets, including adrenergic, dopaminergic, and histaminergic receptors, monoamine transporters, and MAOs (Eshleman et al. 2018; Kolaczynska et al. 2019; Luethi et al. 2018d; Noble et al. 2018; Rickli et al. 2015c; Wagmann et al. 2019a). However, most of these interactions are weak compared with the potent interactions with serotonergic receptors. Therefore, they most likely have little or no pharmacological relevance to the actions of phenethylamine psychedelics. Rodent studies have suggested reinforcing effects for NBOMe derivatives that involve the dopaminergic system (Custodio et al. 2019; Seo et al. 2019). The NBOMe derivative 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) was shown to increase extracellular dopamine, 5-HT, and glutamate levels in the rat frontal cortex (Herian et al. 2019), but unknown are the ways in which these findings translate to humans.
Adverse effects of phenethylamines
Most of the frequently reported adverse effects of phenethylamine psychedelics are shared by psychedelics of other chemical classes, including agitation, hallucinations, drowsiness, confusion, mydriasis, aggression, hyperthermia, hypertension, and tachycardia (Dean et al. 2013; Forrester 2013, 2014; Hermanns-Clausen et al. 2017; Hill et al. 2013; Iwersen-Bergmann et al. 2019; Rose et al. 2013; Srisuma et al. 2015; Stellpflug et al. 2014; Stoller et al. 2017; Tang et al. 2014; Topeff et al. 2011; Wood et al. 2015). Moreover, severe adverse effects have been linked to the use of psychedelic phenethylamines, including acute psychosis, seizures, coma, cerebral edema, long-lasting severe neurological impairment, serotonin syndrome, prolonged respiratory failure, renal failure, multi-organ failure, metabolic acidosis, and rhabdomyolysis (Bosak et al. 2013; Grautoff and Kähler 2014; Halberstadt 2017; Huang and Bai 2011; Miyajima et al. 2008; Srisuma et al. 2015; Tang et al. 2014; Wood et al. 2009). Furthermore, 1-(4-bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (Bromo-dragonFLY) has been associated with potent vasoconstriction, ischemia, and tissue necrosis in patients, which may be caused by the activation of serotonergic and adrenergic receptors combined with metabolic stability and long-lasting effects (Hill and Thomas 2011; Noble et al. 2018; Thorlacius et al. 2008; Wood et al. 2009). A remarkable case of mass intoxication with 4-ethyl-2,5-dimethoxyphenethylamine (2C-E) and Bromo-dragonFLY among 29 attendees of an esoteric weekend seminar was reported (Iwersen-Bergmann et al. 2019). Upon the arrival of paramedics, some of the seminar attendees were rolling on the ground and screaming, and others were unconscious or unresponsive. Several attendees exhibited severe delusions and physical symptoms, including generalized seizures, pain, respiratory distress, and tachycardia (Iwersen-Bergmann et al. 2019). In some severe cases, the use of psychedelic phenethylamines has even resulted in death (Curtis et al. 2003; Kueppers and Cooke 2015; Poklis et al. 2014; Shanks et al. 2015a; Topeff et al. 2011; Walterscheid et al. 2014). Adverse effects of different phenethylamine designer drugs are mostly comparable. However, a higher incidence of hallucinations, delusions, and single-episode seizures has been observed for NBOMe derivatives compared with 2C derivatives (Srisuma et al. 2015). This may be explained by the higher potency of NBOMe derivatives compared with most other phenethylamine psychedelics (Braden et al. 2006; Elmore et al. 2018; Halberstadt and Geyer 2014; Rickli et al. 2015c). Several reports have linked severe intoxication to substituted phenethylamines, but the lack of analytical confirmation of the drug prevents the direct attribution of adverse effects to phenethylamines. For example, a 43-year-old woman was reported to have developed severe headaches, progressive encephalopathy, and quadraparesis within 48 h after taking a liquid form of 2C-B that was synthesized according to a manual on the Internet (Ambrose et al. 2010). However, the patient’s urine tested positive for cannabinoids only, and a sample of the ingested drug could not be obtained for analysis (Ambrose et al. 2010). Similarly, a patient presented to an emergency department with hallucinations and agitation that progressed to status epilepticus after using of 4-chloro-2,5-dimethoxyamphetamine (DOC). In addition to the analytically confirmed presence of DOC, however, the toxicology screen was positive for cannabinoids and opioids, thus hampering the attribution of seizure development to DOC (Burish et al. 2015). Additionally, several fatalities from 2C derivative use have been reported in the media, but the accuracy of this information cannot be verified (Dean et al. 2013).
Tryptamines
The core structure of tryptamine designer drugs contains an indole ring that is connected to an amino group by an ethyl side chain, a structural feature that is shared by 5-HT. DMT as an ingredient in the psychoactive brew ayahuasca and psilocybin that is contained in Psilocybe spp. mushrooms have been used in sociocultural and ritual contexts since ancient times. They have recently regained interest for their therapeutic use (Araújo et al. 2015; Carhart-Harris et al. 2018; Muttoni et al. 2019; Palhano-Fontes et al. 2019; Roseman et al. 2017). In addition to naturally occurring compounds, psychedelic properties of various synthetic tryptamines (Fig. 9) have been described (Shulgin and Shulgin 1997).
Mechanism of action of tryptamines
Similar to other psychedelics, 5-HT2A receptor agonism plays a key role in mediating the psychedelic effects of naturally occurring and synthetic tryptamine psychedelics (Fantegrossi et al. 2008; Halberstadt 2016; Madsen et al. 2019; Vollenweider et al. 1998). Although mediating opposing functional effects on 5-HT2A receptors, the concurrent activation of 5-HT1A receptors has been suggested to contribute to the qualitative effects of tryptamine psychedelics, distinguishing them from phenethylamine psychedelics (Fantegrossi et al. 2008; Halberstadt and Geyer 2011; Nichols 2004, 2016; Winter et al. 2000). Most traditional and novel tryptamine psychedelics bind to 5-HT1A and 5-HT2A receptors with similar affinity. Some tryptamines are slightly more selective for one or the other receptor subtype (Rickli et al. 2016). However, various tryptamine psychedelics have been reported to be inactive at the 5-HT1A receptor in functional assays at relevant concentrations (EC50 > 10 μM) or act as mostly partial agonists with significantly lower potency compared with 5-HT2A receptors, at which tryptamine psychedelics act as moderate to full agonists (Blough et al. 2014; Rickli et al. 2016). At 5-HT2B receptors, traditional and novel tryptamine psychedelics have very heterogeneous profiles, with different potencies and efficacies. For example, 5-methoxy-α-methyltryptamine (5-MeO-αMT) is a potent 5-HT2B receptor full agonist with an EC50 in the low nanomolar range, whereas psilocin and 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET) are inactive at the 5-HT2B receptor (EC50 > 20 μM) (Rickli et al. 2016). Tryptamine designer drugs have been shown to bind to 5-HT2C receptors but with slightly lower affinity compared with 5-HT2A receptors (Rickli et al. 2016). In addition to their primary effects at serotonergic receptors, tryptamines have been shown to bind to various targets in vitro, including adrenergic, dopaminergic, and histaminergic receptors (Klein et al. 2018; Rickli et al. 2016). Furthermore, unlike phenethylamine or lysergamide psychedelics, many tryptamine psychedelics interact with monoamine transporters at pharmacologically relevant concentrations. In addition to some interactions with the DAT and NET for some compounds, tryptamines have the most potent transporter interactions at the SERT (Blough et al. 2014; Cozzi et al. 2009; Rickli et al. 2016). DMT and other tryptamine psychedelics have been reported to elicit 5-HT efflux, suggesting that they are transporter substrates (Blough et al. 2014; Cozzi et al. 2009; Rickli et al. 2016). In contrast, other tryptamine psychedelics, including psilocin, act as transporter inhibitors that are devoid of substrate activity (Rickli et al. 2016). In addition to interactions with transmembrane monoamine transporters, substrate activity at the VMAT has been described for tryptamine psychedelics (Cozzi et al. 2009). Tryptamines are prone to metabolism by MAOs, and MAO inhibitors counteract extensive degradation of tryptamines after oral use (Halberstadt et al. 2012; Ott 1999, 2001; Riba et al. 2015).
Adverse effects of tryptamines
Similar to other psychedelics, tryptamine psychedelics alter perception and can induce psychological disturbances in users, including acute psychosis (Meatherall and Sharma 2003; Nichols 2004, 2016; Shulgin and Shulgin 1997; Taljemark and Johansson 2012). Adverse effects of tryptamine designer drugs include restlessness, disorientation, clouding of consciousness, confusion, hallucinations, amnesia, catalepsy, mydriasis, tachypnea, hypertension, and tachycardia (Alatrash et al. 2006; Itokawa et al. 2007; Jovel et al. 2014; Muller 2004; Smolinske et al. 2005). 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) use has been associated with hallucinogen-persisting perception disorder and was proposed to play a role in the development of prolonged delusions (Fuse-Nagase and Nishikawa 2013; Ikeda et al. 2005). In severe cases, the use of tryptamine designer drugs has resulted in acute renal failure and rhabdomyolysis (Alatrash et al. 2006; Jovel et al. 2014). Furthermore, several fatalities after the use of tryptamine designer drugs have been reported (Boland et al. 2005; Sklerov et al. 2005; Tanaka et al. 2006).
Lysergamides
Several derivatives of LSD have been described in the scientific literature, and such derivatives are increasingly emerging as designer drugs (Fig. 9) (Brandt et al. 2016, 2017a, b, 2018, 2019; Shulgin and Shulgin 1997; Troxler and Hofmann 1957). The LSD-derived designer drugs 1-acetyl-LSD (ALD-52), 1-propionyl-LSD (1P-LSD), and 1-butyryl-LSD (1B-LSD) have been shown to be metabolized to LSD in vitro and are thus considered precursors of LSD with very similar effects (Wagmann et al. 2019b). Whereas self-reported effects of some LSD analogs are similar to LSD but with slightly weaker or less pleasurable effects, other LSD analogs have been reported to be distinctively less potent or significantly differ from LSD in terms of effects (Coney et al. 2017; Shulgin and Shulgin 1997).
Mechanism of action of lysergamides
Several LSD-derived designer drugs induce a head twitch response in mice, and pretreatment with a selective 5-HT2A receptor antagonist abolished the 1P-LSD-induced head twitch response (Brandt et al. 2017a; Brandt et al. 2016). This indicates that, similar to LSD, 5-HT2A receptor activation mediates the behavioral effects of LSD analogs (Kraehenmann et al. 2017; Liechti 2017; Preller et al. 2017, 2018). Additionally, 5-HT1A receptor activation likely contributes to the qualitative effects of lysergamide designer drugs similarly to LSD and tryptamine psychedelics (Fantegrossi et al. 2008; Halberstadt and Geyer 2011; Nichols 2004, 2016; Rickli et al. 2016; Winter et al. 2000). In addition to differences in affinity, LSD-derived designer drugs may activate 5-HT2A receptors with lower relative potency compared with LSD, but more research is needed to test this hypothesis (Brandt et al. 2017a). Furthermore, unclear are the ways in which the behavioral effects of lysergamide designer drugs in animals translate to humans.
Adverse effects of lysergamides
Little is known about the adverse effects of lysergamide designer drugs. One case of a 17-year-old male who developed anxiety, hallucinations, restlessness, elevations of blood pressure, palpitations, and tachycardia after ingesting 1P-LSD was reported (Grumann et al. 2019). 1P-LSD was confirmed as an ingredient of the ingested blotter paper but could not be detected in urine or serum samples, despite being sufficiently stable in these matrices. However, LSD was detected in both samples, thus strengthening the assumption that 1P-LSD is readily metabolized to LSD in humans (Grumann et al. 2019). The patient reported that he recently used the stimulant phenmetrazine derivative 3-FPM. The low serum concentrations of 3-FPM that were detected at the time of hospital admission are, however, not expected to result in acute effects (Grumann et al. 2019). The symptoms of this 1P-LSD intoxication case are consistent with reported adverse effects of LSD, which is known to potentially cause psychological disturbances and moderately increase body temperature, blood pressure, and heart rate (Dolder et al. 2016; Schmid et al. 2015). Acute physiological adverse effects of LSD include difficulty concentrating, imbalance, feelings of exhaustion, dizziness, headache, dry mouth, lack of appetite, and nausea (Dolder et al. 2016; Schmid et al. 2015). Nichols and Grob recently reviewed the risk of LSD toxicity in users, which they concluded was very low (Nichols and Grob 2018). The few cases of fatality that were attributed to LSD toxicity were either associated with massive overdoses or physical restraint, or they were potentially caused by drugs that remained undetected in the toxicological analysis (Nichols and Grob 2018). Currently, no evidence suggests that any of the currently available lysergamide designer drugs are significantly more toxic than LSD.
Performance-enhancing designer drugs
Designer doping agents have become increasingly popular outside of the professional athletic community and include anabolic steroids, peptide hormones, growth factor mimetics, and hormone and metabolic modulators (Joseph and Parr 2015; Poplawska and Blazewicz 2019; Rahnema et al. 2015; Weber et al. 2017). Such substances are mainly used for performance and image enhancement, exerting effects through several different mechanisms within the hormone system (Graham et al. 2009; Kicman 2008). Adverse effects that are associated with performance-enhancing designer drugs include secondary hypogonadism, gynecomastia, infertility, hypertension, ischemic stroke, cardiotoxicity, hepatotoxicity, and renal failure (Rahnema et al. 2015). In addition to substances that are taken to enhance athletic performance and appearance, designer drugs that are taken to enhance sexual performance, such as phosphodiesterase-5 inhibitors with no known safety profile, have also appeared. These substances may potentially induce visual disturbances or severe drug–drug interactions (Venhuis et al. 2008).
Miscellaneous risks associated with designer drug use
In addition to adverse effects that are associated with specific classes of designer drugs, some general risks are essentially the same as for traditional drugs of abuse. For example, quality assurance is not guaranteed for clandestine designer drugs. A lack of information about purity, mislabeling, pharmaceutical impurities, and hazardous cutting agents can pose a risk for drug users. A series of patients who presented to a hospital with coagulopathy and bleeding diathesis that were related to long-acting anticoagulant rodenticide adulterants of synthetic cannabinoids exemplifies their potentially fatal consequences (Devgun et al. 2019; Kelkar et al. 2018). Potentially severe drug–drug interactions are a risk when more than one substance is used, including prescription medications (Contrucci et al. 2020; Inan et al. 2020). Byproducts and impurities can pose such risks as septum perforation when insufflated or necrotic ulcers and infections when injected (Lafferty et al. 2016; Parks et al. 2015). Hallucinogen-persisting perception disorder has been associated with psychedelics, cannabinoids, and psychostimulants, manifesting in prolonged or reoccurring perceptual symptoms (Ikeda et al. 2005; Orsolini et al. 2017; Skryabin et al. 2019). The neurological and psychological changes that are associated with designer drugs can impair safe driving, and driving under the influence can severely jeopardize traffic safety (Adamowicz and Lechowicz 2015; Maas et al. 2015; Musshoff et al. 2014).
Concluding remarks
Designer drugs are often used in combination with other substances, thus hindering precise evaluations of the degree of involvement of individual substances to clinical toxicity in patients. Furthermore, designer drugs may remain undetected by routine drug screenings. Nevertheless, the pharmacological and toxicological profiles of most designer drug classes are similar to their related traditional drugs of abuse. Stimulants primarily act as substrates or inhibitors of monoamine transporters. Intoxication with stimulants mostly manifests as sympathomimetic adverse effects, the treatment of which is mainly supportive. Benzodiazepines may be given to control agitation, hypertension, and convulsions. Certain stimulants, including MDMA, have a marked serotonergic profile. Their associated adverse effects, such as serotonin syndrome, can be potentially severe clinical complications. Agonism at μ-opioid receptors mediates the main pharmacological effects of opioids, and GABAA and GABAB receptors drive the effects of designer benzodiazepines and GHB analogs, respectively. Sedatives, including synthetic opioids and GHB analogs, pose a risk of cardiorespiratory arrest, especially when they are used in combination with other depressants, such as alcohol and benzodiazepines. Initial patient care should focus on protecting the airways and maintaining breathing and circulation. Naloxone is an effective antidote to opioid toxicity. Dissociative designer drugs act as NMDA receptor antagonists and induce adverse effects that are similar to the dissociative anesthetics ketamine and PCP. Compared with Δ9-THC, synthetic cannabinoids act as more potent and effective agonists of CB1 and CB2 receptors, but the predominance of CB1 receptors in the central nervous system suggests that they mainly mediate the psychoactive effects. Compared with cannabis, effects of synthetic cannabinoids are less desirable, and adverse effects are more severe. Serotonergic psychedelics alter perception and cognition mainly through 5-HT2A receptor agonism. In addition to psychological disturbances, psychedelics may induce physical adverse effects, which are usually short-lived. Rarely, designer drug use can lead to severe psychiatric and physical complications and even death. Single-drug use and more precise knowledge of substance identity, potency, and purity can reduce the risks of designer drug use.
Change history
03 March 2022
A Correction to this paper has been published: https://doi.org/10.1007/s00204-022-03244-y
References
Aarde SM, Taffe MA (2017) Predicting the abuse liability of entactogen-class, new and emerging psychoactive substances via preclinical models of drug self-administration. Curr Top Behav Neurosci 32:145–164. https://doi.org/10.1007/7854_2016_54
Adamowicz P (2016) Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int 261:e5–10. https://doi.org/10.1016/j.forsciint.2016.02.024
Adamowicz P, Lechowicz W (2015) The influence of synthetic cannabinoid UR-144 on human psychomotor performance–a case report demonstrating road traffic risks. Traffic Inj Prev 16(8):754–759. https://doi.org/10.1080/15389588.2015.1018990
Adamowicz P, Zuba D (2015) Fatal intoxication with methoxetamine. J Forensic Sci 60(Suppl 1):S264–S268. https://doi.org/10.1111/1556-4029.12594
Adamowicz P, Zuba D, Byrska B (2014) Fatal intoxication with 3-methyl-N-methylcathinone (3-MMC) and 5-(2-aminopropyl)benzofuran (5-APB). Forensic Sci Int 245:126–132. https://doi.org/10.1016/j.forsciint.2014.10.016
Adamowicz P, Gieron J, Gil D, Lechowicz W, Skulska A, Tokarczyk B (2016) 3-Methylmethcathinone-interpretation of blood concentrations based on analysis of 95 cases. J Anal Toxicol 40(4):272–276. https://doi.org/10.1093/jat/bkw018
Adamowicz P, Gieron J, Gil D, Lechowicz W, Skulska A, Tokarczyk B (2017) The effects of synthetic cannabinoid UR-144 on the human body—a review of 39 cases. Forensic Sci Int 273:e18–e21. https://doi.org/10.1016/j.forsciint.2017.02.031
Adamowicz P, Meissner E, Maslanka M (2019) Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA. Clin Toxicol (Phila) 57(11):1103–1108. https://doi.org/10.1080/15563650.2019.1580371
Adedinsewo DA, Odewole O, Todd T (2016) Acute rhabdomyolysis following synthetic cannabinoid ingestion. N Am J Med Sci 8(6):256–258. https://doi.org/10.4103/1947-2714.185038
Akram H, Mokrysz C, Curran HV (2019) What are the psychological effects of using synthetic cannabinoids? A systematic review. J Psychopharmacol 33(3):271–283. https://doi.org/10.1177/0269881119826592
Alatrash G, Majhail NS, Pile JC (2006) Rhabdomyolysis after ingestion of "foxy", a hallucinogenic tryptamine derivative. Mayo Clin Proc 81(4):550–551. https://doi.org/10.4065/81.4.550
Alhadi S, Tiwari A, Vohra R, Gerona R, Acharya J, Bilello K (2013) High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 9(2):199–206. https://doi.org/10.1007/s13181-013-0288-9
Al-Hasani R, Bruchas MR (2011) Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 115(6):1363–1381. https://doi.org/10.1097/ALN.0b013e318238bba6
Alipour A, Patel PB, Shabbir Z, Gabrielson S (2019) Review of the many faces of synthetic cannabinoid toxicities. Ment Health Clin 9(2):93–99. https://doi.org/10.9740/mhc.2019.03.093
Alles GA, Feigen GA (1941) Comparative physiological actions of phenyl-, thienyl- and furylisopropylamines. J Pharmacol Exp Ther 72(3):265–275
Al-Matrouk A, Alqallaf M, AlShemmeri A, BoJbarah H (2019) Identification of synthetic cannabinoids that were seized, consumed, or associated with deaths in Kuwait in 2018 using GC–MS and LC–MS–MS analysis. Forensic Sci Int 303:109960. https://doi.org/10.1016/j.forsciint.2019.109960
Alon MH, Saint-Fleur MO (2017) Synthetic cannabinoid induced acute respiratory depression: case series and literature review. Respir Med Case Rep 22:137–141. https://doi.org/10.1016/j.rmcr.2017.07.011
Altintas M, Inanc L, Oruc GA, Arpacioglu S, Gulec H (2016) Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients. Neuropsychiatr Dis Treat 12:1893–1900. https://doi.org/10.2147/ndt.s107622
Ambrose JB, Bennett HD, Lee HS, Josephson SA (2010) Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion. Neurologist 16(3):199–202. https://doi.org/10.1097/NRL.0b013e3181a3cb53
Amoroso T, Workman M (2016) Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy. J Psychopharmacol 30(7):595–600. https://doi.org/10.1177/0269881116642542
Andersson M, Kjellgren A (2017) The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. Nord Stud Alcohol Drugs 34(3):217–229. https://doi.org/10.1177/1455072517706304
Andreu V, Mas A, Bruguera M, Salmerón JM, Moreno V, Nogué S, Rodés J (1998) Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 29(3):394–397. https://doi.org/10.1016/s0168-8278(98)80056-1
Angerer V, Jacobi S, Franz F, Auwärter V, Pietsch J (2017) Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. Forensic Sci Int 281:e9–e15. https://doi.org/10.1016/j.forsciint.2017.10.042
Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79(2):565–575. https://doi.org/10.1111/j.1476-5381.1983.tb11031.x
Anne S, Tse R, Cala AD (2015) A fatal case of isolated methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane) toxicity: a case report. Am J Forensic Med Pathol 36(3):205–206. https://doi.org/10.1097/paf.0000000000000170
Araújo AM, Carvalho F, Bastos MDL, Guedes De Pinho P, Carvalho M (2015) The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 89(8):1151–1173. https://doi.org/10.1007/s00204-015-1513-x
Arbo MD, Bastos ML, Carmo HF (2012) Piperazine compounds as drugs of abuse. Drug Alcohol Depend 122(3):174–185. https://doi.org/10.1016/j.drugalcdep.2011.10.007
Arbo MD, Melega S, Stöber R, Schug M, Rempel E, Rahnenführer J, Godoy P, Reif R, Cadenas C, De Lourdes BM, Carmo H, Hengstler JG (2016a) Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis. Arch Toxicol 90(12):3045–3060. https://doi.org/10.1007/s00204-016-1665-3
Arbo MD, Silva R, Barbosa DJ, Dias da Silva D, Silva SP, Teixeira JP, Bastos ML, Carmo H (2016b) In vitro neurotoxicity evaluation of piperazine designer drugs in differentiated human neuroblastoma SH-SY5Y cells. J Appl Toxicol 36(1):121–130. https://doi.org/10.1002/jat.3153
Argamany JR, Reveles KR, Duhon B (2016) Synthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure. Am J Emerg Med 34(4):765.e1–2. https://doi.org/10.1016/j.ajem.2015.08.051
Armenian P, Olson A, Anaya A, Kurtz A, Ruegner R, Gerona RR (2017) Fentanyl and a novel synthetic opioid U-47700 masquerading as street "Norco" in Central California: a case report. Ann Emerg Med 69(1):87–90. https://doi.org/10.1016/j.annemergmed.2016.06.014
Armenian P, Darracq M, Gevorkyan J, Clark S, Kaye B, Brandehoff NP (2018a) Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: a case series and review of the literature. Neuropharmacology 134(Pt A):82–91. https://doi.org/10.1016/j.neuropharm.2017.10.017
Armenian P, Vo KT, Barr-Walker J, Lynch KL (2018b) Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology 134(Pt A):121–132. https://doi.org/10.1016/j.neuropharm.2017.10.016
Armstrong F, McCurdy MT, Heavner MS (2019) Synthetic cannabinoid-associated multiple organ failure: case series and literature review. Pharmacotherapy 39(4):508–513. https://doi.org/10.1002/phar.2241
Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160(3):585–593. https://doi.org/10.1111/j.1476-5381.2009.00582.x
Aydin G, Bakar B (2019) Delayed intracerebral hemorrhage after synthetic cannabis (Bonsai) abuse; case report and literature review. Bull Emerg Trauma 7(3):330–334. https://doi.org/10.29252/beat-0703019
Babi MA, Robinson CP, Maciel CB (2017) A spicy status: synthetic cannabinoid (spice) use and new-onset refractory status epilepticus–a case report and review of the literature. SAGE Open Med Case Rep 5:205. https://doi.org/10.1177/2050313x17745206
Bäckberg M, Beck O, Hulten P, Rosengren-Holmberg J, Helander A (2014) Intoxications of the new psychoactive substance 5-(2-aminopropyl)indole (5-IT): a case series from the Swedish STRIDA project. Clin Toxicol (Phila) 52(6):618–624. https://doi.org/10.3109/15563650.2014.920088
Bäckberg M, Beck O, Helander A (2015a) Phencyclidine analog use in Sweden–intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol (Phila) 53(9):856–864. https://doi.org/10.3109/15563650.2015.1079325
Bäckberg M, Beck O, Jonsson KH, Helander A (2015b) Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project. Clin Toxicol (Phila) 53(7):609–617. https://doi.org/10.3109/15563650.2015.1054505
Bäckberg M, Lindeman E, Beck O, Helander A (2015c) Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project. Clin Toxicol (Phila) 53(1):46–53. https://doi.org/10.3109/15563650.2014.981823
Bäckberg M, Westerbergh J, Beck O, Helander A (2016) Adverse events related to the new psychoactive substance 3-fluorophenmetrazine—results from the Swedish STRIDA project. Clin Toxicol (Phila) 54(9):819–825. https://doi.org/10.1080/15563650.2016.1211288
Bäckberg M, Tworek L, Beck O, Helander A (2017) Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA project. J Med Toxicol 13(1):52–60. https://doi.org/10.1007/s13181-016-0584-2
Bäckberg M, Pettersson Bergstrand M, Beck O, Helander A (2019) Occurrence and time course of NPS benzodiazepines in Sweden–results from intoxication cases in the STRIDA project. Clin Toxicol (Phila) 57(3):203–212. https://doi.org/10.1080/15563650.2018.1506130
Bailey K, Richards-Waugh L, Clay D, Gebhardt M, Mahmoud H, Kraner JC (2010) Fatality involving the ingestion of phenazepam and poppy seed tea. J Anal Toxicol 34(8):527–532. https://doi.org/10.1093/jat/34.8.527
Bailey GP, Ho JH, Hudson S, Dines A, Archer JR, Dargan PI, Wood DM (2015) Nopaine no gain: recreational ethylphenidate toxicity. Clin Toxicol 53(5):498–499. https://doi.org/10.3109/15563650.2015.1033062
Bakota E, Arndt C, Romoser AA, Wilson SK (2016) Fatal intoxication involving 3-MeO–PCP: a case report and validated method. J Anal Toxicol 40(7):504–510. https://doi.org/10.1093/jat/bkw056
Baldo BA (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol 92(8):2457–2473. https://doi.org/10.1007/s00204-018-2244-6
Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M (2001) Tödliches Hirnödem nach Einnahme von Ecstasy und Benzylpiperazin. Dtsch Med Wochenschr 126(28–29):809–811. https://doi.org/10.1055/s-2001-15702
Banister SD, Connor M (2018) The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: origins. Handb Exp Pharmacol 252:165–190. https://doi.org/10.1007/164_2018_143
Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M (2015a) Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci 6(9):1546–1559. https://doi.org/10.1021/acschemneuro.5b00112
Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (2015b) Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci 6(8):1445–1458. https://doi.org/10.1021/acschemneuro.5b00107
Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JB, Glass M, McGregor IS, Connor M, Kassiou M (2016) Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci 7(9):1241–1254. https://doi.org/10.1021/acschemneuro.6b00137
Banister SD, Adams A, Kevin RC, Macdonald C, Glass M, Boyd R, Connor M, McGregor IS, Havel CM, Bright SJ, Vilamala MV, Lladanosa CG, Barratt MJ, Gerona RR (2019a) Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Test Anal 11(2):279–291. https://doi.org/10.1002/dta.2491
Banister SD, Kevin RC, Martin L, Adams A, Macdonald C, Manning JJ, Boyd R, Cunningham M, Stevens MY, McGregor IS, Glass M, Connor M, Gerona RR (2019b) The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. Drug Test Anal 11(7):976–989. https://doi.org/10.1002/dta.2583
Barann M, Stamer UM, Lyutenska M, Stuber F, Bonisch H, Urban B (2015) Effects of opioids on human serotonin transporters. Naunyn Schmiedeberg’s Arch Pharmacol 388(1):43–49. https://doi.org/10.1007/s00210-014-1056-3
Barrios L, Grison-Hernando H, Boels D, Bouquie R, Monteil-Ganiere C, Clement R (2016) Death following ingestion of methylone. Int J Legal Med 130(2):381–385. https://doi.org/10.1007/s00414-015-1212-4
Bassir Nia A, Mann CL, Spriggs S, DeFrancisco DR, Carbonaro S, Parvez L, Galynker II, Perkel CA, Hurd YL (2019) The relevance of sex in the association of synthetic cannabinoid use with psychosis and agitation in an inpatient population. J Clin Psychiatry 80(4):1. https://doi.org/10.4088/JCP.18m12539
Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, Rothman RB (2000) Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 36(2):102–113. https://doi.org/10.1002/(SICI)1098-2396(200005)36:2<102::AID-SYN3>3.0.CO;2-%23
Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB (2005) N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30(3):550–560. https://doi.org/10.1038/sj.npp.1300585
Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37(5):1192–1203. https://doi.org/10.1038/npp.2011.304
Baumann MH, Partilla JS, Lehner KR (2013) Psychoactive "bath salts": not so soothing. Eur J Pharmacol 698(1–3):1–5. https://doi.org/10.1016/j.ejphar.2012.11.020
Baumann MH, Majumdar S, Le Rouzic V, Hunkele A, Uprety R, Huang XP, Xu J, Roth BL, Pan YX, Pasternak GW (2018) Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology 134(Pt A):101–107. https://doi.org/10.1016/j.neuropharm.2017.08.016
Bay T, Eghorn LF, Klein AB, Wellendorph P (2014) GHB receptor targets in the CNS: focus on high-affinity binding sites. Biochem Pharmacol 87(2):220–228. https://doi.org/10.1016/j.bcp.2013.10.028
Bebarta VS, Ramirez S, Varney SM (2012) Complication of spice use in a deployed combat setting-seizure while on duty. Am J Addict 21(5):496–497. https://doi.org/10.1111/j.1521-0391.2012.00264.x
Beck O, Franzén L, Bäckberg M, Signell P, Helander A (2015) Intoxications involving MDPV in Sweden during 2010–2014: results from the STRIDA project. Clin Toxicol (Phila) 53(9):865–873. https://doi.org/10.3109/15563650.2015.1089576
Beck O, Franzén L, Bäckberg M, Signell P, Helander A (2016) Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project. Clin Toxicol (Phila) 54(7):568–575. https://doi.org/10.1080/15563650.2016.1190979
Behonick G, Shanks KG, Firchau DJ, Mathur G, Lynch CF, Nashelsky M, Jaskierny DJ, Meroueh C (2014) Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol 38(8):559–562. https://doi.org/10.1093/jat/bku048
Benesch MGK, Iqbal SJ (2018) Novel psychoactive substances: overdose of 3-fluorophenmetrazine (3-FPM) and etizolam in a 33-year-old man. BMJ Case Rep. https://doi.org/10.1136/bcr-2018-224995
Benford DM, Caplan JP (2011) Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 52(3):295. https://doi.org/10.1016/j.psym.2011.01.004
Berkowitz EA, Henry TS, Veeraraghavan S, Staton GW Jr, Gal AA (2015) Pulmonary effects of synthetic marijuana: chest radiography and CT findings. AJR Am J Roentgenol 204(4):750–757. https://doi.org/10.2214/ajr.14.13138
Bernson-Leung ME, Leung LY, Kumar S (2014) Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis 23(5):1239–1241. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.07.030
Berry-Caban CS, Ee J, Ingram V, Berry CE, Kim EH (2013) Synthetic cannabinoid overdose in a 20-year-old male US soldier. Subst Abus 34(1):70–72. https://doi.org/10.1080/08897077.2012.677754
Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D (2013) AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 8(4):523–526. https://doi.org/10.2215/cjn.05690612
Bick BL, Szostek JH, Mangan TF (2014) Synthetic cannabinoid leading to cannabinoid hyperemesis syndrome. Mayo Clin Proc 89(8):1168–1169. https://doi.org/10.1016/j.mayocp.2014.06.013
Bingham C, Beaman M, Nicholls AJ, Anthony PP (1998) Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy'). Nephrol Dial Transplant 13(10):2654–2655. https://doi.org/10.1093/ndt/13.10.2654
Blicke FF, Burckhalter JH (1942) α-Thienylaminoalkanes. J Am Chem Soc 64(3):477–480. https://doi.org/10.1021/ja01255a001
Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (2014) Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology 231(21):4135–4144. https://doi.org/10.1007/s00213-014-3557-7
Boland DM, Andollo W, Hime GW, Hearn WL (2005) Fatality due to acute α-methyltryptamine intoxication. J Anal Toxicol 29(5):394–397. https://doi.org/10.1093/jat/29.5.394
Boland DM, Reidy LJ, Seither JM, Radtke JM, Lew EO (2019) Forty-three fatalities involving the synthetic cannabinoid, 5-fluoro-ADB: forensic pathology and toxicology implications. J Forensic Sci. https://doi.org/10.1111/1556-4029.14098
Bonaccorso S, Metastasio A, Ricciardi A, Stewart N, Jamal L, Rujully NU, Theleritis C, Ferracuti S, Ducci G, Schifano F (2018) Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues. Brain Sci 8(7):1. https://doi.org/10.3390/brainsci8070133
Borek HA, Holstege CP (2012) Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 60(1):103–105. https://doi.org/10.1016/j.annemergmed.2012.01.005
Bosak A, LoVecchio F, Levine M (2013) Recurrent seizures and serotonin syndrome following "2C-I" ingestion. J Med Toxicol 9(2):196–198. https://doi.org/10.1007/s13181-013-0287-x
Bossong MG, Brunt TM, Van Dijk JP, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ (2010) mCPP: an undesired addition to the ecstasy market. J Psychopharmacol 24(9):1395–1401. https://doi.org/10.1177/0269881109102541
Boulanger-Gobeil C, St-Onge M, Laliberte M, Auger PL (2012) Seizures and hyponatremia related to ethcathinone and methylone poisoning. J Med Toxicol 8(1):59–61. https://doi.org/10.1007/s13181-011-0159-1
Braden MR, Parrish JC, Naylor JC, Nichols DE (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe 339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70(6):1956–1964. https://doi.org/10.1124/mol.106.028720
Brandt SD, Baumann MH, Partilla JS, Kavanagh PV, Power JD, Talbot B, Twamley B, Mahony O, O'Brien J, Elliott SP, Archer RP, Patrick J, Singh K, Dempster NM, Cosbey SH (2014) Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni'). Drug Test Anal 6(7–8):684–695. https://doi.org/10.1002/dta.1668
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, Wallach J, Halberstadt AL (2016) Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Test Anal 8(9):891–902. https://doi.org/10.1002/dta.1884
Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, Burrow TE, Chapman SJ, Stratford A, Nichols DE, Halberstadt AL (2017a) Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2ʹS,4ʹS)-lysergic acid 2,4-dimethylazetidide (LSZ). Drug Test Anal 9(1):38–50. https://doi.org/10.1002/dta.1985
Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, Nichols DE, Halberstadt AL (2017b) Return of the lysergamides. Part III: Analytical characterization of N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). Drug Test Anal 9(10):1641–1649. https://doi.org/10.1002/dta.2196
Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL (2018) Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Test Anal 10(2):310–322. https://doi.org/10.1002/dta.2222
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Wallach J, Halberstadt AL (2019) Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD). Drug Test Anal 11(8):1122–1133. https://doi.org/10.1002/dta.2613
Brennan R, Van Hout MC (2014) Gamma-hydroxybutyrate (GHB): a scoping review of pharmacology, toxicology, motives for use, and user groups. J Psychoactive Drugs 46(3):243–251. https://doi.org/10.1080/02791072.2014.921746
Brown PC, Alfonso J, Dunn ME (2011) Gamma hydroxybutyrate use: exploring the influence of outcome expectancies through memory modeling. Am J Addict 20(2):127–136. https://doi.org/10.1111/j.1521-0391.2010.00113.x
Burish MJ, Thoren KL, Madou M, Toossi S, Shah M (2015) Hallucinogens causing seizures? A case report of the synthetic amphetamine 2,5-dimethoxy-4-chloroamphetamine. Neurohospitalist 5(1):32–34. https://doi.org/10.1177/1941874414528939
Burns G, DeRienz RT, Baker DD, Casavant M, Spiller HA (2016) Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse? Clin Toxicol (Phila) 54(5):420–423. https://doi.org/10.3109/15563650.2016.1157722
Busardò FP, Jones AW (2015) GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol 13(1):47–70. https://doi.org/10.2174/1570159x13666141210215423
Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S (2015) Mephedrone related fatalities: a review. Eur Rev Med Pharmacol Sci 19(19):3777–3790
Buser GL, Gerona RR, Horowitz BZ, Vian KP, Troxell ML, Hendrickson RG, Houghton DC, Rozansky D, Su SW, Leman RF (2014) Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol (Phila) 52(7):664–673. https://doi.org/10.3109/15563650.2014.932365
Campbell GA, Rosner MH (2008) The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol 3(6):1852–1860. https://doi.org/10.2215/cjn.02080508
Canning H, Goff D, Leach MJ, Miller AA, Tateson JE, Wheatley PL (1979) The involvement of dopamine in the central actions of bupropion, a new antidepressant [proceedings]. Br J Pharmacol 66(1):104p–105p
Carai MA, Colombo G, Brunetti G, Melis S, Serra S, Vacca G, Mastinu S, Pistuddi AM, Solinas C, Cignarella G, Minardi G, Gessa GL (2001) Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid. Eur J Pharmacol 428(3):315–321. https://doi.org/10.1016/s0014-2999(01)01334-6
Carbone PN, Carbone DL, Carstairs SD, Luzi SA (2013) Sudden cardiac death associated with methylone use. Am J Forensic Med Pathol 34(1):26–28. https://doi.org/10.1097/PAF.0b013e31827ab5da
Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235(2):399–408. https://doi.org/10.1007/s00213-017-4771-x
Carpenter JE, Murray BP, Dunkley C, Kazzi ZN, Gittinger MH (2019) Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014–2017. Clin Toxicol (Phila) 57(4):282–286. https://doi.org/10.1080/15563650.2018.1510502
Carter LP, Chen W, Wu H, Mehta AK, Hernandez RJ, Ticku MK, Coop A, Koek W, France CP (2005) Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV). Drug Alcohol Depend 78(1):91–99. https://doi.org/10.1016/j.drugalcdep.2004.10.002
Carter LP, Koek W, France CP (2009) Behavioral analyses of GHB: receptor mechanisms. Pharmacol Ther 121(1):100–114. https://doi.org/10.1016/j.pharmthera.2008.10.003
Carvalho M, Pontes H, Remiao F, Bastos ML, Carvalho F (2010) Mechanisms underlying the hepatotoxic effects of ecstasy. Curr Pharm Biotechnol 11(5):476–495. https://doi.org/10.2174/138920110791591535
Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, MeL B (2012) Toxicity of amphetamines: an update. Arch Toxicol 86(8):1167–1231. https://doi.org/10.1007/s00204-012-0815-5
Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76(1):70–81. https://doi.org/10.1016/j.neuron.2012.09.020
Chait LD, Uhlenhuth EH, Johanson CE (1987) Reinforcing and subjective effects of several anorectics in normal human volunteers. J Pharmacol Exp Ther 242(3):777–783
Chan WL, Wood DM, Hudson S, Dargan PI (2013) Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. J Med Toxicol 9(3):278–281. https://doi.org/10.1007/s13181-013-0306-y
Charbogne P, Kieffer BL, Befort K (2014) 15 years of genetic approaches in vivo for addiction research: opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology 76(Pt B):204–217. https://doi.org/10.1016/j.neuropharm.2013.08.028
Chiappini S, Claridge H, Corkery JM, Goodair C, Loi B, Schifano F (2015) Methoxetamine-related deaths in the UK: an overview. Hum Psychopharmacol 30(4):244–248. https://doi.org/10.1002/hup.2422
Chinnadurai T, Shrestha S, Ayinla R (2016) A curious case of inhalation fever caused by synthetic cannabinoid. Am J Case Rep 17:379–383. https://doi.org/10.12659/ajcr.898500
Chu PS, Kwok SC, Lam KM, Chu TY, Chan SW, Man CW, Ma WK, Chui KL, Yiu MK, Chan YC, Tse ML, Lau FL (2007) 'Street ketamine'-associated bladder dysfunction: a report of ten cases. Hong Kong Med J 13(4):311–313
Clark BC, Georgekutty J, Berul CI (2015) Myocardial ischemia secondary to synthetic cannabinoid (K2) use in pediatric patients. J Pediatr 167(3):757–61.e1. https://doi.org/10.1016/j.jpeds.2015.06.001
Codd EE, Shank RP, Schupsky JJ, Raffa RB (1995) Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 274(3):1263–1270
Colado MI, Murray TK, Green AR (1993) 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol 108(3):583–589. https://doi.org/10.1111/j.1476-5381.1993.tb12846.x
Cole JB, Dunbar JF, McIntire SA, Regelmann WE, Slusher TM (2015) Butyrfentanyl overdose resulting in diffuse alveolar hemorrhage. Pediatrics 135(3):e740–e743. https://doi.org/10.1542/peds.2014-2878
Concheiro M, Chesser R, Pardi J, Cooper G (2018) Postmortem toxicology of new synthetic opioids. Front Pharmacol 9:1210. https://doi.org/10.3389/fphar.2018.01210
Coney LD, Maier LJ, Ferris JA, Winstock AR, Barratt MJ (2017) Genie in a blotter: a comparative study of LSD and LSD analogues' effects and user profile. Hum Psychopharmacol 32(3):1. https://doi.org/10.1002/hup.2599
Contrucci RR, Brunt TM, Inan F, Franssen EJF, Hondebrink L (2020) Synthetic cathinones and their potential interactions with prescription drugs. Ther Drug Monit 42(1):75–82. https://doi.org/10.1097/ftd.0000000000000682
Coopman V, Blanckaert P, Van Parys G, Van Calenbergh S, Cordonnier J (2016a) A case of acute intoxication due to combined use of fentanyl and 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700). Forensic Sci Int 266:68–72. https://doi.org/10.1016/j.forsciint.2016.05.001
Coopman V, Cordonnier J, De Leeuw M, Cirimele V (2016b) Ocfentanil overdose fatality in the recreational drug scene. Forensic Sci Int 266:469–473. https://doi.org/10.1016/j.forsciint.2016.07.005
Coppola M, Mondola R (2013a) 5-Iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects. Toxicol Lett 218(1):24–29. https://doi.org/10.1016/j.toxlet.2013.01.008
Coppola M, Mondola R (2013b) A new stimulant of abuse: 5-(2-aminopropyl)indole. Am J Psychiatry 170(2):226. https://doi.org/10.1176/appi.ajp.2012.12091168
Corkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH (2013) MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') toxicity: a brief overview and update. Hum Psychopharmacol 28(4):345–355. https://doi.org/10.1002/hup.2298
Corkery JM, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, Schifano F (2015) Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev 53:52–78. https://doi.org/10.1016/j.neubiorev.2015.03.012
Cosbey S, Kirk S, McNaul M, Peters L, Prentice B, Quinn A, Elliott SP, Brandt SD, Archer RP (2014) Multiple fatalities involving a new designer drug: para-methyl-4-methylaminorex. J Anal Toxicol 38(6):383–384. https://doi.org/10.1093/jat/bku031
Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE (2009) Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm (Vienna) 116(12):1591–1599. https://doi.org/10.1007/s00702-009-0308-8
Crichton ML, Shenton CF, Drummond G, Beer LJ, Seetohul LN, Maskell PD (2015) Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and tissues. Drug Test Anal 7(10):926–936. https://doi.org/10.1002/dta.1790
Crunelli V, Emri Z, Leresche N (2006) Unravelling the brain targets of γ-hydroxybutyric acid. Curr Opin Pharmacol 6(1):44–52. https://doi.org/10.1016/j.coph.2005.10.001
Cunningham G (1963) Diethylpropion in the treatment of obesity. Br J Gen Pract 6(2):347
Cunningham M (1997) Ecstasy-induced rhabdomyolysis and its role in the development of acute renal failure. Intensive Crit Care Nurs 13(4):216–223. https://doi.org/10.1016/s0964-3397(97)80056-0
Cunningham SM, Haikal NA, Kraner JC (2016) Fatal intoxication with acetyl fentanyl. J Forensic Sci 61(Suppl 1):S276–S280. https://doi.org/10.1111/1556-4029.12953
Curtis B, Kemp P, Harty L, Choi C, Christensen D (2003) Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J Anal Toxicol 27(7):493–498. https://doi.org/10.1093/jat/27.7.493
Custodio RJP, Sayson LV, Botanas CJ, Abiero A, You KY, Kim M, Lee HJ, Yoo SY, Lee KW, Lee YS, Seo JW, Ryu IS, Kim HJ, Cheong JH (2019) 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: evidence of abuse potential. Addict Biol. https://doi.org/10.1111/adb.12850
Dal Cason TA, Young R, Glennon RA (1997) Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav 58(4):1109–1116. https://doi.org/10.1016/s0091-3057(97)00323-7
Daniulaityte R, Juhascik MP, Strayer KE, Sizemore IE, Harshbarger KE, Antonides HM, Carlson RR (2017) Overdose deaths related to fentanyl and its analogs—Ohio, January–February 2017. MMWR Morb Mortal Wkly Rep 66(34):904–908. https://doi.org/10.15585/mmwr.mm6634a3
Dargan PI, Tang HC, Liang W, Wood DM, Yew DT (2014) Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin Toxicol (Phila) 52(3):176–180. https://doi.org/10.3109/15563650.2014.892605
Darke S, Duflou J, Farrell M, Peacock A, Lappin J (2019) Characteristics and circumstances of synthetic cannabinoid-related death. Clin Toxicol (Phila) 1:1–7. https://doi.org/10.1080/15563650.2019.1647344
Daveluy A, Castaing N, Cherifi H, Richeval C, Humbert L, Faure I, Labadie M, Allorge D, Haramburu F, Molimard M, Titier K (2016) Acute methiopropamine intoxication after “synthacaine" consumption. J Anal Toxicol 40(9):758–760. https://doi.org/10.1093/jat/bkw073
Davis C, Boddington D (2015) Teenage cardiac arrest following abuse of synthetic cannabis. Heart Lung Circ 24(10):e162–e163. https://doi.org/10.1016/j.hlc.2015.04.176
Davis FT, Brewster ME (1988) A fatality involving U4Euh, a cyclic derivative of phenylpropanolamine. J Forensic Sci 33(2):549–553
Dawson P, Opacka-Juffry J, Moffatt JD, Daniju Y, Dutta N, Ramsey J, Davidson C (2014) The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 48:57–63. https://doi.org/10.1016/j.pnpbp.2013.08.013
De Carlis L, De Gasperi A, Slim AO, Giacomoni A, Corti A, Mazza E, Di Benedetto F, Lauterio A, Arcieri K, Maione G, Rondinara GF, Forti D (2001) Liver transplantation for ecstasy-induced fulminant hepatic failure. Transplant Proc 33(5):2743–2744. https://doi.org/10.1016/s0041-1345(01)02176-5
De Havenon A, Chin B, Thomas KC, Afra P (2011) The secret "spice": an undetectable toxic cause of seizure. Neurohospitalist 1(4):182–186. https://doi.org/10.1177/1941874411417977
De Jong LAA, Olyslager EJH, Duijst W (2019) The risk of emerging new psychoactive substances: the first fatal 3-MeO-PCP intoxication in The Netherlands. J Forensic Leg Med 65:101–104. https://doi.org/10.1016/j.jflm.2019.05.011
Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2013) 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 9(2):172–178. https://doi.org/10.1007/s13181-013-0295-x
Deng H, Verrico CD, Kosten TR, Nielsen DA (2018) Psychosis and synthetic cannabinoids. Psychiatry Res 268:400–412. https://doi.org/10.1016/j.psychres.2018.08.012
Denton JS, Donoghue ER, McReynolds J, Kalelkar MB (2008) An epidemic of illicit fentanyl deaths in Cook County, Illinois: September 2005 through April 2007. J Forensic Sci 53(2):452–454. https://doi.org/10.1111/j.1556-4029.2008.00669.x
Derlet RW, Rice P, Horowitz BZ, Lord RV (1989) Amphetamine toxicity: experience with 127 cases. J Emerg Med 7(2):157–161. https://doi.org/10.1016/0736-4679(89)90263-1
DeRoux SJ, Dunn WA (2017) "Bath Salts" the New York City medical examiner experience: a 3-year retrospective review. J Forensic Sci 62(3):695–699. https://doi.org/10.1111/1556-4029.13316
Derungs A, Schwaninger AE, Mansella G, Bingisser R, Kraemer T, Liechti ME (2013) Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol 31(1):164–171. https://doi.org/10.1007/s11419-012-0166-1
Deutsch HM, Shi Q, Gruszecka-Kowalik E, Schweri MM (1996) Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs. J Med Chem 39(6):1201–1209. https://doi.org/10.1021/jm950697c
Devgun JM, Rasin A, Kim T, Mycyk MB, Bryant SM, Wahl MS, DesLauriers C, Navon L, Moritz ED, Thompson TM, Swoboda HD, Lu J, Aks SE (2019) An outbreak of severe coagulopathy from synthetic cannabinoids tainted with long-acting anticoagulant rodenticides. Clin Toxicol (Phila) 1:1–8. https://doi.org/10.1080/15563650.2019.1690149
Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, Svenningsson P, Brocco M, Gobert A, De Groote L, Cistarelli L, Veiga S, De Montrion C, Rodriguez M, Galizzi JP, Lockhart BP, Coge F, Boutin JA, Vayer P, Verdouw PM, Groenink L, Millan MJ (2011) Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J Neurosci 31(47):16928–16940. https://doi.org/10.1523/JNEUROSCI.2502-11.2011
Dias da Silva D, Silva MJ, Moreira P, Martins MJ, Valente MJ, Carvalho F, Bastos ML, Carmo H (2017) In vitro hepatotoxicity of 'Legal X': the combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis. Arch Toxicol 91(3):1413–1430. https://doi.org/10.1007/s00204-016-1777-9
Dias da Silva D, Ferreira B, Roque Bravo R, Rebelo R, Duarte de Almeida T, Valente MJ, Silva JP, Carvalho F, Bastos ML, Carmo H (2019) The new psychoactive substance 3-methylmethcathinone (3-MMC or metaphedrone) induces oxidative stress, apoptosis, and autophagy in primary rat hepatocytes at human-relevant concentrations. Arch Toxicol 93(9):2617–2634. https://doi.org/10.1007/s00204-019-02539-x
Dias-da-Silva D, Arbo MD, Valente MJ, Bastos ML, Carmo H (2015) Hepatotoxicity of piperazine designer drugs: comparison of different in vitro models. Toxicol In Vitro 29(5):987–996. https://doi.org/10.1016/j.tiv.2015.04.001
Dolder PC, Schmid Y, Müller F, Borgwardt S, Liechti ME (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41(11):2638–2646. https://doi.org/10.1038/npp.2016.82
Dolder PC, Strajhar P, Vizeli P, Hammann F, Odermatt A, Liechti ME (2017) Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with D-amphetamine in healthy subjects. Front Pharmacol 8:617. https://doi.org/10.3389/fphar.2017.00617
Domanski K, Kleinschmidt KC, Schulte JM, Fleming S, Frazee C, Menendez A, Tavakoli K (2017) Two cases of intoxication with new synthetic opioid, U-47700. Clin Toxicol (Phila) 55(1):46–50. https://doi.org/10.1080/15563650.2016.1209763
Domingo O, Roider G, Stover A, Graw M, Musshoff F, Sachs H, Bicker W (2017) Mitragynine concentrations in two fatalities. Forensic Sci Int 271:e1–e7. https://doi.org/10.1016/j.forsciint.2016.12.020
Domino EF (1980) History and pharmacology of PCP and PCP-related analogs. J Psychedelic Drugs 12(3–4):223–227. https://doi.org/10.1080/02791072.1980.10471430
Droogmans S, Cosyns B, D'Haenen H, Creeten E, Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, Vandenbossche JL, Bechet S, Van Camp G (2007) Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 100(9):1442–1445. https://doi.org/10.1016/j.amjcard.2007.06.045
Dunlop LC, Wood D, Archer J, Hudson S, Dargan P (2019) Severe toxicity to the new psychoactive substances 3-hydroxyphencyclidine and N-ethylhexedrone: an analytically confirmed case report. J Med Toxicol. https://doi.org/10.1007/s13181-019-00734-x
Durand D, Delgado LL, De la Parra-Pellot DM, Nichols-Vinueza D (2015) Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin Schizophr Relat Psychoses 8(4):205–208. https://doi.org/10.3371/csrp.dude.031513
Dussy FE, Hangartner S, Hamberg C, Berchtold C, Scherer U, Schlotterbeck G, Wyler D, Briellmann TA (2016) An acute ocfentanil fatality: a case report with postmortem concentrations. J Anal Toxicol 40(9):761–766. https://doi.org/10.1093/jat/bkw096
Dwyer JB, Janssen J, Luckasevic TM, Williams KE (2018) Report of increasing overdose deaths that include acetyl fentanyl in multiple counties of the southwestern region of the Commonwealth of Pennsylvania in 2015–2016. J Forensic Sci 63(1):195–200. https://doi.org/10.1111/1556-4029.13517
Eiden C, Mathieu O, Cathala P, Debruyne D, Baccino E, Petit P, Peyriere H (2013) Toxicity and death following recreational use of 2-pyrrolidino valerophenone. Clin Toxicol (Phila) 51(9):899–903. https://doi.org/10.3109/15563650.2013.847187
El Balkhi S, Monchaud C, Herault F, Geniaux H, Saint-Marcoux F (2020) Designer benzodiazepines' pharmacological effects and potencies: how to find the information. J Psychopharmacol 1:2. https://doi.org/10.1177/0269881119901096
El Zahran T, Gerona R, Morgan BW, Pomerleau AC (2019) A novel synthetic cannabinoid (cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it's not meningitis. Clin Toxicol (Phila) 57(6):421–422. https://doi.org/10.1080/15563650.2018.1534241
Elangbam CS (2010) Drug-induced valvulopathy: an update. Toxicol Pathol 38(6):837–848. https://doi.org/10.1177/0192623310378027
Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N (2008) 5-Hydroxytryptamine (5-HT)-induced valvulopathy: compositional valvular alterations are associated with 5-HT2B receptor and 5-HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60(4–5):253–262. https://doi.org/10.1016/j.etp.2008.03.005
Ellefsen KN, Taylor EA, Simmons P, Willoughby V, Hall BJ (2017) Multiple drug-toxicity involving novel psychoactive substances, 3-fluorophenmetrazine and U-47700. J Anal Toxicol 41(9):765–770. https://doi.org/10.1093/jat/bkx060
Elliott S, Evans J (2014) A 3-year review of new psychoactive substances in casework. Forensic Sci Int 243:55–60. https://doi.org/10.1016/j.forsciint.2014.04.017
Elliott SP, Brandt SD, Wallach J, Morris H, Kavanagh PV (2015) First reported fatalities associated with the 'research chemical' 2-methoxydiphenidine. J Anal Toxicol 39(4):287–293. https://doi.org/10.1093/jat/bkv006
Elliott SP, Brandt SD, Smith C (2016) The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis. Drug Test Anal 8(8):875–879. https://doi.org/10.1002/dta.1984
Ellis AJ, Wendon JA, Portmann B, Williams R (1996) Acute liver damage and ecstasy ingestion. Gut 38(3):454–458. https://doi.org/10.1136/gut.38.3.454
Elmore JS, Decker AM, Sulima A, Rice KC, Partilla JS, Blough BE, Baumann MH (2018) Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology 142:240–250. https://doi.org/10.1016/j.neuropharm.2018.02.033
Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85(12):1803–1815. https://doi.org/10.1016/j.bcp.2013.04.004
Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB (2014) Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology 231(5):875–888. https://doi.org/10.1007/s00213-013-3303-6
Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A (2017) Structure-activity relationships of substituted cathinones, with transporter binding, uptake, and release. J Pharmacol Exp Ther 360(1):33–47. https://doi.org/10.1124/jpet.116.236349
Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27–34. https://doi.org/10.1016/j.bcp.2018.09.024
European Monitoring Centre for Drugs and Drug Addiction (2015) Report on the risk assessment of 4,4ʹ-DMAR. https://www.emcdda.europa.eu/system/files/publications/1864/TDAK14005ENN.pdf, Accessed 7 Jan 2020
European Monitoring Centre for Drugs and Drug Addiction (2019) European drug report 2019. https://www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF.pdf. Accessed 7 Jan 2020
Every-Palmer S (2010) Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 105(10):1859–1860. https://doi.org/10.1111/j.1360-0443.2010.03119.x
Fahal IH, Sallomi DF, Yaqoob M, Bell GM (1992) Acute renal failure after ecstasy. BMJ 305(6844):29. https://doi.org/10.1136/bmj.305.6844.29
Fallon JK, Shah D, Kicman AT, Hutt AJ, Henry JA, Cowan DA, Forsling M (2002) Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci 965:399–409. https://doi.org/10.1111/j.1749-6632.2002.tb04181.x
Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH (2005) Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology 181(3):496–503. https://doi.org/10.1007/s00213-005-0009-4
Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC (2008) Hallucinogen-like effects of N, N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav 88(3):358–365. https://doi.org/10.1016/j.pbb.2007.09.007
Farah R, Farah R (2008) Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion. Pediatr Emerg Care 24(9):615–617. https://doi.org/10.1097/PEC.0b013e3181850c91
Faroqui R, Mena P, Wolfe AR, Bibawy J, Visvikis GA, Mantello MT (2018) Acute carotid thrombosis and ischemic stroke following overdose of the synthetic cannabinoid K2 in a previously healthy young adult male. Radiol Case Rep 13(3):747–752. https://doi.org/10.1016/j.radcr.2018.02.023
Fawzy M, Wong-Morrow WS, Beaumont A, Farmer CKT (2017) Acute kidney injury and critical limb ischaemia associated with the use of the so called "legal high" 3-fluorophenmetrazine. CEN Case Rep 6(2):152–155. https://doi.org/10.1007/s13730-017-0263-4
Fels H, Krueger J, Sachs H, Musshoff F, Graw M, Roider G, Stoever A (2017) Two fatalities associated with synthetic opioids: AH-7921 and MT-45. Forensic Sci Int 277:e30–e35. https://doi.org/10.1016/j.forsciint.2017.04.003
Fels H, Lottner-Nau S, Sax T, Roider G, Graw M, Auwärter V, Musshoff F (2019) Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drug. Forensic Sci Int 301:e20–e28. https://doi.org/10.1016/j.forsciint.2019.04.010
Finlay DB, Manning JJ, Ibsen MS, Macdonald CE, Patel M, Javitch JA, Banister SD, Glass M (2019) Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chem Neurosci 10(10):4350–4360. https://doi.org/10.1021/acschemneuro.9b00429
Fleckenstein AE, Gibb JW, Hanson GR (2000) Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 406(1):1–13. https://doi.org/10.1016/s0014-2999(00)00639-7
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681–698. https://doi.org/10.1146/annurev.pharmtox.47.120505.105140
Forrester MB (2012a) Adolescent synthetic cannabinoid exposures reported to Texas poison centers. Pediatr Emerg Care 28(10):985–989. https://doi.org/10.1097/PEC.0b013e31826c9a97
Forrester MB (2012b) Synthetic cathinone exposures reported to Texas poison centers. Am J Drug Alcohol Abuse 38(6):609–615. https://doi.org/10.3109/00952990.2012.677890
Forrester MB (2013) 2C series phenethylamine derivative exposures in Texas. Subst Abus 34(1):81–82. https://doi.org/10.1080/08897077.2012.715623
Forrester MB (2014) NBOMe designer drug exposures reported to Texas poison centers. J Addict Dis 33(3):196–201. https://doi.org/10.1080/10550887.2014.950027
Forrester MB, Kleinschmidt K, Schwarz E, Young A (2011) Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 30(4):351–358. https://doi.org/10.1080/10550887.2011.609807
Forrester MB, Kleinschmidt K, Schwarz E, Young A (2012) Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 31(10):1006–1011. https://doi.org/10.1177/0960327111421945
Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Henry JA (2001) Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): is metabolism a contributory factor? J Pharm Pharmacol 53(10):1357–1363. https://doi.org/10.1211/0022357011777855
Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135(3):649–656. https://doi.org/10.1038/sj.bjp.0704502
Fort C, Curtis B, Nichols C, Niblo C (2016) Acetyl fentanyl toxicity: two case reports. J Anal Toxicol 40(9):754–757. https://doi.org/10.1093/jat/bkw068
Foti F, Marti M, Ossato A, Bilel S, Sangiorgi E, Botre F, Cerbelli B, Baldi A, De-Giorgio F (2019) Phenotypic effects of chronic and acute use of methiopropamine in a mouse model. Int J Legal Med 133(3):811–820. https://doi.org/10.1007/s00414-018-1891-8
Franzén L, Bäckberg M, Beck O, Helander A (2018) Acute intoxications involving α-pyrrolidinobutiophenone (α-PBP): results from the Swedish STRIDA project. J Med Toxicol 14(4):265–271. https://doi.org/10.1007/s13181-018-0668-2
Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS (2013) Ischemic stroke after use of the synthetic marijuana "spice". Neurology 81(24):2090–2093. https://doi.org/10.1212/01.wnl.0000437297.05570.a2
Freudenmann RW, Oxler F, Bernschneider-Reif S (2006) The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction 101(9):1241–1245. https://doi.org/10.1111/j.1360-0443.2006.01511.x
Frisoni P, Bacchio E, Bilel S, Talarico A, Gaudio RM, Barbieri M, Neri M, Marti M (2018) Novel synthetic opioids: the pathologist's point of view. Brain Sci 8(9):1. https://doi.org/10.3390/brainsci8090170
Fröhlich S, Lambe E, O'Dea J (2011) Acute liver failure following recreational use of psychotropic "head shop" compounds. Ir J Med Sci 180(1):263–264. https://doi.org/10.1007/s11845-010-0636-6
Fuller RW (1992) Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem Res 17(5):449–456. https://doi.org/10.1007/bf00969891
Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF (2004) The Xyrem risk management program. Drug Saf 27(5):293–306. https://doi.org/10.2165/00002018-200427050-00002
Fuse-Nagase Y, Nishikawa T (2013) Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-NN-diisopropyltryptamine abuser. Addict Sci Clin Pract 8(1):9. https://doi.org/10.1186/1940-0640-8-9
Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA (2000) Recreational use of aminorex and pulmonary hypertension. Chest 118(5):1496–1497. https://doi.org/10.1378/chest.118.5.1496
Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF (2018) Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA. J Pharmacol Exp Ther 365(2):437–446. https://doi.org/10.1124/jpet.117.246983
Gannon BM, Galindo KI, Mesmin MP, Sulima A, Rice KC, Collins GT (2018) Relative reinforcing effects of second-generation synthetic cathinones: acquisition of self-administration and fixed ratio dose-response curves in rats. Neuropharmacology 134(Pt A):28–35. https://doi.org/10.1016/j.neuropharm.2017.08.018
Garbino J, Henry JA, Mentha G, Romand JA (2001) Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option. Vet Hum Toxicol 43(2):99–102
Gardos G, Cole JO (1971) Evaluation of pyrovalerone in chronically fatigued volunteers. Curr Ther Res Clin Exp 13(10):631–635
Garneau B, Desharnais B, Beauchamp-Dore A, Lavallee C, Mireault P, Lajeunesse A (2019) Challenges related to three cases of fatal intoxication to multiple novel synthetic opioids. J Anal Toxicol. https://doi.org/10.1093/jat/bkz018
Gaunitz F, Lehmann S, Thomas A, Thevis M, Rothschild MA, Mercer-Chalmers-Bender K (2018) Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. Int J Legal Med 132(6):1645–1657. https://doi.org/10.1007/s00414-018-1911-8
Gee P, Richardson S, Woltersdorf W, Moore G (2005) Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch. New Zealand N Z Med J 118(1227):U1784
Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P (2008) Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol (Phila) 46(9):802–807. https://doi.org/10.1080/15563650802307602
Gee P, Jerram T, Bowie D (2010) Multiorgan failure from 1-benzylpiperazine ingestion—legal high or lethal high? Clin Toxicol (Phila) 48(3):230–233. https://doi.org/10.3109/15563651003592948
Gerace E, Bovetto E, Corcia DD, Vincenti M, Salomone A (2017) A case of nonfatal intoxication associated with the recreational use of diphenidine. J Forensic Sci 62(4):1107–1111. https://doi.org/10.1111/1556-4029.13355
Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 29(9):445–453. https://doi.org/10.1016/j.tips.2008.06.006
Ghatol A, Kazory A (2012) Ecstasy-associated acute severe hyponatremia and cerebral edema: a role for osmotic diuresis? J Emerg Med 42(6):e137–e140. https://doi.org/10.1016/j.jemermed.2009.05.001
Gillespie TJ, Gandolfi AJ, Davis TP, Morano RA (1982) Identification and quantification of alpha-methylfentanyl in post mortem specimens. J Anal Toxicol 6(3):139–142. https://doi.org/10.1093/jat/6.3.139
Ginsberg MD, Hertzman M, Schmidt-Nowara WW (1970) Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure: a syndrome resembling heatstroke. Ann Intern Med 73(1):81–85. https://doi.org/10.7326/0003-4819-73-1-81
Gladden RM, O'Donnell J, Mattson CL, Seth P (2019) Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine—25 states, July–December 2017 to January–June 2018. MMWR Morb Mortal Wkly Rep 68(34):737–744. https://doi.org/10.15585/mmwr.mm6834a2
Glanville J, Dargan PI, Wood DM (2015) 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4ʹ-DMAR, 4,4ʹ-dimethylaminorex): availability, prevalence of use, desired effects and acute toxicity. Hum Psychopharmacol 30(3):193–198. https://doi.org/10.1002/hup.2472
Glue P, Al-Shaqsi S, Hancock D, Gale C, Strong B, Schep L (2013) Hospitalisation associated with use of the synthetic cannabinoid K2. N Z Med J 126(1377):18–23
González D, Torrens M, Farré M (2015) Acute effects of the novel psychoactive drug 2C-B on emotions. Biomed Res Int 2015:643878. https://doi.org/10.1155/2015/643878
Graham MR, Ryan P, Baker JS, Davies B, Thomas NE, Cooper SM, Evans P, Easmon S, Walker CJ, Cowan D, Kicman AT (2009) Counterfeiting in performance- and image-enhancing drugs. Drug Test Anal 1(3):135–142. https://doi.org/10.1002/dta.30
Grautoff S, Kähler J (2014) Lebensgefährliche Intoxikation mit der neuen psychoaktiven Substanz 25C-NBOMe. Medizinische Klinik Intensivmedizin und Notfallmedizin 109(4):271–275. https://doi.org/10.1007/s00063-014-0360-5
Green AR, Mechan AO, Elliott JM, Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 55(3):463. https://doi.org/10.1124/pr.55.3.3
Greene SL, Dargan PI, O'Connor N, Jones AL, Kerins M (2003) Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med 21(2):121–124. https://doi.org/10.1053/ajem.2003.50028
Grumann C, Henkel K, Stratford A, Hermanns-Clausen M, Passie T, Brandt SD, Auwärter V (2019) Validation of an LC–MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions. J Pharm Biomed Anal 174:270–276. https://doi.org/10.1016/j.jpba.2019.05.062
Gudsoorkar VS, Perez JA Jr (2015) A new differential diagnosis: synthetic cannabinoids-associated acute renal failure. Methodist Debakey Cardiovasc J 11(3):189–191. https://doi.org/10.14797/mdcj-11-3-189
Guerrieri D, Rapp E, Roman M, Druid H, Kronstrand R (2017) Postmortem and toxicological findings in a series of furanylfentanyl-related deaths. J Anal Toxicol 41(3):242–249. https://doi.org/10.1093/jat/bkw129
Gugelmann H, Gerona R, Li C, Tsutaoka B, Olson KR, Lung D (2014) 'Crazy Monkey' poisons man and dog: human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol (Phila) 52(6):635–638. https://doi.org/10.3109/15563650.2014.925562
Halachanova V, Sansone RA, McDonald S (2001) Delayed rhabdomyolysis after ecstasy use. Mayo Clin Proc 76(1):112–113. https://doi.org/10.4065/76.1.112
Halberstadt AL (2016) Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N, N-dimethyltryptamine. Pharmacol Biochem Behav 143:1–10. https://doi.org/10.1016/j.pbb.2016.01.005
Halberstadt AL (2017) Pharmacology and toxicology of N-benzylphenethylamine ("NBOMe") hallucinogens. Curr Top Behav Neurosci 32:283–311. https://doi.org/10.1007/7854_2016_64
Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61(3):364–381. https://doi.org/10.1016/j.neuropharm.2011.01.017
Halberstadt AL, Geyer MA (2014) Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 77:200–207. https://doi.org/10.1016/j.neuropharm.2013.08.025
Halberstadt AL, Nichols DE, Geyer MA (2012) Behavioral effects of α, α, β, β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology 221(4):709–718. https://doi.org/10.1007/s00213-011-2616-6
Halberstadt AL, Chatha M, Stratford A, Grill M, Brandt SD (2019) Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs. Neuropharmacology 144:368–376. https://doi.org/10.1016/j.neuropharm.2018.10.037
Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD (2020) Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology 1:107933. https://doi.org/10.1016/j.neuropharm.2019.107933
Hamilton RJ, Keyfes V, Banka SS (2017) Synthetic cannabinoid abuse resulting in ST-segment elevation myocardial infarction requiring percutaneous coronary intervention. J Emerg Med 52(4):496–498. https://doi.org/10.1016/j.jemermed.2016.09.023
Harris CR, Brown A (2013) Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 44(2):360–366. https://doi.org/10.1016/j.jemermed.2012.07.061
Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA (2002) Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. QJM 95(7):431–437. https://doi.org/10.1093/qjmed/95.7.431
Hasegawa K, Wurita A, Minakata K, Gonmori K, Yamagishi I, Nozawa H, Watanabe K, Suzuki O (2015) Identification and quantitation of 5-fluoro-ADB, one of the most dangerous synthetic cannabinoids, in the stomach contents and solid tissues of a human cadaver and in some herbal products. Forensic Toxicol 33(1):112–121. https://doi.org/10.1007/s11419-014-0259-0
Heal DJ, Smith SL, Gosden J, Nutt DJ (2013) Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol 27(6):479–496. https://doi.org/10.1177/0269881113482532
Heim R (2004) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts. Dissertation, Freie Universität Berlin. https://refubium.fu-berlin.de/bitstream/handle/fub188/11995/0_RalfHeimTitelblatt.pdf?sequence=1&isAllowed=y. Accessed 7 Jan 2020
Helander A, Bäckberg M, Beck O (2014) MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clin Toxicol (Phila) 52(8):901–904. https://doi.org/10.3109/15563650.2014.943908
Helander A, Beck O, Bäckberg M (2015) Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin Toxicol (Phila) 53(5):446–453. https://doi.org/10.3109/15563650.2015.1033630
Helander A, Bäckberg M, Beck O (2016) Intoxications involving the fentanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfentanyl: results from the Swedish STRIDA project. Clin Toxicol (Phila) 54(4):324–332. https://doi.org/10.3109/15563650.2016.1139715
Helander A, Bäckberg M, Signell P, Beck O (2017a) Intoxications involving acrylfentanyl and other novel designer fentanyls – results from the Swedish STRIDA project. Clin Toxicol (Phila) 55(6):589–599. https://doi.org/10.1080/15563650.2017.1303141
Helander A, Bradley M, Hasselblad A, Norlen L, Vassilaki I, Bäckberg M, Lapins J (2017b) Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45. Br J Dermatol 176(4):1021–1027. https://doi.org/10.1111/bjd.15174
Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340(8816):384–387. https://doi.org/10.1016/0140-6736(92)91469-o
Herian M, Wojtas A, Kaminska K, Swit P, Wach A, Golembiowska K (2019) Hallucinogen-like action of the novel designer drug 25I-NBOMe and its effect on cortical neurotransmitters in rats. Neurotox Res 36(1):91–100. https://doi.org/10.1007/s12640-019-00033-x
Hermanns-Clausen M, Kneisel S, Hutter M, Szabo B, Auwärter V (2013a) Acute intoxication by synthetic cannabinoids—four case reports. Drug Test Anal 5(9–10):790–794. https://doi.org/10.1002/dta.1483
Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013b) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108(3):534–544. https://doi.org/10.1111/j.1360-0443.2012.04078.x
Hermanns-Clausen M, Angerer V, Kithinji J, Grumann C, Auwärter V (2017) Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus. Clin Toxicol (Phila) 55(8):922–924. https://doi.org/10.1080/15563650.2017.1319572
Herraiz T, Brandt SD (2014) 5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO). Drug Test Anal 6(7–8):607–613. https://doi.org/10.1002/dta.1530
Hill SL, Thomas SH (2011) Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 49(8):705–719. https://doi.org/10.3109/15563650.2011.615318
Hill SL, Doris T, Gurung S, Katebe S, Lomas A, Dunn M, Blain P, Thomas SH (2013) Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila) 51(6):487–492. https://doi.org/10.3109/15563650.2013.802795
Hirapara K, Aggarwal R (2015) Synthetic cannabis and myocardial infarction: a complication less known! Psychosomatics 56(6):712–713. https://doi.org/10.1016/j.psym.2015.07.009
Ho JH, Bailey GP, Archer JR, Dargan PI, Wood DM (2015) Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance. Eur J Clin Pharmacol 71(10):1185–1196. https://doi.org/10.1007/s00228-015-1906-z
Hobbs M, Kalk NJ, Morrison PD, Stone JM (2018) Spicing it up—synthetic cannabinoid receptor agonists and psychosis—a systematic review. Eur Neuropsychopharmacol 28(12):1289–1304. https://doi.org/10.1016/j.euroneuro.2018.10.004
Hofer KE, Grager B, Müller DM, Rauber-Lüthy C, Kupferschmidt H, Rentsch KM, Ceschi A (2012) Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med 60(1):97–99. https://doi.org/10.1016/j.annemergmed.2011.11.018
Hofer KE, Degrandi C, Müller DM, Zürrer-Härdi U, Wahl S, Rauber-Lüthy C, Ceschi A (2014) Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine. Clin Toxicol (Phila) 52(10):1288–1291. https://doi.org/10.3109/15563650.2014.974264
Hofmann A, Troxler F (1962) Nouveaux dérivés de l'indole, procédé de préparation et médicaments les contenant. FR1344579
Hondebrink L, Nugteren-van Lonkhuyzen JJ, Rietjens SJ, Brunt TM, Venhuis B, Soerdjbalie-Maikoe V, Smink BE, Van Riel A, De Vries I (2018) Fatalities, cerebral hemorrhage, and severe cardiovascular toxicity after exposure to the new psychoactive substance 4-fluoroamphetamine: a prospective cohort study. Ann Emerg Med 71(3):294–305. https://doi.org/10.1016/j.annemergmed.2017.07.482
Hopkins CY, Gilchrist BL (2013) A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med 45(4):544–546. https://doi.org/10.1016/j.jemermed.2012.11.034
Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ (2012) A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 60(4):435–438. https://doi.org/10.1016/j.annemergmed.2012.03.007
Huang HH, Bai YM (2011) Persistent psychosis after ingestion of a single tablet of '2C-B'. Prog Neuropsychopharmacol Biol Psychiatry 35(1):293–294. https://doi.org/10.1016/j.pnpbp.2010.10.018
Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL (2009) Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment. Mol Pharmacol 76(4):710–722. https://doi.org/10.1124/mol.109.058057
Hurst D, Loeffler G, McLay R (2011) Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 168(10):1119. https://doi.org/10.1176/appi.ajp.2011.11010176
Ibrahim S, Al-Saffar F, Wannenburg T (2014) A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol 2014:120607. https://doi.org/10.1155/2014/120607
Ikeda A, Sekiguchi K, Fujita K, Yamadera H, Koga Y (2005) 5-methoxy-N, N-diisopropyltryptamine-induced flashbacks. Am J Psychiatry 162(4):815. https://doi.org/10.1176/appi.ajp.162.4.815
Imbert L, Boucher A, Delhome G, Cueto T, Boudinaud M, Maublanc J, Dulaurent S, Descotes J, Lachatre G, Gaulier JM (2014) Analytical findings of an acute intoxication after inhalation of methoxetamine. J Anal Toxicol 38(7):410–415. https://doi.org/10.1093/jat/bku052
Inan F, Brunt TM, Contrucci RR, Hondebrink L, Franssen EJF (2020) Novel phenethylamines and their potential interactions with prescription drugs: a systematic critical review. Ther Drug Monit. https://doi.org/10.1097/ftd.0000000000000725
Isoardi KZ, Kulawickrama S, Isbister GK (2020) Severe phenibut poisoning: an adolescent case cluster. J Paediatr Child Health 56(2):330–331. https://doi.org/10.1111/jpc.14605
Itokawa M, Iwata K, Takahashi M, Sugihara G, Sasaki T, Abe Y, Uno M, Hobo M, Jitoku D, Inoue K, Arai M, Yasuda I, Shintani M (2007) Acute confusional state after designer tryptamine abuse. Psychiatry Clin Neurosci 61(2):196–199. https://doi.org/10.1111/j.1440-1819.2007.01638.x
Ivanov ID, Stoykova S, Ivanova E, Vlahova A, Burdzhiev N, Pantcheva I, Atanasov VN (2019) A case of 5F-ADB/FUB-AMB abuse: drug-induced or drug-related death? Forensic Sci Int 297:372–377. https://doi.org/10.1016/j.forsciint.2019.02.005
Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL (2013) Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 700(1–3):147–151. https://doi.org/10.1016/j.ejphar.2012.12.006
Iwersen-Bergmann S, Lehmann S, Heinemann A, Schröder C, Müller A, Jungen H, Andresen-Streichert H, Pueschel K, Vidal C, Mercer-Chalmers-Bender K (2019) Mass poisoning with NPS: 2C-E and Bromo-DragonFly. Int J Legal Med 133(1):123–129. https://doi.org/10.1007/s00414-018-1882-9
James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, Thomas SH (2011) Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 28(8):686–689. https://doi.org/10.1136/emj.2010.096636
Javadi-Paydar M, Nguyen JD, Vandewater SA, Dickerson TJ, Taffe MA (2018) Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats. Neuropharmacology 134(Pt A):57–64. https://doi.org/10.1016/j.neuropharm.2017.09.002
Jebadurai J, Schifano F, Deluca P (2013) Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl)benzofuran (benzofury/6-APB) and NRG-2 with review of available evidence-based literature. Hum Psychopharmacol 28(4):356–364. https://doi.org/10.1002/hup.2302
Jensen AA, McCorvy JD, Leth-Petersen S, Bundgaard C, Liebscher G, Kenakin TP, Brauner-Osborne H, Kehler J, Kristensen JL (2017) Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J Pharmacol Exp Ther 361(3):441–453. https://doi.org/10.1124/jpet.117.239905
Jerrard DA (1990) "Designer drugs”—a current perspective. J Emerg Med 8(6):733–741. https://doi.org/10.1016/0736-4679(90)90288-7
Jinwala FN, Gupta M (2012) Synthetic cannabis and respiratory depression. J Child Adolesc Psychopharmacol 22(6):459–462. https://doi.org/10.1089/cap.2011.0122
Johansson A, Lindstedt D, Roman M, Thelander G, Nielsen EI, Lennborn U, Sandler H, Rubertsson S, Ahlner J, Kronstrand R, Kugelberg FC (2017) A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP. Forensic Sci Int 275:76–82. https://doi.org/10.1016/j.forsciint.2017.02.034
Johnson MP, Huang XM, Oberlender R, Nash JF, Nichols DE (1990) Behavioral, biochemical and neurotoxicological actions of the α-ethyl homologue of p-chloroamphetamine. Eur J Pharmacol 191(1):1–10. https://doi.org/10.1016/0014-2999(90)94090-k
Johnson LA, Johnson RL, Alfonzo C (2011) Spice: a legal marijuana equivalent. Mil Med 176(6):718–720. https://doi.org/10.7205/milmed-d-10-00356
Jones AL, Jarvie DR, McDermid G, Proudfoot AT (1994) Hepatocellular damage following amphetamine intoxication. J Toxicol Clin Toxicol 32(4):435–444. https://doi.org/10.3109/15563659409011046
Jones JD, Mogali S, Comer SD (2012) Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 125(1–2):8–18. https://doi.org/10.1016/j.drugalcdep.2012.07.004
Jones MJ, Hernandez BS, Janis GC, Stellpflug SJ (2017) A case of U-47700 overdose with laboratory confirmation and metabolite identification. Clin Toxicol (Phila) 55(1):55–59. https://doi.org/10.1080/15563650.2016.1209767
Joseph JF, Parr MK (2015) Synthetic androgens as designer supplements. Curr Neuropharmacol 13(1):89–100. https://doi.org/10.2174/1570159x13666141210224756
Jovel A, Felthous A, Bhattacharyya A (2014) Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. J Forensic Sci 59(3):844–846. https://doi.org/10.1111/1556-4029.12367
Kamel M, Thajudeen B (2015) A case of acute kidney injury and calcium oxalate deposition associated with synthetic cannabinoids. Saudi J Kidney Dis Transpl 26(4):802–803. https://doi.org/10.4103/1319-2442.160222
Kamijo Y, Soma K, Nishida M, Namera A, Ohwada T (2002) Acute liver failure following intravenous methamphetamine. Vet Hum Toxicol 44(4):216–217
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1):309–380. https://doi.org/10.1152/physrev.00019.2008
Kapil V, Green JL, Le Lait C, Wood DM, Dargan PI (2014) Misuse of benzodiazepines and Z-drugs in the UK. Br J Psychiatry 205(5):407–408. https://doi.org/10.1192/bjp.bp.114.149252
Karinen R, Tuv SS, Rogde S, Peres MD, Johansen U, Frost J, Vindenes V, Oiestad AM (2014) Lethal poisonings with AH-7921 in combination with other substances. Forensic Sci Int 244:e21–e24. https://doi.org/10.1016/j.forsciint.2014.08.013
Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S (2015) 5-(2-aminopropyl)indole: a new player in the drama of 'legal highs' alerts the community. Drug Alcohol Rev 34(1):51–57. https://doi.org/10.1111/dar.12136
Katz DP, Deruiter J, Bhattacharya D, Ahuja M, Bhattacharya S, Clark CR, Suppiramaniam V, Dhanasekaran M (2016a) Benzylpiperazine: “a messy drug". Drug Alcohol Depend 164:1–7. https://doi.org/10.1016/j.drugalcdep.2016.04.010
Katz KD, Leonetti AL, Bailey BC, Surmaitis RM, Eustice ER, Kacinko S, Wheatley SM (2016b) Case series of synthetic cannabinoid intoxication from one toxicology center. West J Emerg Med 17(3):290–294. https://doi.org/10.5811/westjem.2016.2.29519
Kazory A, Aiyer R (2013) Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J 6(3):330–333. https://doi.org/10.1093/ckj/sft047
Kelkar AH, Smith NA, Martial A, Moole H, Tarantino MD, Roberts JC (2018) An outbreak of synthetic cannabinoid-associated coagulopathy in Illinois. N Engl J Med 379(13):1216–1223. https://doi.org/10.1056/NEJMoa1807652
Kendrick WC, Hull AR, Knochel JP (1977) Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med 86(4):381–387. https://doi.org/10.7326/0003-4819-86-4-381
Kesha K, Boggs CL, Ripple MG, Allan CH, Levine B, Jufer-Phipps R, Doyon S, Chi P, Fowler DR (2013) Methylenedioxypyrovalerone ("bath salts"), related death: case report and review of the literature. J Forensic Sci 58(6):1654–1659. https://doi.org/10.1111/1556-4029.12202
Khan M, Pace L, Truong A, Gordon M, Moukaddam N (2016) Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis. Am J Addict 25(1):25–27. https://doi.org/10.1111/ajad.12318
Kicman AT (2008) Pharmacology of anabolic steroids. Br J Pharmacol 154(3):502–521. https://doi.org/10.1038/bjp.2008.165
Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20(1):19–26. https://doi.org/10.1016/s0165-6147(98)01279-6
Kim HK, Nelson LS (2015) Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf 14(7):1137–1146. https://doi.org/10.1517/14740338.2015.1037274
Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL (2018) Receptor binding profiles and behavioral pharmacology of ring-substituted N, N-diallyltryptamine analogs. Neuropharmacology 142:231–239. https://doi.org/10.1016/j.neuropharm.2018.02.028
Knudsen K, Jonsson U, Abrahamsson J (2010) Twenty-three deaths with γ-hydroxybutyrate overdose in western Sweden between 2000 and 2007. Acta Anaesthesiol Scand 54(8):987–992. https://doi.org/10.1111/j.1399-6576.2010.02278.x
Koch K, Auwärter V, Hermanns-Clausen M, Wilde M, Neukamm MA (2018) Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: pharmacokinetic data. Drug Test Anal. https://doi.org/10.1002/dta.2391
Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2019) Receptor interaction profiles of 4-alkoxy-substituted 2,5-dimethoxyphenethylamines and related amphetamines. Front Pharmacol 10:1423. https://doi.org/10.3389/fphar.2019.01423
Kovacs K, Kereszty E, Berkecz R, Tiszlavicz L, Sija E, Kormoczi T, Jenei N, Revesz-Schmehl H, Institoris L (2019) Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption. J Forensic Leg Med 65:92–100. https://doi.org/10.1016/j.jflm.2019.04.012
Kovaleva J, Devuyst E, De Paepe P, Verstraete A (2008) Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit 30(3):394–398. https://doi.org/10.1097/FTD.0b013e318170a879
Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, Vollenweider FX (2017) Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology. https://doi.org/10.1007/s00213-017-4610-0
Kraemer M, Fels H, Dame T, Musshoff F, Halter S, Mogler L, Hess C, Madea B, Maas A (2019) Mono-/polyintoxication with 5F-ADB: a case series. Forensic Sci Int 301:e29–e37. https://doi.org/10.1016/j.forsciint.2019.05.017
Kriikku P, Pelander A, Rasanen I, Ojanpera I (2019) Toxic lifespan of the synthetic opioid U-47,700 in Finland verified by re-analysis of UPLC–TOF–MS data. Forensic Sci Int 300:85–88. https://doi.org/10.1016/j.forsciint.2019.04.030
Kronstrand R, Roman M, Dahlgren M, Thelander G, Wikström M, Druid H (2013) A cluster of deaths involving 5-(2-aminopropyl)indole (5-IT). J Anal Toxicol 37(8):542–546. https://doi.org/10.1093/jat/bkt058
Kronstrand R, Thelander G, Lindstedt D, Roman M, Kugelberg FC (2014) Fatal intoxications associated with the designer opioid AH-7921. J Anal Toxicol 38(8):599–604. https://doi.org/10.1093/jat/bku057
Krotulski AJ, Papsun DM, Friscia M, Swartz JL, Holsey BD, Logan BK (2018) Fatality following ingestion of tetrahydrofuranylfentanyl, U-49900 and methoxy-phencyclidine. J Anal Toxicol 42(3):e27–e32. https://doi.org/10.1093/jat/bkx092
Krueger J, Sachs H, Musshoff F, Dame T, Schaeper J, Schwerer M, Graw M, Roider G (2014) First detection of ethylphenidate in human fatalities after ethylphenidate intake. Forensic Sci Int 243:126–129. https://doi.org/10.1016/j.forsciint.2014.07.017
Kudo K, Usumoto Y, Kikura-Hanajiri R, Sameshima N, Tsuji A, Ikeda N (2015) A fatal case of poisoning related to new cathinone designer drugs, 4-methoxy PV8, PV9, and 4-methoxy PV9, and a dissociative agent, diphenidine. Leg Med (Tokyo) 17(5):421–426. https://doi.org/10.1016/j.legalmed.2015.06.005
Kueppers VB, Cooke CT (2015) 25I-NBOMe related death in Australia: a case report. Forensic Sci Int 249:e15–e18. https://doi.org/10.1016/j.forsciint.2015.02.010
Kuhar MJ, Ritz MC, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14(7):299–302. https://doi.org/10.1016/0166-2236(91)90141-g
Kusano M, Zaitsu K, Taki K, Hisatsune K, Nakajima J, Moriyasu T, Asano T, Hayashi Y, Tsuchihashi H, Ishii A (2018) Fatal intoxication by 5F-ADB and diphenidine: detection, quantification, and investigation of their main metabolic pathways in humans by LC/MS/MS and LC/Q–TOFMS. Drug Test Anal 10(2):284–293. https://doi.org/10.1002/dta.2215
Labay LM, Caruso JL, Gilson TP, Phipps RJ, Knight LD, Lemos NP, McIntyre IM, Stoppacher R, Tormos LM, Wiens AL, Williams E, Logan BK (2016) Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int 260:31–39. https://doi.org/10.1016/j.forsciint.2015.12.046
Lafferty C, Smith L, Coull A, Shanley J (2016) The experience of an increase in the injection of ethylphenidate in Lothian April 2014–March 2015. Scott Med J 61(2):74–83. https://doi.org/10.1177/0036933016649871
Lam RP, Yip WL, Tsui MS, Ng SW, Ching CK, Mak TW (2016) Severe rhabdomyolysis and acute kidney injury associated with methoxphenidine. Clin Toxicol (Phila) 54(5):464–465. https://doi.org/10.3109/15563650.2016.1157724
Lapin I (2001) Phenibut (β-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev 7(4):471–481. https://doi.org/10.1111/j.1527-3458.2001.tb00211.x
Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH (2011) Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 49(8):760–764. https://doi.org/10.3109/15563650.2011.609822
Law R, Schier J, Martin C, Chang A, Wolkin A (2015) Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use—United States, January–May 2015. MMWR Morb Mortal Wkly Rep 64(22):618–619
Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D (2017) Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther 101(2):220–229. https://doi.org/10.1002/cpt.563
Lawn W, Borschmann R, Cottrell A, Winstock A (2016) Methoxetamine: prevalence of use in the USA and UK and associated urinary problems. J Subst Use 21(2):115–120. https://doi.org/10.3109/14659891.2014.966345
Lee HM, Wood DM, Hudson S, Archer JR, Dargan PI (2014) Acute toxicity associated with analytically confirmed recreational use of methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane). J Med Toxicol 10(3):299–302. https://doi.org/10.1007/s13181-014-0399-y
Lee D, Chronister CW, Hoyer J, Goldberger BA (2015) Ethylone-related deaths: toxicological findings. J Anal Toxicol 39(7):567–571. https://doi.org/10.1093/jat/bkv053
Leibu E, Garakani A, McGonigle DP, Liebman LS, Loh D, Bryson EO, Kellner CH (2013) Electroconvulsive therapy (ECT) for catatonia in a patient with schizophrenia and synthetic cannabinoid abuse: a case report. J ECT 29(4):e61–e62. https://doi.org/10.1097/YCT.0b013e318290fa36
Li L, Vlisides PE (2016) Ketamine: 50 years of modulating the mind. Front Hum Neurosci 10:612. https://doi.org/10.3389/fnhum.2016.00612
Liakoni E, Walther F, Nickel CH, Liechti ME (2016) Presentations to an urban emergency department in Switzerland due to acute γ-hydroxybutyrate toxicity. Scand J Trauma Resusc Emerg Med 24(1):107. https://doi.org/10.1186/s13049-016-0299-z
Liechti ME (2017) Modern clinical research on LSD. Neuropsychopharmacology 42(11):2114–2127. https://doi.org/10.1038/npp.2017.86
Lin JC, Jan RK, Lee H, Jensen MA, Kydd RR, Russell BR (2011) Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology 214(3):761–768. https://doi.org/10.1007/s00213-010-2081-7
Liveri K, Constantinou MA, Afxentiou M, Kanari P (2016) A fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus. Forensic Sci Int 265:160–165. https://doi.org/10.1016/j.forsciint.2016.02.017
Loi B, Zloh M, De Luca MA, Pintori N, Corkery J, Schifano F (2017) 4,4ʹ-Dimethylaminorex (“4,4ʹ-DMAR”; “Serotoni”) misuse: a Web-based study. Hum Psychopharmacol 32(3):1. https://doi.org/10.1002/hup.2575
Longo LP, Johnson B (2000) Addiction. Part I Benzodiazepines–side effects, abuse risk and alternatives. Am Fam Physician 61(7):2121–2128
Longworth M, Connor M, Banister SD, Kassiou M (2017) Synthesis and pharmacological profiling of the metabolites of synthetic cannabinoid drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. ACS Chem Neurosci 8(8):1673–1680. https://doi.org/10.1021/acschemneuro.7b00116
Lucyk SN, Nelson LS (2017) Novel synthetic opioids: an opioid epidemic within an opioid epidemic. Ann Emerg Med 69(1):91–93. https://doi.org/10.1016/j.annemergmed.2016.08.445
Luethi D, Liechti ME (2018) Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int J Neuropsychopharmacol 21(10):926–931. https://doi.org/10.1093/ijnp/pyy047
Luethi D, Liechti ME, Krähenbühl S (2017) Mechanisms of hepatocellular toxicity associated with new psychoactive synthetic cathinones. Toxicology 387:57–66. https://doi.org/10.1016/j.tox.2017.06.004
Luethi D, Hoener MC, Liechti ME (2018a) Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems. Eur J Pharmacol 819:242–247. https://doi.org/10.1016/j.ejphar.2017.12.012
Luethi D, Kaeser PJ, Brandt SD, Krähenbühl S, Hoener MC, Liechti ME (2018b) Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology 134(Pt A):133–140. https://doi.org/10.1016/j.neuropharm.2017.08.020
Luethi D, Kolaczynska KE, Docci L, Krähenbühl S, Hoener MC, Liechti ME (2018c) Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology 134(Pt A):4–12. https://doi.org/10.1016/j.neuropharm.2017.07.026
Luethi D, Trachsel D, Hoener MC, Liechti ME (2018d) Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology 134(Pt A):141–148. https://doi.org/10.1016/j.neuropharm.2017.07.012
Luethi D, Kolaczynska KE, Walter M, Suzuki M, Rice KC, Blough BE, Hoener MC, Baumann MH, Liechti ME (2019a) Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems. J Psychopharmacol 33(7):831–841. https://doi.org/10.1177/0269881119844185
Luethi D, Walter M, Zhou X, Rudin D, Krähenbühl S, Liechti ME (2019b) Para-halogenation affects monoamine transporter inhibition properties and hepatocellular toxicity of amphetamines and methcathinones. Front Pharmacol 10:438. https://doi.org/10.3389/fphar.2019.00438
Luethi D, Widmer R, Trachsel D, Hoener MC, Liechti ME (2019c) Monoamine receptor interaction profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI derivatives). Eur J Pharmacol 855:103–111. https://doi.org/10.1016/j.ejphar.2019.05.014
Lüthi D, Liechti ME (2019) Clinical aspects related to methylphenidate-based NPS. In: Corazza O, Roman-Urrestarazu A (eds) Handbook of novel psychoactive substances: what clinicians should know about NPS. Routledge, New York, pp 227–244
Maas A, Wippich C, Madea B, Hess C (2015) Driving under the influence of synthetic phenethylamines: a case series. Int J Legal Med 129(5):997–1003. https://doi.org/10.1007/s00414-015-1150-1
Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbaek DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44(7):1328–1334. https://doi.org/10.1038/s41386-019-0324-9
Maeda H, Kikura-Hanajiri R, Kawamura M, Nagashima E, Yoshida KI (2018) AB-CHMINACA-induced sudden death from non-cardiogenic pulmonary edema. Clin Toxicol (Phila) 56(2):143–145. https://doi.org/10.1080/15563650.2017.1340648
Maguire P, Tsai N, Kamal J, Cometta-Morini C, Upton C, Loew G (1992) Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors. Eur J Pharmacol 213(2):219–225. https://doi.org/10.1016/0014-2999(92)90685-w
Maier J, Mayer FP, Brandt SD, Sitte HH (2018a) DARK classics in chemical neuroscience: aminorex analogues. ACS Chem Neurosci 9(10):2484–2502. https://doi.org/10.1021/acschemneuro.8b00415
Maier J, Mayer FP, Luethi D, Holy M, Jäntsch K, Reither H, Hirtler L, Hoener MC, Liechti ME, Pifl C, Brandt SD, Sitte HH (2018b) The psychostimulant (±)-cis-4,4ʹ-dimethylaminorex (4,4ʹ-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. Neuropharmacology 138:282–291. https://doi.org/10.1016/j.neuropharm.2018.06.018
Majchrzak M, Celinski R, Kowalska T, Sajewicz M (2018) Fatal case of poisoning with a new cathinone derivative: α-propylaminopentiophenone (N-PP). Forensic Toxicol 36(2):525–533. https://doi.org/10.1007/s11419-018-0417-x
Majrashi M, Almaghrabi M, Fadan M, Fujihashi A, Lee W, Deruiter J, Randall Clark C, Dhanasekaran M (2018) Dopaminergic neurotoxic effects of 3-TFMPP derivatives. Life Sci 209:357–369. https://doi.org/10.1016/j.lfs.2018.07.052
Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD (2018) The emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug Test Anal 10(1):37–53. https://doi.org/10.1002/dta.2211
Marinetti LJ, Antonides HM (2013) Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol 37(3):135–146. https://doi.org/10.1093/jat/bks136
Markowitz JS, Zhu HJ, Patrick KS (2013) Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability. J Child Adolesc Psychopharmacol 23(10):648–654. https://doi.org/10.1089/cap.2013.0074
Martinotti G, Santacroce R, Papanti D, Elgharably Y, Prilutskaya M, Corazza O (2017) Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset. CNS Neurol Disord Drug Targets 16(5):567–575. https://doi.org/10.2174/1871527316666170413101839
Martucci HFH, Ingle EA, Hunter MD, Rodda LN (2018) Distribution of furanyl fentanyl and 4-ANPP in an accidental acute death: a case report. Forensic Sci Int 283:e13–e17. https://doi.org/10.1016/j.forsciint.2017.12.005
Marusich JA, Antonazzo KR, Blough BE, Brandt SD, Kavanagh PV, Partilla JS, Baumann MH (2016) The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue. Neuropharmacology 101:68–75. https://doi.org/10.1016/j.neuropharm.2015.09.004
Maskell PD, De Paoli G, Seneviratne C, Pounder DJ (2011a) Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35(3):188–191. https://doi.org/10.1093/anatox/35.3.188
Maskell PD, Paoli GD, Seetohul LN, Pounder DJ (2011b) Phenazepam is currently being misused in the UK. BMJ 343:d4207. https://doi.org/10.1136/bmj.d4207
Maskell PD, Smith PR, Cole R, Hikin L, Morley SR (2016) Seven fatalities associated with ethylphenidate. Forensic Sci Int 265:70–74. https://doi.org/10.1016/j.forsciint.2015.12.045
Mayer FP, Wimmer L, Dillon-Carter O, Partilla JS, Burchardt NV, Mihovilovic MD, Baumann MH, Sitte HH (2016) Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters. Br J Pharmacol 173(17):2657–2668. https://doi.org/10.1111/bph.13547
Mayer FP, Burchardt NV, Decker AM, Partilla JS, Li Y, McLaughlin G, Kavanagh PV, Sandtner W, Blough BE, Brandt SD, Baumann MH, Sitte HH (2018) Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family. Neuropharmacology 134(Pt A):149–157. https://doi.org/10.1016/j.neuropharm.2017.10.006
Mayer FP, Cintulova D, Pittrich DA, Wimmer L, Luethi D, Holy M, Jaentsch K, Tischberger S, Gmeiner G, Hoener MC, Liechti ME, Mihovilovic MD, Sitte HH (2019a) Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter. Neuropharmacology 148:199–209. https://doi.org/10.1016/j.neuropharm.2018.12.032
Mayer FP, Schmid D, Holy M, Daws LC, Sitte HH (2019b) "Polytox" synthetic cathinone abuse: a potential role for organic cation transporter 3 in combined cathinone-induced efflux. Neurochem Int 123:7–12. https://doi.org/10.1016/j.neuint.2018.09.008
McCabe DJ, Bangh SA, Arens AM, Cole JB (2019) Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med 37(11):2066–2071. https://doi.org/10.1016/j.ajem.2019.02.044
McIlroy G, Ford L, Khan JM (2016) Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report. BMC Pharmacol Toxicol 17:2. https://doi.org/10.1186/s40360-016-0045-1
McIntyre IM, Gary RD, Trochta A, Stolberg S, Stabley R (2015a) Acute 5-(2-aminopropyl)benzofuran (5-APB) intoxication and fatality: a case report with postmortem concentrations. J Anal Toxicol 39(2):156–159. https://doi.org/10.1093/jat/bku131
McIntyre IM, Trochta A, Gary RD, Malamatos M, Lucas JR (2015b) An acute acetyl fentanyl fatality: a case report with postmortem concentrations. J Anal Toxicol 39(6):490–494. https://doi.org/10.1093/jat/bkv043
McIntyre IM, Trochta A, Gary RD, Storey A, Corneal J, Schaber B (2015c) A fatality related to two novel hallucinogenic compounds: 4-methoxyphencyclidine and 4-hydroxy-N-methyl-N-ethyltryptamine. J Anal Toxicol 39(9):751–755. https://doi.org/10.1093/jat/bkv089
McIntyre IM, Trochta A, Gary RD, Wright J, Mena O (2016) An acute butyr-fentanyl fatality: a case report with postmortem concentrations. J Anal Toxicol 40(2):162–166. https://doi.org/10.1093/jat/bkv138
McIntyre IM, Gary RD, Joseph S, Stabley R (2017) A fatality related to the synthetic opioid U-47700: postmortem concentration distribution. J Anal Toxicol 41(2):158–160. https://doi.org/10.1093/jat/bkw124
McKeever RG, Vearrier D, Jacobs D, LaSala G, Okaneku J, Greenberg MI (2015) K2–not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report. J Med Toxicol 11(1):129–131. https://doi.org/10.1007/s13181-014-0424-1
McLaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O'Brien J, Talbot B, Dowling G, Mahony O, Brandt SD, Patrick J, Archer RP, Partilla JS, Baumann MH (2015) Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3ʹ,4ʹ-methylenedioxy-4-methylaminorex (MDMAR). Drug Test Anal 7(7):555–564. https://doi.org/10.1002/dta.1732
McLaughlin G, Baumann MH, Kavanagh PV, Morris N, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Westphal F, Walther D, Brandt SD (2018) Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers. Drug Test Anal 10(9):1404–1416. https://doi.org/10.1002/dta.2396
McQuade D, Hudson S, Dargan PI, Wood DM (2013) First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 69(3):373–376. https://doi.org/10.1007/s00228-012-1379-2
Meatherall R, Sharma P (2003) Foxy, a designer tryptamine hallucinogen. J Anal Toxicol 27(5):313–317. https://doi.org/10.1093/jat/27.5.313
Mehta JJ, Mahendran AK, Bajaj RK, Doshi AR (2017) Myocardial ischemia with cannabinoid use in an adolescent. Cureus 9(11):e1899. https://doi.org/10.7759/cureus.1899
Meijer KA, Russo RR, Adhvaryu DV (2014) Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations. Orthopedics 37(4):e391–e394. https://doi.org/10.3928/01477447-20140401-62
Mensen VT, Vreeker A, Nordgren J, Atkinson A, De la Torre R, Farre M, Ramaekers JG, Brunt TM (2019) Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. Psychopharmacology 236(9):2677–2685. https://doi.org/10.1007/s00213-019-05238-8
Miliano C, Margiani G, Fattore L, De Luca MA (2018) Sales and advertising channels of new psychoactive substances (NPS): Internet, social networks, and smartphone apps. Brain Sci 8(7):1. https://doi.org/10.3390/brainsci8070123
Miller KJ, Anderholm DC, Ames MM (1986) Metabolic activation of the serotonergic neurotoxin para-chloroamphetamine to chemically reactive intermediates by hepatic and brain microsomal preparations. Biochem Pharmacol 35(10):1737–1742. https://doi.org/10.1016/0006-2952(86)90332-1
Mills EM, Banks ML, Sprague JE, Finkel T (2003) Pharmacology: uncoupling the agony from ecstasy. Nature 426(6965):403–404. https://doi.org/10.1038/426403a
Mills EM, Rusyniak DE, Sprague JE (2004) The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J Mol Med (Berl) 82(12):787–799. https://doi.org/10.1007/s00109-004-0591-7
Mills B, Dishner E, Velasco CE (2018) Acute myocardial infarction triggered by use of synthetic cannabis. Proc (Bayl Univ Med Cent) 31(2):200–202. https://doi.org/10.1080/08998280.2017.1416243
Mir A, Obafemi A, Young A, Kane C (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128(6):e1622–e1627. https://doi.org/10.1542/peds.2010-3823
Misra M, Shi Q, Ye X, Gruszecka-Kowalik E, Bu W, Liu Z, Schweri MM, Deutsch HM, Venanzi CA (2010) Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem 18(20):7221–7238. https://doi.org/10.1016/j.bmc.2010.08.034
Mitchell-Mata C, Thomas B, Peterson B, Couper F (2017) Two fatal intoxications involving 3-methoxyphencyclidine. J Anal Toxicol 41(6):503–507. https://doi.org/10.1093/jat/bkx048
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25(4):439–452. https://doi.org/10.1177/0269881110378371
Mithoefer MC, Grob CS, Brewerton TD (2016) Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry 3(5):481–488. https://doi.org/10.1016/s2215-0366(15)00576-3
Miyajima M, Matsumoto T, Ito S (2008) 2C-T-4 intoxication: acute psychosis caused by a designer drug. Psychiatry Clin Neurosci 62(2):243. https://doi.org/10.1111/j.1440-1819.2008.01764.x
Moeller S, Lücke C, Struffert T, Schwarze B, Gerner ST, Schwab S, Köhrmann M, Machold K, Philipsen A, Müller HH (2017) Ischemic stroke associated with the use of a synthetic cannabinoid (spice). Asian J Psychiatr 25:127–130. https://doi.org/10.1016/j.ajp.2016.10.019
Mohammed D (2019) Occurrence of takotsubo cardiomyopathy after synthetic cannabinoid consumption. Addict Health 11(3):202–206. https://doi.org/10.22122/ahj.v11i3.239
Mohr AL, Friscia M, Papsun D, Kacinko SL, Buzby D, Logan BK (2016) Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC–MS/MS in postmortem casework. J Anal Toxicol 40(9):709–717. https://doi.org/10.1093/jat/bkw086
Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (1993) Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. J Med Chem 36(23):3700–3706. https://doi.org/10.1021/jm00075a027
Moosmann B, Auwärter V (2018) Designer benzodiazepines: another class of new psychoactive substances. Handb Exp Pharmacol 252:383–410. https://doi.org/10.1007/164_2018_154
Morgan CJ, Curran HV (2006) Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology 188(4):408–424. https://doi.org/10.1007/s00213-006-0572-3
Moritz ML, Kalantar-Zadeh K, Ayus JC (2013) Ecstacy-associated hyponatremia: why are women at risk? Nephrol Dial Transplant 28(9):2206–2209. https://doi.org/10.1093/ndt/gft192
Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6(7–8):614–632. https://doi.org/10.1002/dta.1620
Morse BL, Vijay N, Morris ME (2012) γ-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose. Mol Pharmacol 82(2):226–235. https://doi.org/10.1124/mol.112.078154
Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321(3):1054–1061. https://doi.org/10.1124/jpet.106.117507
Muller AA (2004) New drugs of abuse update: Foxy Methoxy. J Emerg Nurs 30(5):507–508. https://doi.org/10.1016/j.jen.2004.07.037
Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM (2010) The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 118(1–3):309–310. https://doi.org/10.1016/j.schres.2009.12.001
Müller D, Neurath H, Neukamm MA, Wilde M, Despicht C, Blaschke S, Grapp M (2019) New synthetic opioid cyclopropylfentanyl together with other novel synthetic opioids in respiratory insufficient comatose patients detected by toxicological analysis. Clin Toxicol (Phila) 57(9):806–812. https://doi.org/10.1080/15563650.2018.1554187
Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, Auwärter V (2014) Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Legal Med 128(1):59–64. https://doi.org/10.1007/s00414-013-0864-1
Muttoni S, Ardissino M, John C (2019) Classical psychedelics for the treatment of depression and anxiety: a systematic review. J Affect Disord 258:11–24. https://doi.org/10.1016/j.jad.2019.07.076
Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J (2013) The synthetic cannabinoid withdrawal syndrome. J Addict Med 7(4):296–298. https://doi.org/10.1097/ADM.0b013e31828e1881
Nagai H, Saka K, Nakajima M, Maeda H, Kuroda R, Igarashi A, Tsujimura-Ito T, Nara A, Komori M, Yoshida K (2014) Sudden death after sustained restraint following self-administration of the designer drug α-pyrrolidinovalerophenone. Int J Cardiol 172(1):263–265. https://doi.org/10.1016/j.ijcard.2013.12.262
Nash C, Butzbach D, Stockham P, Scott T, Abroe G, Painter B, Gilbert J, Kostakis C (2019) A fatality involving furanylfentanyl and MMMP, with presumptive identification of three MMMP metabolites in urine. J Anal Toxicol 43(4):291–298. https://doi.org/10.1093/jat/bky099
Nguyen PT, Dang DK, Tran HQ, Shin EJ, Jeong JH, Nah SY, Cho MC, Lee YS, Jang CG, Kim HC (2019) Methiopropamine, a methamphetamine analogue, produces neurotoxicity via dopamine receptors. Chem Biol Interact 305:134–147. https://doi.org/10.1016/j.cbi.2019.03.017
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002
Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264–355. https://doi.org/10.1124/pr.115.011478
Nichols DE, Grob CS (2018) Is LSD toxic? Forensic Sci Int 284:141–145. https://doi.org/10.1016/j.forsciint.2018.01.006
Nichols DE, Johnson MP, Oberlender R (1991) 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine. Pharmacol Biochem Behav 38(1):135–139. https://doi.org/10.1016/0091-3057(91)90601-w
Niello M, Cintulova D, Hellsberg E, Jäntsch K, Holy M, Ayatollahi LH, Cozzi NV, Freissmuth M, Sandtner W, Ecker GF, Mihovilovic MD, Sitte HH (2019) para-Trifluoromethyl-methcathinone is an allosteric modulator of the serotonin transporter. Neuropharmacology 161:107615. https://doi.org/10.1016/j.neuropharm.2019.04.021
Noble C, Holm NB, Mardal M, Linnet K (2018) Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A. Toxicol Lett 295:397–407. https://doi.org/10.1016/j.toxlet.2018.07.018
Nugteren-van Lonkhuyzen JJ, Van Riel AJ, Brunt TM, Hondebrink L (2015) Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans. Drug Alcohol Depend 157:18–27. https://doi.org/10.1016/j.drugalcdep.2015.10.011
Öcal N, Dogan D, Cicek AF, Yücel O, Tozkoparan E (2016) Acute eosinophilic pneumonia with respiratory failure induced by synthetic cannabinoid inhalation. Balkan Med J 33(6):688–690. https://doi.org/10.5152/balkanmedj.2016.151145
Ojanperä I, Gergov M, Rasanen I, Lunetta P, Toivonen S, Tiainen E, Vuori E (2006) Blood levels of 3-methylfentanyl in 3 fatal poisoning cases. Am J Forensic Med Pathol 27(4):328–331. https://doi.org/10.1097/01.paf.0000188097.78132.e5
Oliveira P, Morais ASF, Madeira N (2017) Synthetic cannabis analogues and suicidal behavior: case report. J Addict Med 11(5):408–410. https://doi.org/10.1097/adm.0000000000000335
Oluwabusi OO, Lobach L, Akhtar U, Youngman B, Ambrosini PJ (2012) Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc Psychopharmacol 22(5):393–395. https://doi.org/10.1089/cap.2012.0004
Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F (2017) The "endless trip" among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry 8:240. https://doi.org/10.3389/fpsyt.2017.00240
Ott J (1999) Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoact Drugs 31(2):171–177. https://doi.org/10.1080/02791072.1999.10471741
Ott J (2001) Pharmepena-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-NN-dimethyl-tryptamine. J Psychoact Drugs 33(4):403–407. https://doi.org/10.1080/02791072.2001.10399925
Owen DR, Wood DM, Archer JR, Dargan PI (2016) Phenibut (4-amino-3-phenyl-butyric acid): availability, prevalence of use, desired effects and acute toxicity. Drug Alcohol Rev 35(5):591–596. https://doi.org/10.1111/dar.12356
Ozturk HM, Yetkin E, Ozturk S (2019) Synthetic cannabinoids and cardiac arrhythmia risk: review of the literature. Cardiovasc Toxicol 19(3):191–197. https://doi.org/10.1007/s12012-019-09522-z
Palenicek T, Lhotkova E, Zidkova M, Balikova M, Kuchar M, Himl M, Miksatkova P, Cegan M, Vales K, Tyls F, Horsley RR (2016) Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): pharmacokinetics, behaviour, thermoregulation and LD50 in rats. Prog Neuropsychopharmacol Biol Psychiatry 69:49–59. https://doi.org/10.1016/j.pnpbp.2016.04.004
Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-Rolim SA, Osório FL, Sanches R, Dos Santos RG, Tófoli LF, de Oliveira SG, Yonamine M, Riba J, Santos FR, Silva-Junior AA, Alchieri JC, Galvão-Coelho NL, Lobão-Soares B, Hallak JEC, Arcoverde E, Maia-de-Oliveira JP, Aráujo DB (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49(4):655–663. https://doi.org/10.1017/s0033291718001356
Pant S, Deshmukh A, Dholaria B, Kaur V, Ramavaram S, Ukor M, Teran GA (2012) Spicy seizure. Am J Med Sci 344(1):67–68. https://doi.org/10.1097/MAJ.0b013e31824cf5c2
Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, Pascolo-Fabrici E, Bonavigo T (2013) "Spiceophrenia": a systematic overview of "spice"-related psychopathological issues and a case report. Hum Psychopharmacol 28(4):379–389. https://doi.org/10.1002/hup.2312
Papsun D, Krywanczyk A, Vose JC, Bundock EA, Logan BK (2016) Analysis of MT-45, a novel synthetic opioid, in human whole blood by LC–MS–MS and its identification in a drug-related death. J Anal Toxicol 40(4):313–317. https://doi.org/10.1093/jat/bkw012
Parks C, McKeown D, Torrance HJ (2015) A review of ethylphenidate in deaths in east and west Scotland. Forensic Sci Int 257:203–208. https://doi.org/10.1016/j.forsciint.2015.08.008
Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319(1):237–246. https://doi.org/10.1124/jpet.106.103622
Partridge E, Trobbiani S, Stockham P, Charlwood C, Kostakis C (2018) A case study involving U-47700, diclazepam and flubromazepam-application of retrospective analysis of HRMS data. J Anal Toxicol 42(9):655–660. https://doi.org/10.1093/jat/bky039
Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH (2013) K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 58(6):1676–1680. https://doi.org/10.1111/1556-4029.12216
Paul ABM, Simms L, Amini S, Paul AE (2018) Teens and spice: a review of adolescent fatalities associated with synthetic cannabinoid use. J Forensic Sci 63(4):1321–1324. https://doi.org/10.1111/1556-4029.13704
Pearson JM, Hargraves TL, Hair LS, Massucci CJ, Frazee CC 3rd, Garg U, Pietak BR (2012) Three fatal intoxications due to methylone. J Anal Toxicol 36(6):444–451. https://doi.org/10.1093/jat/bks043
Peglow S, Buchner J, Briscoe G (2012) Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict 21(3):287–288. https://doi.org/10.1111/j.1521-0391.2012.00222.x
Penders TM, Gestring RE, Vilensky DA (2012) Excited delirium following use of synthetic cathinones (bath salts). Gen Hosp Psychiatry 34(6):647–650. https://doi.org/10.1016/j.genhosppsych.2012.06.005
Peterson AB, Gladden RM, Delcher C, Spies E, Garcia-Williams A, Wang Y, Halpin J, Zibbell J, McCarty CL, DeFiore-Hyrmer J, DiOrio M, Goldberger BA (2016) Increasses in fentanyl-related overdose deaths—Florida and Ohio, 2013–2015. MMWR Morb Mortal Wkly Rep 65(33):844–849. https://doi.org/10.15585/mmwr.mm6533a3
Pieprzyca E, Skowronek R, Korczynska M, Kulikowska J, Chowaniec M (2018) A two fatal cases of poisoning involving new cathinone derivative PV8. Leg Med (Tokyo) 33:42–47. https://doi.org/10.1016/j.legalmed.2018.05.002
Pinterova N, Horsley RR, Palenicek T (2017) Synthetic aminoindanes: a summary of existing knowledge. Front Psychiatry 8:236. https://doi.org/10.3389/fpsyt.2017.00236
Poklis JL, Nanco CR, Troendle MM, Wolf CE, Poklis A (2014) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 6(7–8):764–769. https://doi.org/10.1002/dta.1522
Poklis J, Poklis A, Wolf C, Hathaway C, Arbefeville E, Chrostowski L, Devers K, Hair L, Mainland M, Merves M, Pearson J (2016) Two fatal intoxications involving butyryl fentanyl. J Anal Toxicol 40(8):703–708. https://doi.org/10.1093/jat/bkw048
Poplawska M, Blazewicz A (2019) Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial. Drug Test Anal 11(1):162–167. https://doi.org/10.1002/dta.2467
Potocka-Banas B, Janus T, Majdanik S, Banas T, Dembinska T, Borowiak K (2017) Fatal intoxication with α-PVP, a synthetic cathinone derivative. J Forensic Sci 62(2):553–556. https://doi.org/10.1111/1556-4029.13326
Prekupec MP, Mansky PA, Baumann MH (2017) Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 11(4):256–265. https://doi.org/10.1097/adm.0000000000000324
Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E, Vollenweider FX (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27(3):451–457. https://doi.org/10.1016/j.cub.2016.12.030
Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stämpfli P, Seifritz E, Repovs G, Krystal JH, Murray JD, Vollenweider FX, Anticevic A (2018) Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. https://doi.org/10.7554/eLife.35082
Raheemullah A, Laurence TN (2016) Repeated thrombosis after synthetic cannabinoid use. J Emerg Med 51(5):540–543. https://doi.org/10.1016/j.jemermed.2016.06.015
Rahnema CD, Crosnoe LE, Kim ED (2015) Designer steroids—over-the-counter supplements and their androgenic component: review of an increasing problem. Andrology 3(2):150–155. https://doi.org/10.1111/andr.307
Riba J, McIlhenny EH, Bouso JC, Barker SA (2015) Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Test Anal 7(5):401–406. https://doi.org/10.1002/dta.1685
Richards JR, Johnson EB, Stark RW, Derlet RW (1999) Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med 17(7):681–685. https://doi.org/10.1016/s0735-6757(99)90159-6
Richeval C, Gaulier JM, Romeuf L, Allorge D, Gaillard Y (2019) Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700. Int J Legal Med 133(1):133–142. https://doi.org/10.1007/s00414-018-1969-3
Rickli A, Hoener MC, Liechti ME (2015a) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 25(3):365–376. https://doi.org/10.1016/j.euroneuro.2014.12.012
Rickli A, Kopf S, Hoener MC, Liechti ME (2015b) Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol 172(13):3412–3425. https://doi.org/10.1111/bph.13128
Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (2015c) Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99:546–553. https://doi.org/10.1016/j.neuropharm.2015.08.034
Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 26(8):1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.001
Rickli A, Liakoni E, Hoener MC, Liechti ME (2018) Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol 175(3):532–543. https://doi.org/10.1111/bph.14105
Rickli A, Kolaczynska K, Hoener MC, Liechti ME (2019) Pharmacological characterization of the aminorex analogs 4-MAR, 4,4ʹ-DMAR, and 3,4-DMAR. Neurotoxicology 72:95–100. https://doi.org/10.1016/j.neuro.2019.02.011
Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237(4819):1219–1223. https://doi.org/10.1126/science.2820058
Roberto AJ, Lorenzo A, Li KJ, Young J, Mohan A, Pinnaka S, Lapidus KA (2016) First-episode of synthetic cannabinoid-induced psychosis in a young adult, successfully managed with hospitalization and risperidone. Case Rep Psychiatry 2016:7257489. https://doi.org/10.1155/2016/7257489
Roque Bravo R, Carmo H, Silva JP, Valente MJ, Carvalho F, Bastos ML, Dias da Silva D (2019) Emerging club drugs: 5-(2-aminopropyl)benzofuran (5-APB) is more toxic than its isomer 6-(2-aminopropyl)benzofuran (6-APB) in hepatocyte cellular models. Arch Toxicol. https://doi.org/10.1007/s00204-019-02638-9
Rose SR, Poklis JL, Poklis A (2013) A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila) 51(3):174–177. https://doi.org/10.3109/15563650.2013.772191
Rose DZ, Guerrero WR, Mokin MV, Gooch CL, Bozeman AC, Pearson JM, Burgin WS (2015) Hemorrhagic stroke following use of the synthetic marijuana "spice". Neurology 85(13):1177–1179. https://doi.org/10.1212/wnl.0000000000001973
Roseman L, Nutt DJ, Carhart-Harris RL (2017) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 8:974. https://doi.org/10.3389/fphar.2017.00974
Rosenson J, Smollin C, Sporer KA, Blanc P, Olson KR (2007) Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med 49(2):164–171. https://doi.org/10.1016/j.annemergmed.2006.09.018
Ross EA, Watson M, Goldberger B (2011) "Bath salts" intoxication. N Engl J Med 365(10):967–968. https://doi.org/10.1056/NEJMc1107097
Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA (2012) Psychoactive "bath salts" intoxication with methylenedioxypyrovalerone. Am J Med 125(9):854–858. https://doi.org/10.1016/j.amjmed.2012.02.019
Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356(1):6–9. https://doi.org/10.1056/NEJMp068265
Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2013) The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS ONE 8(3):e59334. https://doi.org/10.1371/journal.pone.0059334
Rothman RB, Baumann MH (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479(1–3):23–40. https://doi.org/10.1016/j.ejphar.2003.08.054
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39(1):32–41. https://doi.org/10.1002/1098-2396(20010101)39:1%3c32:aid-syn5%3e3.0.co;2-3
Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE, Baumann MH (2002) Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol 447(1):51–57. https://doi.org/10.1016/s0014-2999(02)01830-7
Ruan X, Chiravuri S, Kaye AD (2016) Comparing fatal cases involving U-47700. Forensic Sci Med Pathol 12(3):369–371. https://doi.org/10.1007/s12024-016-9795-8
Rudd RA, Seth P, David F, Scholl L (2016) Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep 65(50–51):1445–1452. https://doi.org/10.15585/mmwr.mm655051e1
Sachdev S, Vemuri K, Banister SD, Longworth M, Kassiou M, Santiago M, Makriyannis A, Connor M (2019) In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. Br J Pharmacol. https://doi.org/10.1111/bph.14829
Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA (2011) Aminoindanes—the next wave of 'legal highs'? Drug Test Anal 3(7–8):479–482. https://doi.org/10.1002/dta.318
Saito T, Namera A, Miura N, Ohta S, Miyazaki S, Osawa M, Inokuchi S (2013) A fatal case of MAM-2201 poisoning. Forensic Toxicol 31(2):333–337. https://doi.org/10.1007/s11419-013-0190-9
Sampson CS, Bedy SM, Carlisle T (2015) Withdrawal seizures seen in the setting of synthetic cannabinoid abuse. Am J Emerg Med 33(11):1712.e3. https://doi.org/10.1016/j.ajem.2015.03.025
Sanchez S (1929) Sur un homologue de l’éphédrine. Bull Soc Chim Fr 45:284–286
Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P (2011) The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol (Phila) 49(3):131–141. https://doi.org/10.3109/15563650.2011.572076
Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B (2012) The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 50(6):458–470. https://doi.org/10.3109/15563650.2012.702218
Schep LJ, Slaughter RJ, Hudson S, Place R, Watts M (2015) Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol 34(5):557–560. https://doi.org/10.1177/0960327114550886
Schifano F, Corkery J, Ghodse AH (2012) Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. J Clin Psychopharmacol 32(5):710–714. https://doi.org/10.1097/JCP.0b013e318266c70c
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78(8):544–553. https://doi.org/10.1016/j.biopsych.2014.11.015
Schneir AB, Baumbacher T (2012) Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 8(1):62–64. https://doi.org/10.1007/s13181-011-0182-2
Schneir A, Metushi IG, Sloane C, Benaron DJ, Fitzgerald RL (2017) Near death from a novel synthetic opioid labeled U-47700: emergence of a new opioid class. Clin Toxicol (Phila) 55(1):51–54. https://doi.org/10.1080/15563650.2016.1209764
Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G (2018) Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Morb Mortal Wkly Rep 67(5152):1419–1427. https://doi.org/10.15585/mmwr.mm675152e1
Schwartz MD, Trecki J, Edison LA, Steck AR, Arnold JK, Gerona RR (2015) A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med 48(5):573–580. https://doi.org/10.1016/j.jemermed.2014.12.038
Screaton GR, Singer M, Cairns HS, Thrasher A, Sarner M, Cohen SL (1992) Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet 339(8794):677–678. https://doi.org/10.1016/0140-6736(92)90834-p
Seaton DA, Duncan LJ, Rose K, Scott AM (1961) Diethyl-propion in the treatment of “refractory” obesity. Br Med J 1(5231):1009–1011. https://doi.org/10.1136/bmj.1.5231.1009
Seetohul LN, Pounder DJ (2013) Four fatalities involving 5-IT. J Anal Toxicol 37(7):447–451. https://doi.org/10.1093/jat/bkt053
Seither JZ, Reidy LJ, Boland DM (2019) Identification and quantification of 5-fluoro ADB and the 5-fluoro ADB ester hydrolysis metabolite in postmortem blood samples by LC–MS/MS. J Anal Toxicol. https://doi.org/10.1093/jat/bkz043
Sellors K, Jones A, Chan B (2014) Death due to intravenous use of α-pyrrolidinopentiophenone. Med J Aust 201(10):601–603. https://doi.org/10.5694/mja13.00203
Seo JY, Hur KH, Ko YH, Kim K, Lee BR, Kim YJ, Kim SK, Kim SE, Lee YS, Kim HC, Lee SY, Jang CG (2019) A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents. Brain Res Bull 152:19–26. https://doi.org/10.1016/j.brainresbull.2019.07.002
Seth P, Scholl L, Rudd RA, Bacon S (2018) Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep 67(12):349–358. https://doi.org/10.15585/mmwr.mm6712a1
Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63(6):1223–1229. https://doi.org/10.1124/mol.63.6.1223
Shah M, Garg J, Patel B, Guthier J, Freudenberger RS (2016) Can your heart handle the spice: a case of acute myocardial infarction and left ventricular apical thrombus. Int J Cardiol 215:129–131. https://doi.org/10.1016/j.ijcard.2016.04.055
Shahbaz A, Gaviria REE, Shahid MF, Yasin MA, Ashraf A, Zaman MA (2018) Acute liver injury induced by synthetic cannabinoid abuse. Cureus 10(9):e3257–e3257. https://doi.org/10.7759/cureus.3257
Shanks KG, Behonick GS (2016) Death after use of the synthetic cannabinoid 5F-AMB. Forensic Sci Int 262:e21–e24. https://doi.org/10.1016/j.forsciint.2016.03.004
Shanks KG, Dahn T, Terrell AR (2012) Detection of JWH-018 and JWH-073 by UPLC–MS–MS in postmortem whole blood casework. J Anal Toxicol 36(3):145–152. https://doi.org/10.1093/jat/bks013
Shanks KG, Sozio T, Behonick GS (2015a) Fatal intoxications with 25B-NBOMe and 25I-NBOMe in Indiana during 2014. J Anal Toxicol 39(8):602–606. https://doi.org/10.1093/jat/bkv058
Shanks KG, Winston D, Heidingsfelder J, Behonick G (2015b) Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int 252:e6–9. https://doi.org/10.1016/j.forsciint.2015.04.021
Shanks KG, Clark W, Behonick G (2016) Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol 40(3):236–239. https://doi.org/10.1093/jat/bkv142
Sharma A, Couture J (2014) A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 48(2):209–225. https://doi.org/10.1177/1060028013510699
Shearer K, Bryce C, Parsons M, Torrance H (2015) Phenazepam: a review of medico-legal deaths in South Scotland between 2010 and 2014. Forensic Sci Int 254:197–204. https://doi.org/10.1016/j.forsciint.2015.07.033
Sheridan J, Butler R, Wilkins C, Russell B (2007) Legal piperazine-containing party pills—a new trend in substance misuse. Drug Alcohol Rev 26(3):335–343. https://doi.org/10.1080/09595230701255791
Sherpa D, Paudel BM, Subedi BH, Chow RD (2015) Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high. J Community Hosp Intern Med Perspect 5(4):27540. https://doi.org/10.3402/jchimp.v5.27540
Shields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS (2012) Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin Toxicol (Phila) 50(5):438–440. https://doi.org/10.3109/15563650.2012.683437
Shoff EN, Kahl JH, Hime GW, Coburn M, Boland DM (2019) 4-Fluoromethylphenidate: fatal intoxication involving a previously unreported novel psychoactive substance in the USA. J Anal Toxicol 43(8):666–672. https://doi.org/10.1093/jat/bkz061
Shulgin A, Shulgin A (1995) PIHKAL: a chemical love story. Transform Press, Berkley
Shulgin A, Shulgin A (1997) TIHKAL: the continuation. Transform Press, Berkley
Siddiqi S, Verney C, Dargan P, Wood DM (2015) Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clin Toxicol (Phila) 53(1):54–59. https://doi.org/10.3109/15563650.2014.983239
Silva JP, Carmo H, Carvalho F (2018) The synthetic cannabinoid XLR-11 induces in vitro nephrotoxicity by impairment of endocannabinoid-mediated regulation of mitochondrial function homeostasis and triggering of apoptosis. Toxicol Lett 287:59–69. https://doi.org/10.1016/j.toxlet.2018.01.023
Silva JP, Araújo AM, De Pinho PG, Carmo H, Carvalho F (2019) Synthetic cannabinoids JWH-122 and THJ-2201 disrupt endocannabinoid-regulated mitochondrial function and activate apoptotic pathways as a primary mechanism of in vitro nephrotoxicity at in vivo relevant concentrations. Toxicol Sci 169(2):422–435. https://doi.org/10.1093/toxsci/kfz050
Simmler LD, Hysek CM, Liechti ME (2011) Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab 96(9):2844–2850. https://doi.org/10.1210/jc.2011-1143
Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168(2):458–470. https://doi.org/10.1111/j.1476-5381.2012.02145.x
Simmler LD, Rickli A, Hoener MC, Liechti ME (2014a) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79:152–160. https://doi.org/10.1016/j.neuropharm.2013.11.008
Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME (2014b) Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem Pharmacol 88(2):237–244. https://doi.org/10.1016/j.bcp.2014.01.024
Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (2016) In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J Pharmacol Exp Ther 357(1):134–144. https://doi.org/10.1124/jpet.115.229765
Sitte HH, Freissmuth M (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36(1):41–50. https://doi.org/10.1016/j.tips.2014.11.006
Sklerov J, Levine B, Moore KA, King T, Fowler D (2005) A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol 29(8):838–841. https://doi.org/10.1093/jat/29.8.838
Skryabin VY, Vinnikova MA (2019) Clinical characteristics of synthetic cannabinoid-induced psychotic disorders: a single-center analysis of hospitalized patients. J Addict Dis 1:1–7. https://doi.org/10.1080/10550887.2019.1627635
Skryabin VY, Vinnikova M, Nenastieva A, Alekseyuk V (2019) Hallucinogen persisting perception disorder: a literature review and three case reports. J Addict Dis 1:1–11. https://doi.org/10.1080/10550887.2019.1673655
Smith DL, Roberts C (2014) Synthetic marijuana use and development of catatonia in a 17-year-old male. Minn Med 97(5):38
Smolinske SC, Rastogi R, Schenkel S (2005) Foxy methoxy: a new drug of abuse. J Med Toxicol 1(1):22–25. https://doi.org/10.1007/BF03160901
Sofalvi S, Schueler HE, Lavins ES, Kaspar CK, Brooker IT, Mazzola CD, Dolinak D, Gilson TP, Perch S (2017) An LC–MS-MS method for the analysis of carfentanil, 3-methylfentanyl, 2-furanyl fentanyl, acetyl fentanyl, fentanyl and norfentanyl in postmortem and impaired-driving cases. J Anal Toxicol 41(6):473–483. https://doi.org/10.1093/jat/bkx052
Solomons E, Sam J (1973) 2-Aminoindans of pharmacological interest. J Med Chem 16(12):1330–1333. https://doi.org/10.1021/jm00270a004
Soroko FE, Mehta NB, Maxwell RA, Ferris RM, Schroeder DH (1977) Bupropion hydrochloride ((±) α-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent. J Pharm Pharmacol 29(12):767–770. https://doi.org/10.1111/j.2042-7158.1977.tb11460.x
Srisuma S, Bronstein AC, Hoyte CO (2015) NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System. Clin Toxicol (Phila) 53(7):624–628. https://doi.org/10.3109/15563650.2015.1054502
Srisung W, Jamal F, Prabhakar S (2015) Synthetic cannabinoids and acute kidney injury. Proc (Bayl Univ Med Cent) 28(4):475–477. https://doi.org/10.1080/08998280.2015.11929313
Staeheli SN, Baumgartner MR, Gauthier S, Gascho D, Jarmer J, Kraemer T, Steuer AE (2016) Time-dependent postmortem redistribution of butyrfentanyl and its metabolites in blood and alternative matrices in a case of butyrfentanyl intoxication. Forensic Sci Int 266:170–177. https://doi.org/10.1016/j.forsciint.2016.05.034
Stanley TH (2014) The fentanyl story. J Pain 15(12):1215–1226. https://doi.org/10.1016/j.jpain.2014.08.010
Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC (2014) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J Med Toxicol 10(1):45–50. https://doi.org/10.1007/s13181-013-0314-y
Sternbach LH (1979) The benzodiazepine story. J Med Chem 22(1):1–7. https://doi.org/10.1021/jm00187a001
Stoller A, Dolder PC, Bodmer M, Hammann F, Rentsch KM, Exadaktylos AK, Liechti ME, Liakoni E (2017) Mistaking 2C-P for 2C-B: what a difference a letter makes. J Anal Toxicol 41(1):77–79. https://doi.org/10.1093/jat/bkw108
Suyama JA, Banks ML, Negus SS (2019) Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats. Psychopharmacology 236(3):1057–1066. https://doi.org/10.1007/s00213-018-5029-y
Suzuki J, El-Haddad S (2017) A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend 171:107–116. https://doi.org/10.1016/j.drugalcdep.2016.11.033
Swanson DM, Hair LS, Strauch Rivers SR, Smyth BC, Brogan SC, Ventoso AD, Vaccaro SL, Pearson JM (2017) Fatalities involving carfentanil and furanyl fentanyl: two case reports. J Anal Toxicol 41(6):498–502. https://doi.org/10.1093/jat/bkx037
Sweeney B, Talebi S, Toro D, Gonzalez K, Menoscal JP, Shaw R, Hassen GW (2016) Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med 34(1):121.e1–2. https://doi.org/10.1016/j.ajem.2015.05.052
Sweet G, Kim S, Martin S, Washington NB, Brahm N (2017) Psychiatric symptoms and synthetic cannabinoid use: information for clinicians. Ment Health Clin 7(4):156–159. https://doi.org/10.9740/mhc.2017.07.156
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 54(1):1–13. https://doi.org/10.3109/15563650.2015.1110590
Takase I, Koizumi T, Fujimoto I, Yanai A, Fujimiya T (2016) An autopsy case of acetyl fentanyl intoxication caused by insufflation of 'designer drugs'. Leg Med (Tokyo) 21:38–44. https://doi.org/10.1016/j.legalmed.2016.05.006
Takematsu M, Hoffman RS, Nelson LS, Schechter JM, Moran JH, Wiener SW (2014) A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol (Phila) 52(9):973–975. https://doi.org/10.3109/15563650.2014.958614
Taljemark J, Johansson BA (2012) Drug-induced acute psychosis in an adolescent first-time user of 4-HO-MET. Eur Child Adolesc Psychiatry 21(9):527–528. https://doi.org/10.1007/s00787-012-0282-9
Tanaka E, Kamata T, Katagi M, Tsuchihashi H, Honda K (2006) A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine. Foxy Forensic Sci Int 163(1–2):152–154. https://doi.org/10.1016/j.forsciint.2005.11.026
Tanaka N, Kinoshita H, Jamal M, Ohkubo E, Kumihashi M, Ameno K (2011a) A case of drowning whilst under the influence of brotizolam, flunitrazepam and ethanol. Soud Lek 56(1):5–6
Tanaka N, Kinoshita H, Nishiguchi M, Jamal M, Kumihashi M, Takahashi M, Nishio H, Ameno K (2011b) An autopsy case of multiple psychotropic drug poisoning. Soud Lek 56(3):38–39
Tang MH, Ching CK, Tsui MS, Chu FK, Mak TW (2014) Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin Toxicol (Phila) 52(5):561–565. https://doi.org/10.3109/15563650.2014.909932
Thirakul P, Hair LS, Bergen KL, Pearson JM (2017) Clinical presentation, autopsy results and toxicology findings in an acute N-ethylpentylone fatality. J Anal Toxicol 41(4):342–346. https://doi.org/10.1093/jat/bkx004
Thomas S, Bliss S, Malik M (2012) Suicidal ideation and self-harm following K2 use. J Okla State Med Assoc 105(11):430–433
Thorlacius K, Borna C, Personne M (2008) Bromo-dragonfly–livsfarlig missbruksdrog. Kan ge vävnadsnekros, visar det första beskrivna fallet. Lakartidningen 105(16):1199–200
Thornton SL, Wood C, Friesen MW, Gerona RR (2013) Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol (Phila) 51(3):189–190. https://doi.org/10.3109/15563650.2013.770870
Thornton S, Lisbon D, Lin T, Gerona R (2017) Beyond ketamine and phencyclidine: analytically confirmed use of multiple novel arylcyclohexylamines. J Psychoactive Drugs 49(4):289–293. https://doi.org/10.1080/02791072.2017.1333660
Tofighi B, Lee JD (2012) Internet highs–seizures after consumption of synthetic cannabinoids purchased online. J Addict Med 6(3):240–241. https://doi.org/10.1097/ADM.0b013e3182619004
Topeff J, Ellsworth H, Willhite L, Bangh S, Edwards E, Cole J (2011) A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol (Phila) 49:526
Trachsel D, Lehmann D, Enzensperger C (2013) Phenethylamine: von der Struktur zur Funktion. Nachtschatten Verlag, Solothurn
Trecki J, Gerona RR, Schwartz MD (2015) Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373(2):103–107. https://doi.org/10.1056/NEJMp1505328
Troxler F, Hofmann A (1957) Substitutionen am Ringsystem der Lysergsäure. I Substitutionen am Indol-Stickstoff. 43. Mitteilung über Mutterkornalkaloide. Helv Chim Acta 40(6):1706–1720. https://doi.org/10.1002/hlca.19570400619
Tsai TH, Cha TL, Lin CM, Tsao CW, Tang SH, Chuang FP, Wu ST, Sun GH, Yu DS, Chang SY (2009) Ketamine-associated bladder dysfunction. Int J Urol 16(10):826–829. https://doi.org/10.1111/j.1442-2042.2009.02361.x
Tse R, Kodur S, Squires B, Collins N (2014) Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use. Intern Med J 44(9):934–936. https://doi.org/10.1111/imj.12521
Tyndall JA, Gerona R, De Portu G, Trecki J, Elie MC, Lucas J, Slish J, Rand K, Bazydlo L, Holder M, Ryan MF, Myers P, Iovine N, Plourde M, Weeks E, Hanley JR, Endres G, St Germaine D, Dobrowolski PJ, Schwartz M (2015) An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol (Phila) 53(10):950–956. https://doi.org/10.3109/15563650.2015.1100306
Ukaigwe A, Karmacharya P, Donato A (2014) A gut gone to pot: a case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med 2014:167098. https://doi.org/10.1155/2014/167098
Umebachi R, Aoki H, Sugita M, Taira T, Wakai S, Saito T, Inokuchi S (2016) Clinical characteristics of α-pyrrolidinovalerophenone (α-PVP) poisoning. Clin Toxicol (Phila) 54(7):563–567. https://doi.org/10.3109/15563650.2016.1166508
Usui K, Fujita Y, Kamijo Y, Kokaji T, Funayama M (2018) Identification of 5-fluoro ADB in human whole blood in four death cases. J Anal Toxicol 42(2):e21–e25. https://doi.org/10.1093/jat/bkx088
Valente MJ, Guedes de Pinho P, De Lourdes BM, Carvalho F, Carvalho M (2014) Khat and synthetic cathinones: a review. Arch Toxicol 88(1):15–45. https://doi.org/10.1007/s00204-013-1163-9
Valente MJ, Aráujo AM, Bastos Mde L, Fernandes E, Carvalho F, Guedes de Pinho P, Carvalho M (2016a) characterization of hepatotoxicity mechanisms triggered by designer cathinone drugs (β-keto amphetamines). Toxicol Sci 153(1):89–102. https://doi.org/10.1093/toxsci/kfw105
Valente MJ, Aráujo AM, Silva R, Bastos Mde L, Carvalho F, Guedes de Pinho P, Carvalho M (2016b) 3,4-Methylenedioxypyrovalerone (MDPV): in vitro mechanisms of hepatotoxicity under normothermic and hyperthermic conditions. Arch Toxicol 90(8):1959–1973. https://doi.org/10.1007/s00204-015-1653-z
Valente MJ, Amaral C, Correia-da-Silva G, Duarte JA, Bastos ML, Carvalho F, Guedes de Pinho P, Carvalho M (2017a) Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity. Arch Toxicol 91(11):3663–3676. https://doi.org/10.1007/s00204-017-1984-z
Valente MJ, Bastos ML, Fernandes E, Carvalho F, Guedes de Pinho P, Carvalho M (2017b) Neurotoxicity of β-keto amphetamines: deathly mechanisms elicited by methylone and MDPV in human dopaminergic SH-SY5Y cells. ACS Chem Neurosci 8(4):850–859. https://doi.org/10.1021/acschemneuro.6b00421
Van Amsterdam J, Brunt T, Van den Brink W (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 29(3):254–263. https://doi.org/10.1177/0269881114565142
Van Dijken GD, Blom RE, Hene RJ, Boer WH, Consortium N (2013) High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dial Transplant 28(9):2277–2283. https://doi.org/10.1093/ndt/gft023
Vanden Eede H, Montenij LJ, Touw DJ, Norris EM (2012) Rhabdomyolysis in MDMA intoxication: a rapid and underestimated killer. “Clean" ecstasy, a safe party drug? J Emerg Med 42(6):655–658. https://doi.org/10.1016/j.jemermed.2009.04.057
Vandewater SA, Creehan KM, Taffe MA (2015) Intravenous self-administration of entactogen-class stimulants in male rats. Neuropharmacology 99:538–545. https://doi.org/10.1016/j.neuropharm.2015.08.030
Van der Veer N, Friday J (2011) Persistent psychosis following the use of Spice. Schizophr Res 130(1–3):285–286. https://doi.org/10.1016/j.schres.2011.04.022
Venhuis BJ, Blok-Tip L, De Kaste D (2008) Designer drugs in herbal aphrodisiacs. Forensic Sci Int 177(2–3):e25–e27. https://doi.org/10.1016/j.forsciint.2007.11.007
Vizeli P, Liechti ME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol 31(5):576–588. https://doi.org/10.1177/0269881117691569
Vogel M, Knöpfli B, Schmid O, Prica M, Strasser J, Prieto L, Wiesbeck GA, Dursteler-Macfarland KM (2013) Treatment or "high": benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav 38(10):2477–2484. https://doi.org/10.1016/j.addbeh.2013.05.008
Vogel M, Bucher P, Strasser J, Liechti ME, Krähenbühl S, Dürsteler KM (2016) Similar and different? Subjective effects of methylphenidate and cocaine in opioid-maintained patients. J Psychoactive Drugs 48(2):93–100. https://doi.org/10.1080/02791072.2015.1130883
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9(17):3897–3902. https://doi.org/10.1097/00001756-199812010-00024
Volz TJ, Hanson GR, Fleckenstein AE (2007) The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem 101(4):883–888. https://doi.org/10.1111/j.1471-4159.2006.04419.x
Vorce SP, Knittel JL, Holler JM, Magluilo J Jr, Levine B, Berran P, Bosy TZ (2014) A fatality involving AH-7921. J Anal Toxicol 38(4):226–230. https://doi.org/10.1093/jat/bku011
Wagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR (2019a) Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. Drug Test Anal 11(2):318–324. https://doi.org/10.1002/dta.2494
Wagmann L, Richter LHJ, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR (2019b) In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal Bioanal Chem 411(19):4751–4763. https://doi.org/10.1007/s00216-018-1558-9
Wallach J, Brandt SD (2018a) 1,2-diarylethylamine- and ketamine-based new psychoactive substances. Handb Exp Pharmacol 252:305–352. https://doi.org/10.1007/164_2018_148
Wallach J, Brandt SD (2018b) Phencyclidine-based new psychoactive substances. Handb Exp Pharmacol 252:261–303. https://doi.org/10.1007/164_2018_124
Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, Lodge D, Halberstadt AL, Brandt SD, Adejare A (2016) Pharmacological investigations of the dissociative ‘legal highs' diphenidine, methoxphenidine and analogues. PLoS ONE 11(6):e0157021. https://doi.org/10.1371/journal.pone.0157021
Walterscheid JP, Phillips GT, Lopez AE, Gonsoulin ML, Chen HH, Sanchez LA (2014) Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol 35(1):20–25. https://doi.org/10.1097/paf.0000000000000082
Wang Q, Wu Q, Wang J, Chen Y, Zhang G, Chen J, Zhao J, Wu P (2017) Ketamine analog methoxetamine induced inflammation and dysfunction of bladder in rats. Int J Mol Sci 18(1):1. https://doi.org/10.3390/ijms18010117
Ward J, Rhyee S, Plansky J, Boyer E (2011) Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol (Phila) 49(9):874–875. https://doi.org/10.3109/15563650.2011.617310
Waters L, Manchester KR, Maskell PD, Haegeman C, Haider S (2018) The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. Sci Justice 58(3):219–225. https://doi.org/10.1016/j.scijus.2017.12.004
Weber C, Krug O, Kamber M, Thevis M (2017) Qualitative and semiquantitative analysis of doping products seized at the Swiss border. Subst Use Misuse 52(6):742–753. https://doi.org/10.1080/10826084.2016.1263665
Wee S, Woolverton WL (2006) Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. Pharmacol Biochem Behav 84(2):337–343. https://doi.org/10.1016/j.pbb.2006.05.022
Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313(2):848–854. https://doi.org/10.1124/jpet.104.080101
Welter S, Lücke C, Lam AP, Custal C, Moeller S, Sörös P, Thiel CM, Philipsen A, Müller HHO (2017) Synthetic cannabinoid use in a psychiatric patient population: a pilot study. Eur Addict Res 23(4):182–193. https://doi.org/10.1159/000479554
Westin AA, Frost J, Brede WR, Gundersen PO, Einvik S, Aarset H, Slordal L (2016) Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol 40(1):86–87. https://doi.org/10.1093/jat/bkv110
White JC, Wood DM, Hill SL, Eddleston M, Officer J, Dargan PI, Dunn M, Thomas SHL (2019) Acute toxicity following analytically confirmed use of the novel psychoactive substance (NPS) methiopropamine. A report from the Identification of Novel psychoActive substances (IONA) study. Clin Toxicol (Phila) 57(7):663–667. https://doi.org/10.1080/15563650.2018.1538519
Wiergowski M, Anand JS, Krzyzanowski M, Jankowski Z (2014) Acute methoxetamine and amphetamine poisoning with fatal outcome: a case report. Int J Occup Med Environ Health 27(4):683–690. https://doi.org/10.2478/s13382-014-0290-8
Wijers CH, Van Litsenburg RT, Hondebrink L, Niesink RJ, Croes EA (2017) Acute toxic effects related to 4-fluoroamphetamine. Lancet 389(10069):600. https://doi.org/10.1016/s0140-6736(17)30281-7
Wikström M, Thelander G, Dahlgren M, Kronstrand R (2013) An accidental fatal intoxication with methoxetamine. J Anal Toxicol 37(1):43–46. https://doi.org/10.1093/jat/bks086
Wilde M, Sommer MJ, Auwärter V, Hermanns-Clausen M (2020) Acute severe intoxication with cyclopropylfentanyl, a novel synthetic opioid. Toxicol Lett 320:109–112. https://doi.org/10.1016/j.toxlet.2019.11.025
Wiley JL, Lefever TW, Marusich JA, Grabenauer M, Moore KN, Huffman JW, Thomas BF (2016) Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice. Neuropharmacology 110(Pt A):143–153. https://doi.org/10.1016/j.neuropharm.2016.07.016
Wilkins C, Sweetsur P, Girling M (2008) Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev 27(6):633–639. https://doi.org/10.1080/09595230801956140
Winstock AR, Barratt MJ (2013) Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 131(1–2):106–111. https://doi.org/10.1016/j.drugalcdep.2012.12.011
Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA (2000) The paradox of 5-methoxy-N, N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol Biochem Behav 65(1):75–82. https://doi.org/10.1016/s0091-3057(99)00178-1
Wolff V, Jouanjus E (2017) Strokes are possible complications of cannabinoids use. Epilepsy Behav 70(Pt B):355–363. https://doi.org/10.1016/j.yebeh.2017.01.031
Wood DM, Button J, Lidder S, Ramsey J, Holt DW, Dargan PI (2008) Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). J Med Toxicol 4(4):254–257. https://doi.org/10.1007/bf03161209
Wood DM, Looker JJ, Shaikh L, Button J, Puchnarewicz M, Davies S, Lidder S, Ramsey J, Holt DW, Dargan PI (2009) Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. J Med Toxicol 5(4):226–229. https://doi.org/10.1007/bf03178273
Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, Dargan PI (2010) Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) 48(9):924–927. https://doi.org/10.3109/15563650.2010.531021
Wood DM, Brailsford AD, Dargan PI (2011) Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 3(7–8):417–425. https://doi.org/10.1002/dta.292
Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI (2012) Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol 68(5):853–856. https://doi.org/10.1007/s00228-011-1199-9
Wood DM, Sedefov R, Cunningham A, Dargan PI (2015) Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol (Phila) 53(2):85–92. https://doi.org/10.3109/15563650.2015.1004179
Wright TH, Cline-Parhamovich K, Lajoie D, Parsons L, Dunn M, Ferslew KE (2013) Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee. J Forensic Sci 58(6):1558–1562. https://doi.org/10.1111/1556-4029.12260
Wyman JF, Lavins ES, Engelhart D, Armstrong EJ, Snell KD, Boggs PD, Taylor SM, Norris RN, Miller FP (2013) Postmortem tissue distribution of MDPV following lethal intoxication by "bath salts". J Anal Toxicol 37(3):182–185. https://doi.org/10.1093/jat/bkt001
Yazici AB, Yazici E, Erol A (2017) Delirium and high creatine kinase and myoglobin levels related to synthetic cannabinoid withdrawal. Case Rep Med 2017:3894749. https://doi.org/10.1155/2017/3894749
Yeruva RR, Mekala HM, Sidhu M, Lippmann S (2019) Synthetic cannabinoids–“Spice" can induce a psychosis: a brief review. Innov Clin Neurosci 16(1–2):31–32
Yirgin G, Ates I, Katipoglu B, Demir BF, Yilmaz N (2018) Pulmonary embolism due to synthetic cannabinoid use: case report. Turk Kardiyol Dern Ars 46(5):411–413. https://doi.org/10.5543/tkda.2018.84425
Yonemitsu K, Sasao A, Mishima S, Ohtsu Y, Nishitani Y (2016) A fatal poisoning case by intravenous injection of "bath salts" containing acetyl fentanyl and 4-methoxy PV8. Forensic Sci Int 267:e6–e9. https://doi.org/10.1016/j.forsciint.2016.08.025
Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, Kleinschmidt K (2012) Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 30(7):1320.e5–7. https://doi.org/10.1016/j.ajem.2011.05.013
Zaami S, Giorgetti R, Pichini S, Pantano F, Marinelli E, Busardo FP (2018) Synthetic cathinones related fatalities: an update. Eur Rev Med Pharmacol Sci 22(1):268–274. https://doi.org/10.26355/eurrev_201801_14129
Zanos P, Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 23(4):801–811. https://doi.org/10.1038/mp.2017.255
Zarifi C, Vyas S (2017) Spice-y kidney failure: a case report and systematic review of acute kidney injury attributable to the use of synthetic cannabis. Perm J. https://doi.org/10.7812/tpp/16-160
Zawilska JB (2014) Methoxetamine—a novel recreational drug with potent hallucinogenic properties. Toxicol Lett 230(3):402–407. https://doi.org/10.1016/j.toxlet.2014.08.011
Zawilska JB, Wojcieszak J (2019) An expanding world of new psychoactive substances-designer benzodiazepines. Neurotoxicology 73:8–16. https://doi.org/10.1016/j.neuro.2019.02.015
Zhao A, Tan M, Maung A, Salifu M, Mallappallil M (2015) Rhabdomyolysis and acute kidney injury requiring dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids. Case Rep Nephrol 2015:235982. https://doi.org/10.1155/2015/235982
Zhou X, Luethi D, Sanvee GM, Bouitbir J, Liechti ME, Krähenbühl S (2019) Molecular toxicological mechanisms of synthetic cathinones on C2C12 myoblasts. Int J Mol Sci 20(7):1. https://doi.org/10.3390/ijms20071561
Zidkova M, Hlozek T, Balik M, Kopecky O, Tesinsky P, Svanda J, Balikova MA (2017) Two cases of non-fatal intoxication with a novel street hallucinogen: 3-methoxy-phencyclidine. J Anal Toxicol 41(4):350–354. https://doi.org/10.1093/jat/bkx009
Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K (2009) Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int 106(27):464–467. https://doi.org/10.3238/arztebl.2009.0464
Zvosec DL, Smith SW (2005) Agitation is common in γ-hydroxybutyrate toxicity. Am J Emerg Med 23(3):316–320. https://doi.org/10.1016/j.ajem.2005.02.003
Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE (2011) Case series of 226 γ-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 29(3):319–332. https://doi.org/10.1016/j.ajem.2009.11.008
Acknowledgements
Open access funding provided by Medical University of Vienna. This work was supported by grants from the Swiss National Science Foundation (Grant no. P2BSP3_181809 to D.L.) and the Federal Office of Public Health (Grant no. 16.921318 to M.E.L.). The authors thank Michael Arends for proofreading the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Luethi, D., Liechti, M.E. Designer drugs: mechanism of action and adverse effects. Arch Toxicol 94, 1085–1133 (2020). https://doi.org/10.1007/s00204-020-02693-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-020-02693-7